guaifenesin has been researched along with Asthma in 705 studies
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Excerpt | Relevance | Reference |
---|---|---|
"This study evaluated substance P and neurokinin 1 protein expression and mucus content in endobronchial biopsy specimens from normal control subjects and asthmatic subjects." | 9.09 | Substance P and its receptor neurokinin 1 expression in asthmatic airways. ( Chu, HW; Kraft, M; Krause, JE; Martin, RJ; Rex, MD, 2000) |
" azedarach fruit extract (MAE) using high-performance liquid chromatography (HPLC) and explored the therapeutic effects of MAE on pulmonary inflammation and mucus hypersecretion using a murine model of ovalbumin (OVA) exposed asthma." | 8.84 | Melia azedarach L. reduces pulmonary inflammation and mucus hypersecretion on a murine model of ovalbumin exposed asthma. ( Kim, T; Kim, WI; Lee, IS; Lee, SJ; Pak, SW; Shin, IS; Yang, YG, 2024) |
"Azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-p hthalazinone hydrochloride), a novel long-acting antiasthmatic/antiallergic drug has been demonstrated to be effective in the treatment both of asthma and of allergic rhinitis." | 8.78 | Azelastine: a multifaceted drug for asthma therapy. ( Achterrath-Tuckermann, U; Minker, E; Paegelow, I; Schmidt, J; Szelenyi, I; Werner, H, 1991) |
"In this study, we investigated whether 4-hydroxycinnamic acid (HA) has a palliative effect on asthmatic inflammatory responses using a mouse model of ovalbumin (OVA)-induced allergic asthma." | 7.96 | 4-Hydroxycinnamic acid suppresses airway inflammation and mucus hypersecretion in allergic asthma induced by ovalbumin challenge. ( Choi, SJ; Kim, JC; Kim, MS; Kim, SH; Kim, YH; Ko, JW; Kwon, HJ; Seo, CS; Shin, IS; Shin, NR, 2020) |
" In this study, we explored the suppressive effects of SAC on allergic airway inflammation induced in an ovalbumin (OVA)-induced asthma mouse model." | 7.91 | S-Allyl cysteine reduces eosinophilic airway inflammation and mucus overproduction on ovalbumin-induced allergic asthma model. ( Kim, JC; Kim, JS; Kim, SH; Ko, JW; Kwon, HJ; Lee, IC; Shin, IS; Shin, NR, 2019) |
"The purpose of this study is to explore the influence of ozone repeated short exposures on airway/lung inflammation, airway hyperresponsiveness (AHR) and airway hypersecretion in ovalbumin (OVA) sensitized/challenged asthmatic mouse model." | 7.88 | Effects of ozone repeated short exposures on the airway/lung inflammation, airway hyperresponsiveness and mucus production in a mouse model of ovalbumin-induced asthma. ( Bao, A; Bao, W; Fei, X; Zhang, M; Zhang, X; Zhang, Y; Zhou, X, 2018) |
" This study aimed to evaluate the preventive activity of IMP in an ovalbumin (OVA)-induced murine model of asthma and to investigate its possible molecular mechanisms." | 7.85 | Isoimperatorin attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma. ( Kwon, HJ; Moon, OS; Park, HS; Seo, CS; Son, HY; Song, JW; Wijerathne, CUB; Won, YS, 2017) |
" In the current study, an ovalbumin (OVA)‑induced allergic asthma model was used to investigate the immune‑modulating effects of pidotimod on airway eosinophilia, mucus metaplasia and inflammatory factor expression compared with dexamethasone (positive control)." | 7.85 | Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma. ( Fu, AK; Fu, LQ; Hu, SL; Li, WF; Li, YL; Wang, YY; Wu, YP, 2017) |
" argyi (TOTAL) and dehydromatricarin A (DA), its active component on ovalbumin (OVA)-induced allergic asthma." | 7.85 | Artemisia argyi attenuates airway inflammation in ovalbumin-induced asthmatic animals. ( Jeong, SH; Kim, HJ; Kim, JC; Ko, JW; Park, SH; Ryu, HW; Shin, IS; Shin, NR; Yuk, HJ, 2017) |
"Repeated inhalation of sevoflurane (SVF) can benefit asthmatic patients by bronchodilation." | 7.81 | Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation. ( Ding, PS; Fang, L; He, F; Liu, RY; Shen, QY; Wu, HM, 2015) |
"We have reported that triptolide inhibited pulmonary inflammation in patients with steroid-resistant asthma." | 7.81 | Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma. ( Chen, M; Huang, L; Jiang, S; Liang, R; Lin, X; Lv, Z; Shi, J; Zhang, W, 2015) |
"We used ovalbumin (OVA)-based mouse models of asthma and primary CD4(+) T cells." | 7.81 | PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. ( Al-Ghareeb, K; Al-Khami, AA; Boulares, AH; El-Bahrawy, AH; Ghonim, MA; Ibba, SV; Lammi, MR; Mansy, MS; Naura, AS; Ochoa, A; Pyakurel, K; Rady, HF; Ramsay, A; Rodriguez, P; Wang, J, 2015) |
"To explore the impact of ozone on the airway hyperresponsinveness (AHR), airway inflammation and mucus production in an allergic asthma mouse model." | 7.81 | [Effects of ozone oxidative stress on the airway hyperresponsiveness and mucus production in mice with acute allergic airway inflammation]. ( Aihua, B; Feng, L; Xin, Z; Yuqing, C; Zhang, M, 2015) |
"The flavonoid naringenin has been shown to attenuate airway inflammation and airway hyper‑reactivity in acute murine models of asthma." | 7.80 | Naringenin inhibits allergen‑induced airway remodeling in a murine model of asthma. ( Gu, W; Mao, S; Shi, Y; Tan, Y, 2014) |
" In this study, we evaluated the protective effects of EBM84 on asthmatic responses, particularly mucus hypersecretion in an ovalbumin (OVA)-induced murine model of asthma." | 7.79 | EBM84 attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma. ( Ha, H; Jeon, WY; Lee, MY; Seo, CS; Shin, IS; Shin, NR, 2013) |
"We investigated the suitability of dendritic polyglycerol sulfates (dPGS), conjugated with a hydrophilic version of the indocyanine green label with 6 sulfonate groups (6S-ICG) to monitor sites of inflammation using an experimental mouse model of allergic asthma." | 7.79 | Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model. ( Alves, F; Biffi, S; Bosnjak, B; Dal Monego, S; Dullin, C; Epstein, MM; Garrovo, C; Licha, K; Welker, P, 2013) |
" In this study, we intend to explore the role of PAR-1 in the process of thrombin-inducing transforming growth factor-β1 (TGF-β1) to promote airway remodeling in ovalbumin (OVA)-allergic rats." | 7.79 | Thrombin promotes airway remodeling via protease-activated receptor-1 and transforming growth factor-β1 in ovalbumin-allergic rats. ( Bi, M; Guo, A; Liu, Y; Lv, H; Pan, F; Qiu, L; Wang, P; Wang, Y; Yao, P; Zhang, N; Zhu, W, 2013) |
"Montelukast, a leukotriene receptor antagonist, is used commercially as a maintenance treatment for asthma and to relieve allergic symptoms." | 7.79 | Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma. ( Jeon, WY; Lee, MY; Shin, HK; Shin, IS, 2013) |
"Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." | 7.78 | Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012) |
" Female BALB/c mice sensitized and challenged with ovalbumin developed airway inflammation." | 7.78 | Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-κB. ( Cheng, C; Goh, FY; Guan, S; Leung, BP; Sethi, G; Shanmugam, MK; Upton, N; Wong, WS, 2012) |
"Evidence suggests that nebulized lidocaine is beneficial in asthma therapy, but to what extent and the mechanisms underlying this effect remain poorly understood." | 7.78 | Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. ( Anjos-Valotta, EA; Arantes, AC; Cordeiro, RS; Cotias, AC; Couto, GC; Ferreira, TP; Jurgilas, PB; Martins, MA; Olsen, PC; Pão, CR; Pires, AL; Serra, MF; Silva, PM, 2012) |
"Altered arginine metabolism, the uncoupling of nitric oxide synthase (NOS) by asymmetric dimethyl-arginine (ADMA), increased oxo-nitrosative stress, and cellular injury were reported in airway epithelial cells in asthma." | 7.77 | Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to asthma. ( Agrawal, A; Ahmad, T; Aich, J; Ghosh, B; Mabalirajan, U; Makhija, L; Sharma, A, 2011) |
"The purposes of this study were to determine whether curcumin inhibits NF-κB-dependent transcription in vitro, and test whether treatment with curcumin reduces allergen-induced airway inflammation and hyper-responsiveness in a mouse model of asthma through inhibition of NF-κB pathway." | 7.77 | Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-κB inhibition. ( Cha, JY; Chang, BC; Jung, JE; Kim, DY; Kwon, HJ; Lee, BR; Oh, SW, 2011) |
" This study aimed to evaluate the therapeutic availability of kefiran on the ovalbumin-induced asthma mouse model in which airway inflammation and airway hyper-responsiveness were found in the lung." | 7.74 | Inhibitory effect of kefiran on ovalbumin-induced lung inflammation in a murine model of asthma. ( Ahn, KS; Kim, MK; Kim, SY; Kwon, OK; Lee, HK; Lee, IY; Lee, MY; Oh, SR; Park, BY, 2008) |
"Sputum was collected from 12 asthmatics (26-73 year), lifelong non-smokers, at baseline, after eformoterol (24 mug) and after mannitol on each of four visits." | 7.74 | Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. ( Anderson, SD; Daviskas, E; Young, IH, 2007) |
"(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma." | 7.73 | Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005) |
"The effects of niflumic acid (NA), a relatively specific blocker of calcium-activated chloride channel (CLCA), on goblet cell hyperplasia, eosinophil accumulation, and airway hyperresponsiveness were evaluated after IL-13 instillation into the airways." | 7.73 | Niflumic acid suppresses interleukin-13-induced asthma phenotypes. ( Aizawa, H; Fukuyama, S; Inoue, H; Matsumoto, K; Matsumoto, T; Matsumura, M; Nakanishi, Y; Nakano, T; Tsuda, M, 2006) |
" As the lipoxygenase pathway is the only operant metabolic system available for arachidonic acid in the presence of aspirin and non-steroidal anti-inflammatory drugs--and as the nonsteroidal anti-inflammatory drugs themselves stimulate mucus production--it is possible that the mechanism responsible for mucus release in aspirin-sensitive asthmatics is the formation of these lipoxygenase products." | 7.66 | Possible mechanisms underlying mucus secretion in aspirin-sensitive asthma. ( Kaliner, M; Marom, Z, 1983) |
"Three patients suffering from severe, chronic, bronchial asthma underwent bronchoscopy and lavage, using in the irrigant fluid acetylcysteine, isoetharine and Solu-Medrol." | 7.66 | Status Asthmaticus: use of acetylcysteine during bronchoscopy and lavage to remove mucous plugs. ( Goldstein, IM; Goodman, AH; Millman, FM; Millman, M; Van Campen, SS, 1983) |
"Allergic asthma is a chronic respiratory disease caused by an inappropriate immune response." | 5.72 | Gekko gecko extract attenuates airway inflammation and mucus hypersecretion in a murine model of ovalbumin-induced asthma. ( Kim, JS; Lee, JH; Lee, S; Moon, BC; Nam, HH; Noh, P; Ryu, SM; Seo, YS; Yang, S, 2022) |
"Ovalbumin (OVA) was used as a stimulant to sensitize BALB/c mice to establish an asthmatic model." | 5.62 | Ding Chuan Tang Attenuates Airway Inflammation and Eosinophil Infiltration in Ovalbumin-Sensitized Asthmatic Mice. ( Chen, LC; Kuo, ML; Liu, MX; Ma, J; Shen, JJ, 2021) |
"Cordycepin (Cor), which is a naturally occurring nucleoside derivative isolated from Cordyceps militaris, has been shown to exert excellent antiinflammatory activity in a murine model of acute lung injury." | 5.42 | Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process. ( Deng, Y; He, Y; Li, T; Li, Y; Lin, R; Wang, W; Wei, J; Yang, X; Zhang, J, 2015) |
"Melatonin was administered by intraperitoneal injection once per day at doses of 10 and 15 mg/kg from days 21 to 23 after the initial OVA sensitization." | 5.40 | Melatonin reduces airway inflammation in ovalbumin-induced asthma. ( Ahn, KS; Jeon, CM; Kim, JC; Kim, JS; Kwon, OK; Oh, SR; Park, JW; Shin, IS; Shin, NR, 2014) |
"Allantoin treatment led to significant reduction in the levels of Ig(immunoglobulin)E and T-helper-2-type cytokines, such as IL(interleukin)-4 and IL-5, in bronchoalveolar lavage (BAL) fluid." | 5.36 | Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma. ( Jung, D; Kim, JH; Lee, H; Lee, JA; Lee, MY; Lee, NH; Seo, CS; Shin, HK, 2010) |
"This study evaluated substance P and neurokinin 1 protein expression and mucus content in endobronchial biopsy specimens from normal control subjects and asthmatic subjects." | 5.09 | Substance P and its receptor neurokinin 1 expression in asthmatic airways. ( Chu, HW; Kraft, M; Krause, JE; Martin, RJ; Rex, MD, 2000) |
"Ovalbumin (OVA) and BaP co-exposure were used to establish the aggravated asthma model." | 4.84 | Qufeng Xuanbi Formula inhibited benzo[a]pyrene-induced aggravated asthma airway mucus secretion by AhR/ROS/ERK pathway. ( Hu, J; Liu, CY; Liu, L; Shi, XL; Sun, XH; Tang, LL; Wang, BH; Wang, Y; Yang, Y; Yu, KY; Zhang, Q; Zhang, XN, 2024) |
" azedarach fruit extract (MAE) using high-performance liquid chromatography (HPLC) and explored the therapeutic effects of MAE on pulmonary inflammation and mucus hypersecretion using a murine model of ovalbumin (OVA) exposed asthma." | 4.84 | Melia azedarach L. reduces pulmonary inflammation and mucus hypersecretion on a murine model of ovalbumin exposed asthma. ( Kim, T; Kim, WI; Lee, IS; Lee, SJ; Pak, SW; Shin, IS; Yang, YG, 2024) |
"Azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-p hthalazinone hydrochloride), a novel long-acting antiasthmatic/antiallergic drug has been demonstrated to be effective in the treatment both of asthma and of allergic rhinitis." | 4.78 | Azelastine: a multifaceted drug for asthma therapy. ( Achterrath-Tuckermann, U; Minker, E; Paegelow, I; Schmidt, J; Szelenyi, I; Werner, H, 1991) |
" It seems likely that this eicosanoid-mucus secretion relationship is very important in all forms of asthma, but most particularly in aspirin-related asthma." | 4.77 | The role of eicosanoids in respiratory mucus hypersecretion. ( Kaliner, MA; Lundgren, JD; Shelhamer, JH, 1985) |
"Ovalbumin (OVA) and cold water-induced cold asthma model were established in male mice." | 4.12 | Processed product (Pinelliae Rhizoma Praeparatum) of Pinellia ternata (Thunb.) Breit. Alleviates the allergic airway inflammation of cold phlegm via regulation of PKC/EGFR/MAPK/PI3K-AKT signaling pathway. ( Chen, S; Cheng, Y; Li, J; Liu, H; Tao, X; Wang, C; Wang, H; Wu, H; Xia, J; Xie, Y; Yu, H; Zeng, P; Zhang, P; Zhang, X, 2022) |
"We established ovalbumin (OVA) induced asthmatic murine model and orally administrated Iristectorigenin A at concentration of 5 and 10 mg/kg and dexamethasone as a positive control substance." | 4.12 | Iristectorigenin A exerts novel protective properties against airway inflammation and mucus hypersecretion in OVA-induced asthmatic mice: Iristectorigenin A ameliorates asthma phenotype. ( Abduwaki, M; Cui, J; Dong, JC; Luo, Q; Lv, Y; Nabijan, M; Nurahmat, M; Qin, J; Tang, W; Teng, F; Wang, S; Wei, Y; Wuniqiemu, T; Zhou, Y; Zhu, X, 2022) |
" An ovalbumin (OVA)-induced mouse asthma model was established and the effect of acupuncture on airway hyperresponsiveness (AHR), mucus hypersecretion and inflammation was assessed." | 4.02 | TMT-based quantitative proteomics reveals suppression of SLC3A2 and ATP1A3 expression contributes to the inhibitory role of acupuncture on airway inflammation in an OVA-induced mouse asthma model. ( Cui, J; Dong, J; Dong, M; Qin, J; Tang, W; Teng, F; Wang, S; Wang, W; Wei, Y; Wuniqiemu, T; Zhu, X, 2021) |
"In this study, we investigated whether 4-hydroxycinnamic acid (HA) has a palliative effect on asthmatic inflammatory responses using a mouse model of ovalbumin (OVA)-induced allergic asthma." | 3.96 | 4-Hydroxycinnamic acid suppresses airway inflammation and mucus hypersecretion in allergic asthma induced by ovalbumin challenge. ( Choi, SJ; Kim, JC; Kim, MS; Kim, SH; Kim, YH; Ko, JW; Kwon, HJ; Seo, CS; Shin, IS; Shin, NR, 2020) |
"Fifty rats (25 males and 25 females) were divided randomly into the control group, ovalbumin asthmatic model group, asthma low-, middle- and high-dose groups (n = 10, 5 males and 5 females each group)." | 3.96 | Effect of NF-κB signal pathway on mucus secretion induced by atmospheric PM ( Liu, Y; Peng, L; Wang, H; Zhang, B; Zhang, T; Zhou, L, 2020) |
"In vivo, mice were sensitized and challenged by ovalbumin (OVA) to induce asthma." | 3.96 | Monocyte chemotactic protein-inducing protein 1 negatively regulating asthmatic airway inflammation and mucus hypersecretion involving γ-aminobutyric acid type A receptor signaling pathway in vivo and in vitro. ( Chen, ZH; Dai, GM; Deng, HJ; Mao, RL; Ran, YJ; Wang, JJ; Zhu, T, 2020) |
" In this study, we explored the suppressive effects of SAC on allergic airway inflammation induced in an ovalbumin (OVA)-induced asthma mouse model." | 3.91 | S-Allyl cysteine reduces eosinophilic airway inflammation and mucus overproduction on ovalbumin-induced allergic asthma model. ( Kim, JC; Kim, JS; Kim, SH; Ko, JW; Kwon, HJ; Lee, IC; Shin, IS; Shin, NR, 2019) |
"The purpose of this study is to explore the influence of ozone repeated short exposures on airway/lung inflammation, airway hyperresponsiveness (AHR) and airway hypersecretion in ovalbumin (OVA) sensitized/challenged asthmatic mouse model." | 3.88 | Effects of ozone repeated short exposures on the airway/lung inflammation, airway hyperresponsiveness and mucus production in a mouse model of ovalbumin-induced asthma. ( Bao, A; Bao, W; Fei, X; Zhang, M; Zhang, X; Zhang, Y; Zhou, X, 2018) |
"NK may be an effective alternative therapeutic option in patients with CRSwNP and comorbid asthma by causing fibrin degradation." | 3.85 | Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus. ( Fujieda, S; Imoto, Y; Ishizuka, T; Kato, Y; Narita, N; Sakashita, M; Takabayashi, T; Tokunaga, T; Yoshida, K, 2017) |
" This study aimed to evaluate the preventive activity of IMP in an ovalbumin (OVA)-induced murine model of asthma and to investigate its possible molecular mechanisms." | 3.85 | Isoimperatorin attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma. ( Kwon, HJ; Moon, OS; Park, HS; Seo, CS; Son, HY; Song, JW; Wijerathne, CUB; Won, YS, 2017) |
" This study evaluates whether intranasally delivered gas-filled microbubble (MB)-associated ovalbumin (OVA), used as a model allergen, can serve as a therapeutic treatment in a mouse model of established allergic asthma." | 3.85 | Therapeutic intranasal instillation of allergen-loaded microbubbles suppresses experimental allergic asthma in mice. ( Bioley, G; Corthésy, B, 2017) |
" In the current study, an ovalbumin (OVA)‑induced allergic asthma model was used to investigate the immune‑modulating effects of pidotimod on airway eosinophilia, mucus metaplasia and inflammatory factor expression compared with dexamethasone (positive control)." | 3.85 | Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma. ( Fu, AK; Fu, LQ; Hu, SL; Li, WF; Li, YL; Wang, YY; Wu, YP, 2017) |
" argyi (TOTAL) and dehydromatricarin A (DA), its active component on ovalbumin (OVA)-induced allergic asthma." | 3.85 | Artemisia argyi attenuates airway inflammation in ovalbumin-induced asthmatic animals. ( Jeong, SH; Kim, HJ; Kim, JC; Ko, JW; Park, SH; Ryu, HW; Shin, IS; Shin, NR; Yuk, HJ, 2017) |
"We sought to determine the effect of Ptx3 deletion on ovalbumin (OVA)-induced allergic inflammation in a murine model of asthma." | 3.85 | Pentraxin 3 deletion aggravates allergic inflammation through a T ( Almiski, MS; Balhara, J; Doeing, D; Gounni, AS; Halayko, AJ; Matzuk, MM; McConville, J; Muhuri, A; Shan, L; Zhang, J, 2017) |
" PRE treatment decreased mucus production in airway epithelium, inflammatory cell number, eosinophilia, type 2 cytokines, and histamine in bronchoalveolar lavage fluid (BALF)." | 3.85 | Reduced allergic lung inflammation by root extracts from two species of Peucedanum through inhibition of Th2 cell activation. ( Chun, JM; Gu, GJ; Kim, HS; Kwon, BI; Lee, AR; Lee, AY, 2017) |
" In addition, to investigate the effects of CuONPs on asthma development, we used a murine model of ovalbumin (OVA)-induced asthma." | 3.83 | Copper oxide nanoparticles aggravate airway inflammation and mucus production in asthmatic mice via MAPK signaling. ( Ahn, KS; Jeon, CM; Kim, JC; Ko, JW; Kwon, OK; Lee, IC; Oh, SR; Park, JW; Shin, IS; Shin, NR, 2016) |
" This study aimed to determine the possible effects and underlying mechanisms of Suhuang on chronic ovalbumin (OVA)-induced airway hyperresponsiveness (AHR), inflammation, and remodeling in mice." | 3.83 | Suhuang antitussive capsule at lower doses attenuates airway hyperresponsiveness, inflammation, and remodeling in a murine model of chronic asthma. ( Che, LQ; Chen, ZH; Lai, TW; Li, W; Shen, HH; Wang, HS; Wu, YF; Xiao, H; Ying, SM; Zhang, C; Zhang, LH, 2016) |
"Repeated inhalation of sevoflurane (SVF) can benefit asthmatic patients by bronchodilation." | 3.81 | Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation. ( Ding, PS; Fang, L; He, F; Liu, RY; Shen, QY; Wu, HM, 2015) |
"We have reported that triptolide inhibited pulmonary inflammation in patients with steroid-resistant asthma." | 3.81 | Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma. ( Chen, M; Huang, L; Jiang, S; Liang, R; Lin, X; Lv, Z; Shi, J; Zhang, W, 2015) |
"We used ovalbumin (OVA)-based mouse models of asthma and primary CD4(+) T cells." | 3.81 | PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. ( Al-Ghareeb, K; Al-Khami, AA; Boulares, AH; El-Bahrawy, AH; Ghonim, MA; Ibba, SV; Lammi, MR; Mansy, MS; Naura, AS; Ochoa, A; Pyakurel, K; Rady, HF; Ramsay, A; Rodriguez, P; Wang, J, 2015) |
"To explore the impact of ozone on the airway hyperresponsinveness (AHR), airway inflammation and mucus production in an allergic asthma mouse model." | 3.81 | [Effects of ozone oxidative stress on the airway hyperresponsiveness and mucus production in mice with acute allergic airway inflammation]. ( Aihua, B; Feng, L; Xin, Z; Yuqing, C; Zhang, M, 2015) |
"The flavonoid naringenin has been shown to attenuate airway inflammation and airway hyper‑reactivity in acute murine models of asthma." | 3.80 | Naringenin inhibits allergen‑induced airway remodeling in a murine model of asthma. ( Gu, W; Mao, S; Shi, Y; Tan, Y, 2014) |
" In this study, we investigated the protective effects of SG extract on allergic asthma in an ovalbumin (OVA)-induced asthma murine model and lipopolysaccharide (LPS)-stimulated RAW264." | 3.80 | Siegesbeckia glabrescens attenuates allergic airway inflammation in LPS-stimulated RAW 264.7 cells and OVA induced asthma murine model. ( Ahn, KS; Hong, JM; Jeon, CM; Kim, HS; Kwon, OK; Myung, PK; Oh, SR; Shin, IS; Shin, NR, 2014) |
" In this study, we evaluated the protective effects of EBM84 on asthmatic responses, particularly mucus hypersecretion in an ovalbumin (OVA)-induced murine model of asthma." | 3.79 | EBM84 attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma. ( Ha, H; Jeon, WY; Lee, MY; Seo, CS; Shin, IS; Shin, NR, 2013) |
"We investigated the suitability of dendritic polyglycerol sulfates (dPGS), conjugated with a hydrophilic version of the indocyanine green label with 6 sulfonate groups (6S-ICG) to monitor sites of inflammation using an experimental mouse model of allergic asthma." | 3.79 | Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model. ( Alves, F; Biffi, S; Bosnjak, B; Dal Monego, S; Dullin, C; Epstein, MM; Garrovo, C; Licha, K; Welker, P, 2013) |
"In the OVA-exposed mice for 6 wks inflammatory cells infiltration, levels of inflammatory cytokines and chemokines, goblet cell metaplasia, collagen deposition and AHR were significantly decreased by treatment with AR inhibitor, fidarestat." | 3.79 | Aldose reductase inhibition prevents allergic airway remodeling through PI3K/AKT/GSK3β pathway in mice. ( Aguilera-Aguirre, L; Boldogh, I; Boulares, HA; Calhoun, WJ; Naura, AS; Ramana, KV; Srivastava, SK; Yadav, UC, 2013) |
" In this study, we intend to explore the role of PAR-1 in the process of thrombin-inducing transforming growth factor-β1 (TGF-β1) to promote airway remodeling in ovalbumin (OVA)-allergic rats." | 3.79 | Thrombin promotes airway remodeling via protease-activated receptor-1 and transforming growth factor-β1 in ovalbumin-allergic rats. ( Bi, M; Guo, A; Liu, Y; Lv, H; Pan, F; Qiu, L; Wang, P; Wang, Y; Yao, P; Zhang, N; Zhu, W, 2013) |
"Montelukast, a leukotriene receptor antagonist, is used commercially as a maintenance treatment for asthma and to relieve allergic symptoms." | 3.79 | Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma. ( Jeon, WY; Lee, MY; Shin, HK; Shin, IS, 2013) |
"Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." | 3.78 | Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012) |
" Female BALB/c mice sensitized and challenged with ovalbumin developed airway inflammation." | 3.78 | Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-κB. ( Cheng, C; Goh, FY; Guan, S; Leung, BP; Sethi, G; Shanmugam, MK; Upton, N; Wong, WS, 2012) |
"Evidence suggests that nebulized lidocaine is beneficial in asthma therapy, but to what extent and the mechanisms underlying this effect remain poorly understood." | 3.78 | Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. ( Anjos-Valotta, EA; Arantes, AC; Cordeiro, RS; Cotias, AC; Couto, GC; Ferreira, TP; Jurgilas, PB; Martins, MA; Olsen, PC; Pão, CR; Pires, AL; Serra, MF; Silva, PM, 2012) |
"Altered arginine metabolism, the uncoupling of nitric oxide synthase (NOS) by asymmetric dimethyl-arginine (ADMA), increased oxo-nitrosative stress, and cellular injury were reported in airway epithelial cells in asthma." | 3.77 | Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to asthma. ( Agrawal, A; Ahmad, T; Aich, J; Ghosh, B; Mabalirajan, U; Makhija, L; Sharma, A, 2011) |
"In the present study, we investigated whether the Lagerstroemia indica Linn (LI) extract has an anti-inflammatory effect on lung inflammation in ovalbumin-induced asthmatic mice." | 3.77 | Anti-inflammatory effects of ethanolic extract from Lagerstroemia indica on airway inflammation in mice. ( Kim, DH; Kim, IS; Lee, JS; Song, BB; Yang, EJ; Yun, CY, 2011) |
"The purposes of this study were to determine whether curcumin inhibits NF-κB-dependent transcription in vitro, and test whether treatment with curcumin reduces allergen-induced airway inflammation and hyper-responsiveness in a mouse model of asthma through inhibition of NF-κB pathway." | 3.77 | Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-κB inhibition. ( Cha, JY; Chang, BC; Jung, JE; Kim, DY; Kwon, HJ; Lee, BR; Oh, SW, 2011) |
" Becker (VM) ethanolic (EtOH) extract in the treatment of bronchial asthma in an ovalbumin (OVA)-induced asthmatic BALB/c mouse model." | 3.76 | Anti-inflammatory and anti-asthmatic effects of Viola mandshurica W. Becker (VM) ethanolic (EtOH) extract on airway inflammation in a mouse model of allergic asthma. ( Ahn, KS; Kim, HS; Kwon, OK; Lee, HK; Lee, MY; Oh, SR; Yuk, JE, 2010) |
"The effect of PET was investigated in ovalbumin (OVA) immunized BALB/c mice given intranasally together with antigen challenge in the murine model of allergic airway disease (asthma) with the analysis of the inflammatory and immune parameters in the lung." | 3.76 | Petasites extract Ze 339 (PET) inhibits allergen-induced Th2 responses, airway inflammation and airway hyperreactivity in mice. ( Brattström, A; Maillet, I; Moser, R; Ryffel, B; Schapowal, A; Schnyder, B, 2010) |
" The data showed that chronic SJ infection suppressed airway eosinophilia, mucus production and antigen-specific IgE responses induced by ovalbumin (OVA) sensitization and challenge." | 3.76 | Helminth infection inhibits airway allergic reaction and dendritic cells are involved in the modulation process. ( An, G; Gao, W; Ji, W; Li, J; Liu, P; Liu, X; Shen, Y; Wang, S; Wu, Z; Yang, X; Zhu, Y, 2010) |
"ITE obtained from leaves by supercritical carbon dioxide extraction was investigated in ovalbumin (OVA) immunised BALB/c mice given intranasally together with antigen challenge in the murine model of allergic airway disease (asthma) with the analysis of the inflammatory and immune parameters in the lung." | 3.76 | The plant extract Isatis tinctoria L. extract (ITE) inhibits allergen-induced airway inflammation and hyperreactivity in mice. ( Brattström, A; Kamal, MA; Maillet, I; Moser, R; Ryffel, B; Schapowal, A, 2010) |
"Theophylline can increase the transepithelial secretion of fluid into the respiratory tract lumen by stimulating the chloride pump which is controlled by cyclic AMP." | 3.76 | Theophylline and mucociliary clearance. ( Ziment, I, 1987) |
") inhibited the number of coughs induced by capsaicin aerosol (P<0." | 3.74 | Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs. ( Kuraya, T; Morimoto, K; Nosaka, E; Takahashi, S; Tsuchida, H; Yamashita, M, 2008) |
" This study aimed to evaluate the therapeutic availability of kefiran on the ovalbumin-induced asthma mouse model in which airway inflammation and airway hyper-responsiveness were found in the lung." | 3.74 | Inhibitory effect of kefiran on ovalbumin-induced lung inflammation in a murine model of asthma. ( Ahn, KS; Kim, MK; Kim, SY; Kwon, OK; Lee, HK; Lee, IY; Lee, MY; Oh, SR; Park, BY, 2008) |
" The expression of GAD in the cytosol and GABAARs in the apical membranes of airway epithelial cells increased markedly when mice were sensitized and then challenged with ovalbumin, an approach for inducing allergic asthmatic reactions." | 3.74 | A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. ( Fan, Y; Hirota, JA; Inman, MD; Ju, W; Kelly, MM; Li, J; Liu, M; Lu, WY; O'Byrne, PM; Orser, B; Wang, S; Xiang, YY; Yang, X; Ye, B, 2007) |
" In order to investigate the pharmacological effects of kefir, we used a mouse asthma model, in which airway inflammation and airway remodeling was produced by ovalbumin sensitization and challenge." | 3.74 | Anti-inflammatory and anti-allergic effects of kefir in a mouse asthma model. ( Ahn, KS; Kim, MJ; Kim, MK; Kwon, OK; Lee, HK; Lee, IY; Lee, MY; Oh, SR, 2007) |
"Sputum was collected from 12 asthmatics (26-73 year), lifelong non-smokers, at baseline, after eformoterol (24 mug) and after mannitol on each of four visits." | 3.74 | Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. ( Anderson, SD; Daviskas, E; Young, IH, 2007) |
"(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma." | 3.73 | Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005) |
"The effects of niflumic acid (NA), a relatively specific blocker of calcium-activated chloride channel (CLCA), on goblet cell hyperplasia, eosinophil accumulation, and airway hyperresponsiveness were evaluated after IL-13 instillation into the airways." | 3.73 | Niflumic acid suppresses interleukin-13-induced asthma phenotypes. ( Aizawa, H; Fukuyama, S; Inoue, H; Matsumoto, K; Matsumoto, T; Matsumura, M; Nakanishi, Y; Nakano, T; Tsuda, M, 2006) |
"An asthma model was sensitized and challenged by ovalbumin (OVA) in male C57BL/6 mice." | 3.73 | CCR3 monoclonal antibody inhibits airway eosinophilic inflammation and mucus overproduction in a mouse model of asthma. ( Shen, HH; Wang, SB; Xu, F; Xu, WH; Zhang, GS, 2006) |
"Twenty-four BALB/c mice were randomly divided into 3 equal groups: asthma group [ovalbumin (OVA) and aluminum hydroxide were injected intraperitoneally on day 0 and day 14 so as to establish mouse asthma model and aerosol inhalation of OVA PBS was conducted for 30 min on the days 21, 22, and 24], asthma + dexamethasone group (OVA and aluminum hydroxide were injected intraperitoneally on days 0 and 14, aerosol inhalation of OVA PBS was conducted for 30 min on the days 21, 22, and 24, and dexamethasone was injected intraperitoneally 1 hour before the aerosol inhalation), and control group (aerosol inhalation of PBS was conducted instead)." | 3.73 | [Effects of glucocorticoid on airway mucus secretion in asthma: experiment with asthmatic mouse model]. ( Liu, JB; Xing, LH; Xu, YJ; Zhang, HL; Zhang, ZX, 2006) |
" To clarify the effects of DE on the exacerbation of asthma, guinea pigs were exposed 12 h daily to 3 mg/m(3) DE or air for 8 wk with or without sensitization to ovalbumin (OVA)." | 3.71 | Exposure to diesel exhaust exacerbates allergen-induced airway responses in guinea pigs. ( Hashimoto, K; Hirano, K; Ishii, Y; Kimura, T; Masuyama, K; Morishima, Y; Nomura, A; Sagai, M; Sakamoto, T; Sekizawa, K; Takano, H; Uchida, Y, 2001) |
" To elucidate whether heparin affects goblet cell secretion in asthmatic airways and, if so, what the mechanism of action is, we studied guinea pigs sensitized with ovalbumin (OVA) by determining the mucus score (MS) of tracheal goblet cells stained with Alcian blue and PAS." | 3.70 | [Effect of heparin on airway goblet cell secretion in sensitized guinea pigs]. ( Kondo, M; Nagai, A; Nakata, J; Takeda, Y; Takeyama, K; Tamaoki, J; Yamawaki, I, 1998) |
"The ovalbumin-sensitized guinea pig is commonly used as a small animal model of allergic asthma." | 3.69 | Effect of dexamethasone on antigen-induced high molecular weight glycoconjugate secretion in allergic guinea pigs. ( Boulet, L; Chan, CC; Plant, M; Pon, DJ; Rodger, IW; Savoie, C; van Staden, CJ; Zwikker, M, 1995) |
"To determine whether markers of mucus secretion can be quantified in airway lining fluid from asthmatic and from healthy subjects, we measured levels of a mucin-like glycoprotein (MLG) and lactoferrin in sputum induced by inhalation of hypertonic (3%) saline in 18 asthmatic and in 10 healthy subjects." | 3.68 | Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects. ( Basbaum, CB; Boushey, HA; Fahy, JV; Finkbeiner, WE; Liu, J; Steiger, DJ, 1993) |
"Nasal mucociliary clearance was measured using a saccharin technique in 172 patients with perennial rhinitis (76 also had asthma) and in 121 patients with chronic infected rhinosinusitis (40 had asthma, 35 had bronchiectasis)." | 3.67 | Abnormal nasal mucociliary clearance in patients with rhinitis and its relationship to concomitant chest disease. ( Cole, PJ; Greenstone, MA; Mackay, IS; Stanley, PJ; Wilson, R, 1985) |
" As the lipoxygenase pathway is the only operant metabolic system available for arachidonic acid in the presence of aspirin and non-steroidal anti-inflammatory drugs--and as the nonsteroidal anti-inflammatory drugs themselves stimulate mucus production--it is possible that the mechanism responsible for mucus release in aspirin-sensitive asthmatics is the formation of these lipoxygenase products." | 3.66 | Possible mechanisms underlying mucus secretion in aspirin-sensitive asthma. ( Kaliner, M; Marom, Z, 1983) |
"Three patients suffering from severe, chronic, bronchial asthma underwent bronchoscopy and lavage, using in the irrigant fluid acetylcysteine, isoetharine and Solu-Medrol." | 3.66 | Status Asthmaticus: use of acetylcysteine during bronchoscopy and lavage to remove mucous plugs. ( Goldstein, IM; Goodman, AH; Millman, FM; Millman, M; Van Campen, SS, 1983) |
"A 14-year-old boy with severe asthma was treated with prednisone and disodium cromoglycate with considerable subjective improvement, though there was persistent airways obstruction." | 3.65 | Sudden death in a young asthmatic. ( Batten, J; Gregg, I, 1969) |
"Neutrophilic inflammation is believed to contribute to the airway obstruction and remodelling in equine asthma." | 2.90 | Randomised study of the immunomodulatory effects of azithromycin in severely asthmatic horses. ( Bédard, C; Hélie, P; Labrecque, O; Lavoie, JP; Mainguy-Seers, S; Vargas, A, 2019) |
"Among these, COPD is more prominent worldwide." | 2.82 | Nanocarrier-based approaches to combat chronic obstructive pulmonary disease. ( Kumar, G; Pathak, K; Sharma, A; Virmani, R; Virmani, T, 2022) |
"Chronic cough is a common problem of various etiologies." | 2.79 | The assessment and management of chronic cough in children according to the British Thoracic Society guidelines: descriptive, prospective, clinical trial. ( Asilsoy, S; Durmaz, C; Usta Guc, B, 2014) |
"Allergic bronchial asthma is a chronic disease of the airways that is characterized by symptoms like respiratory distress, chest tightness, wheezing, productive cough, and acute episodes of broncho-obstruction." | 2.66 | More Than Just a Barrier: The Immune Functions of the Airway Epithelium in Asthma Pathogenesis. ( Ehlers, JC; Frey, A; Lunding, LP; Weckmann, M; Wegmann, M; Zissler, UM, 2020) |
"Asthma, chronic obstructive pulmonary disease, and cystic fibrosis are three chronic pulmonary diseases that affect an estimated 420 million individuals across the globe." | 2.58 | Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases. ( Breitzig, MT; Kolliputi, N; Lockey, RF; Saco, TV, 2018) |
"In asthma and chronic obstructive pulmonary disease (COPD), airway mucus hypersecretion contributes to impaired mucociliary clearance, mucostasis and, potentially, the development of mucus plugging of the airways." | 2.53 | Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases. ( Ha, EV; Rogers, DF, 2016) |
"The hallmark traits of chronic obstructive airway diseases are inflammation, airway constriction due to hyperreactivity and mucus overproduction." | 2.52 | CLCA1 and TMEM16A: the link towards a potential cure for airway diseases. ( Brett, TJ, 2015) |
"The term phenotype in the field of COPD is defined as "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes"." | 2.48 | Clinical phenotypes of COPD: identification, definition and implications for guidelines. ( Calle, M; Miravitlles, M; Soler-Cataluña, JJ, 2012) |
"Although cough is one of the defining symptoms of asthma, wheeze, chest tightness and breathlessness have generally received more attention." | 2.46 | Interrupting the cough reflex in asthma. ( Smith, JA, 2010) |
"Chronic bronchitis is characterized by mucus hypersecretion." | 2.37 | The pathology of obstructive and inflammatory airway diseases. ( Reid, LM, 1986) |
"Occasionally, segmental or subsegmental atelectasis develops, but in most series radiographically visible atelectasis is uncommon." | 2.37 | Clinical aspects of mucus and mucous plugging in asthma. ( Fanta, CH, 1985) |
"IL-13 develops bronchial asthma by elevating bronchial hyperresponsiveness and enables production of immunoglobulin M (IgM) and IgE." | 1.72 | High throughput virtual screening strategy to develop a potential treatment for bronchial asthma by targeting interleukin 13 cytokine signaling. ( Jing, J; Ma, Q; Tong, H, 2022) |
"Allergic asthma is a chronic respiratory disease caused by an inappropriate immune response." | 1.72 | Gekko gecko extract attenuates airway inflammation and mucus hypersecretion in a murine model of ovalbumin-induced asthma. ( Kim, JS; Lee, JH; Lee, S; Moon, BC; Nam, HH; Noh, P; Ryu, SM; Seo, YS; Yang, S, 2022) |
"Ovalbumin (OVA) was used as a stimulant to sensitize BALB/c mice to establish an asthmatic model." | 1.62 | Ding Chuan Tang Attenuates Airway Inflammation and Eosinophil Infiltration in Ovalbumin-Sensitized Asthmatic Mice. ( Chen, LC; Kuo, ML; Liu, MX; Ma, J; Shen, JJ, 2021) |
"Tectochrysin treatment reduced the level of IgE in plasma, the percentage of eosinophils in total white blood cells in peripheral blood, the total number of cells in BAL fluid, and eosinophil peroxidase activity in lung tissues." | 1.62 | Tectochrysin ameliorates murine allergic airway inflammation by suppressing Th2 response and oxidative stress. ( Fang, L; He, Z; Jiang, X; Wu, F; Xu, Z; Yan, Y; Yu, D; Yuan, X; Zhang, T; Zhou, S, 2021) |
"The percentages of airway obstruction due to mucus plugs were notably higher in the fourth- and fifth-generation bronchi (17." | 1.56 | Changes in airway diameter and mucus plugs in patients with asthma exacerbation. ( Kurashima, K; Nakamoto, Y; Takaku, Y; Takayanagi, N; Takizawa, H; Yanagisawa, T; Yoshida, Y, 2020) |
"Dithiothreitol and P3001 were directly compared with NAC in vitro and both exhibited superior reducing activities." | 1.51 | An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. ( Boucher, RC; Delion, MF; Donaldson, SH; Ehre, C; Esther, CR; Fontana, NC; Grubb, BR; Hill, DB; Hothem, LN; Kato, T; Livraghi-Butrico, A; Markovetz, MR; Morrison, CB; Rushton, ZL; Thelin, WR; Villalon, D; Wang, B, 2019) |
"Pneumocystis associates to more severe Chronic Obstructive Pulmonary Disease (COPD), asthma, respiratory distress of premature newborns, and is a consistent subclinical infection between 2 and 5 months of age when hospitalizations for respiratory cause and infant mortality are higher." | 1.51 | Increase in secreted airway mucins and partial Muc5b STAT6/FoxA2 regulation during Pneumocystis primary infection. ( Bórquez, P; Bustamante, R; Gallo, M; Iturra, PA; Méndez, A; Ponce, CA; Rojas, DA; Vargas, SL, 2019) |
"Mucus plugs are a plausible mechanism of chronic airflow obstruction in severe asthma, and EPO-generated oxidants may mediate mucus plug formation." | 1.48 | Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. ( Bleecker, ER; Castro, M; Di Maio, S; Dunican, EM; Elicker, BM; Erzurum, SC; Fahy, JV; Fain, SB; Gierada, DS; Gordon, ED; Hoffman, EA; Israel, E; Jarjour, NN; Lachowicz-Scroggins, ME; Levy, BD; Mauger, DT; Meyers, DA; Nagle, SK; Newell, JD; Peters, MC; Phillips, BR; Raymond, WW; Schiebler, ML; Wenzel, SE; Woodruff, PG, 2018) |
"Daily cough was recorded in 28." | 1.48 | Mucus hypersecretion in asthma is associated with rhinosinusitis, polyps and exacerbations. ( Crespo, A; García-Rivero, JL; López-Viña, A; Marina-Malanda, N; Martínez-Rivera, C; Mayoralas-Alises, S; Padilla, A; Pallarés-Sanmartín, A; Pascual-Erquicia, S; Picado, C; Pinedo-Sierra, C; Plaza, V, 2018) |
"Casticin is an active compound that possesses broad biological activities including anti-inflammatory effect." | 1.48 | Casticin alleviates lipopolysaccharide-induced inflammatory responses and expression of mucus and extracellular matrix in human airway epithelial cells through Nrf2/Keap1 and NF-κB pathways. ( Wang, J, 2018) |
"TAS2R agonists attenuated features of airway remodeling including smooth muscle mass, extracellular matrix deposition and pro-fibrotic signaling, and also prevented mucus accumulation and development of AHR in mice." | 1.46 | Bitter Taste Receptor Agonists Mitigate Features of Allergic Asthma in Mice. ( Deshpande, DA; Knight, MJ; Nayak, AP; Oliver, B; Pan, S; Sharma, P; Tang, F; Wang, N; Yi, R, 2017) |
"①In 2014, the acute attacks of bronchial asthma were (1." | 1.46 | [Clinical therapeutic effect on bronchial asthma in children of different body constitutions treated with ( Deng, Y; Shi, Y; Tang, M; Wang, P; Yang, H; Zhang, L, 2017) |
"Mice lacking the endogenous β2-adrenoceptor (β2AR) agonist epinephrine (phenylethanolamine N-methyltransferase [PNMT]-knockout mice) are resistant to developing an "asthma-like" phenotype in an ovalbumin sensitization and challenge (Ova S/C) model, and chronic administration of β2AR agonists to PNMT-KO mice restores the phenotype." | 1.43 | Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice. ( Al-Sawalha, N; Bond, RA; Forkuo, GS; Gonnella, PA; Joshi, R; Kim, H; Knoll, BJ; Parra, S; Penn, RB; Pera, T; Thanawala, VJ; Valdez, D; Walker, JK, 2016) |
"Cordycepin (Cor), which is a naturally occurring nucleoside derivative isolated from Cordyceps militaris, has been shown to exert excellent antiinflammatory activity in a murine model of acute lung injury." | 1.42 | Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process. ( Deng, Y; He, Y; Li, T; Li, Y; Lin, R; Wang, W; Wei, J; Yang, X; Zhang, J, 2015) |
"We used a murine model of respiratory allergy to the mite Blomia tropicalis (Bt) and evaluated certain parameters known to be altered in this model." | 1.42 | The anti-allergic activity of Cymbopogon citratus is mediated via inhibition of nuclear factor kappa B (Nf-Κb) activation. ( Alcântara-Neves, NM; Alves de Souza, S; da Silva Velozo, E; Ferreira Silva, HB; Figueiredo, CA; Meneses Souza, FL; Pires de Oliveira, A; Pontes-de-Carvalho, LC; Rios, R; Santos Alves, W; Santos Costa, R; Santos Serafim Machado, M; Sarmento Silva, TM; Silva, ML; Vilany Queiroz Carneiro, N, 2015) |
"Sesamin is a natural polyphenolic compound with strong anti-oxidative effects." | 1.40 | Protective effects of the polyphenol sesamin on allergen-induced T(H)2 responses and airway inflammation in mice. ( Kao, ST; Lee, CC; Lin, CH; Shen, ML; Wu, DC; Zhou, N, 2014) |
"Melatonin was administered by intraperitoneal injection once per day at doses of 10 and 15 mg/kg from days 21 to 23 after the initial OVA sensitization." | 1.40 | Melatonin reduces airway inflammation in ovalbumin-induced asthma. ( Ahn, KS; Jeon, CM; Kim, JC; Kim, JS; Kwon, OK; Oh, SR; Park, JW; Shin, IS; Shin, NR, 2014) |
"Additionally, acute respiratory infections did not affect the microbiological colonization in asthmatics' airways (P = 0." | 1.40 | No direct association between asthma and the microbiome based on currently available techniques. ( Yayan, J, 2014) |
"Inflammation was assessed by the total and differential cell counts and IL-4 and IL-5 levels in bronchoalveolar lavage (BAL) fluid." | 1.38 | The AGC kinase inhibitor H89 attenuates airway inflammation in mouse models of asthma. ( Daubeuf, F; Frossard, N; Nemska, S; Reber, LL, 2012) |
"Allantoin treatment led to significant reduction in the levels of Ig(immunoglobulin)E and T-helper-2-type cytokines, such as IL(interleukin)-4 and IL-5, in bronchoalveolar lavage (BAL) fluid." | 1.36 | Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma. ( Jung, D; Kim, JH; Lee, H; Lee, JA; Lee, MY; Lee, NH; Seo, CS; Shin, HK, 2010) |
" Smoking and asthma were risk factors for CMH, with a dose-response effect of tobacco consumption, and smoking habits also predicting incidence of CMH." | 1.36 | Chronic mucus hypersecretion: prevalence and risk factors in younger individuals. ( Backer, V; Harmsen, L; Ingebrigtsen, T; Kyvik, KO; Skadhauge, LR; Steffensen, IE; Thomsen, SF, 2010) |
"In both asthma and COPD mouse models, pendrin was up-regulated at the apical side of airway epithelial cells in association with mucus overproduction." | 1.35 | Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease. ( Aizawa, H; Arima, K; Fukuda, T; Green, ED; Hasegawa, M; Hayashi, H; Hoshino, T; Inoue, H; Inoue, M; Izuhara, K; Kanaji, S; Kubo, H; Matsushita, H; Nagai, H; Nakao, I; Nakayama, K; Ohta, S; Okinami, S; Sagara, H; Shiraki, A; Sugiyama, K; Suzuki, K; Tanaka, H; Toda, S; Watanabe, M; Yamaya, M; Yuyama, N, 2008) |
"To evaluate lung inflammation, mucus metaplasia and AHR in relationship with age in murine models of allergic asthma comparing young and older mice." | 1.34 | Effect of ageing on pulmonary inflammation, airway hyperresponsiveness and T and B cell responses in antigen-sensitized and -challenged mice. ( Busse, PJ; Li, XM; Schofield, B; Srivastava, K; Zhang, TF, 2007) |
"Guaifenesin is a commonly used expectorant whose use may lead to the occasional formation of guaifenesin urinary stones." | 1.33 | Spontaneous dissolution of a guaifenesin stone. ( Fallon, B; Nguyen, TT; Winfield, HN, 2005) |
" Inhalation of aerosolized p38alpha-ASO using an aerosol chamber dosing system produced measurable lung deposition of ASO and significant reduction of ovalbumin (OVA-)-induced increases in total cells, eosinophils, and interleukin 4 (IL-4), IL-5, and IL-13 levels in bronchoalveolar lavage fluid, and dose-dependent inhibition of airway hyperresponsiveness in allergen-challenged mice." | 1.33 | Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. ( Chan, JH; Choo, HH; Crosby, JR; Duan, W; Karras, JG; Leung, BP; McKay, K; Wong, WS, 2005) |
" In the present study, we have investigated the effect of a therapeutic dosing regimen with an anti-IL-13 monoclonal antibody (mAb) in a chronic mouse model of persistent asthma." | 1.33 | Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. ( Bugelski, PJ; Das, AM; Emmell, E; Giles-Komar, J; Griswold, DE; Lakshminarayanan, M; Li, L; Petley, T; Rafferty, P; Volk, A; Yang, G, 2005) |
"Treatment was administered therapeutically, with dosing starting after the onset of established eosinophilic airway inflammation and hyper-reactivity." | 1.33 | Therapeutic administration of Budesonide ameliorates allergen-induced airway remodelling. ( Lloyd, CM; McMillan, SJ; Xanthou, G, 2005) |
"Based on time from onset of symptoms to death, cases fell into two distinct groups: short course <3 (1." | 1.33 | Time to death, airway wall inflammation and remodelling in fatal asthma. ( Abramson, MJ; Elliot, JG; James, AL; Walters, EH, 2005) |
"Airway eosinophilia was observed during both responses." | 1.33 | Effect of disodium cromoglycate on airway mucus secretion during antigen-induced late asthmatic responses in a murine model of asthma. ( Arakawa, H; Koyama, H; Mayuzumi, H; Mizuno, T; Mochizuki, H; Morikawa, A; Nishimura, H; Ohki, Y; Tokuyama, K, 2005) |
"Human bronchial asthma is characterized by airway hyperresponsiveness (AHR), eosinophilic airway inflammation, mucus hypersecretion and high serum level of IgE." | 1.33 | Contribution of IL-18-induced innate T cell activation to airway inflammation with mucus hypersecretion and airway hyperresponsiveness. ( Ishikawa, Y; Nakanishi, K; Yoshimoto, T, 2006) |
"This is the first evidence that autoimmune diabetes-prone NOD mice can also give rise to enhanced Th2-mediated responses and might thus provide a useful model for the study of common genetic and cellular components, including NKT cells that contribute to both asthma and type 1 diabetes." | 1.32 | Exacerbated Th2-mediated airway inflammation and hyperresponsiveness in autoimmune diabetes-prone NOD mice: a critical role for CD1d-dependent NKT cells. ( Araujo, LM; Bach, JF; Diem, S; Dy, M; Herbelin, A; Lefort, J; Leite-de-Moraes, MC; Nahori, MA; Vargaftig, BB; Zhu, R, 2004) |
"One hundred and two COPD patients and 183 controls, together with 46 asthma patients and 48 patients with chronic mucous hypersecretion (CMH) were examined." | 1.32 | Association of vitamin D binding protein variants with chronic mucus hypersecretion in Iceland. ( Andrason, H; Gislason, T; Gulcher, JR; Hakonarson, H; Halapi, E; Jónasson, K; Laufs, J; Sigvaldason, A; Söebech, E; Stefansson, K; Thorsteinsson, L, 2004) |
"These findings suggest that bronchial asthma with mucoid impactions is among several pathogeneses that cause increased levels of CEA in serum and BALF." | 1.32 | [Concentrations of carcinoembryonic antigen in serum and bronchoalveolar lavage fluid of asthmatic patients with mucoid impaction]. ( Fukui, Y; Harada, T; Hizawa, N; Kikuchi, E; Maeda, Y; Nagai, K; Nishimura, M; Suko, N; Takahashi, D, 2004) |
"Plastic bronchitis was observed in 44 years old man, who expectorated white, branching, bronchial casts for three months." | 1.31 | [Plastic bronchitis and mucoid impaction--uncommon disease syndromes with expectoration mucus plugs]. ( Bestry, I; Pirozynski, M; Płodziszewska, M; Rowińska-Zakrzewska, E; Sledziewska, J; Wiatr, E; Załeska, J; Załeska, M, 2001) |
"We encountered a patient with bronchial asthma and mucoid impaction who presented with a high concentration of carcinoembryonic antigen (CEA) in serum." | 1.30 | [A patient with bronchial asthma and mucoid impaction who presented with a high concentration of carcinoembryonic antigen in serum]. ( Araki, M; Hiraki, S; Matsuo, K; Watanabe, Y, 1997) |
"Eosinophilia was abolished, yet mucus staining in the epithelium persisted." | 1.30 | Th2-induced airway mucus production is dependent on IL-4Ralpha, but not on eosinophils. ( Bottomly, K; Brombacher, F; Cohn, L; Homer, RJ; MacLeod, H; Mohrs, M, 1999) |
"These results show that in bronchial asthma patients, mucus hypersecretion is more often observed clinically in those with SDIA and in women, and that this hypersecretion is closely correlated with BAL eosinophilia, which is a feature of the pathophysiological changes that occur in the airways of these patients." | 1.29 | Mucus hypersecretion and eosinophils in bronchoalveolar lavage fluid in adult patients with bronchial asthma. ( Kimura, I; Kitani, H; Mifune, T; Mitsunobu, F; Okazaki, M; Tanizaki, Y, 1993) |
"Fifty patients with bronchial asthma were divided into four groups according to the amount of expectoration per day: 0-24, 25-49, 50-99 and 100+ ml/day." | 1.29 | [Clinical features of bronchial asthma with mucus hypersecretion]. ( Kimura, I; Kitani, H; Mifune, T; Mitsunobu, F; Okazaki, M; Soda, R; Tada, S; Takahashi, K; Tanizaki, Y, 1993) |
"Eosinophilia was associated with asthma and with phlegm production." | 1.28 | Asthma, hay fever, and phlegm production associated with distinct patterns of allergy skin test reactivity, eosinophilia, and serum IgE levels. The Normative Aging Study. ( O'Connor, GT; Sparrow, D; Tollerud, DJ; Weiss, ST, 1991) |
"Cough was due to one condition in 73%, two in 23%, and three in 3%." | 1.28 | Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. ( Curley, FJ; French, CL; Irwin, RS, 1990) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 211 (29.93) | 18.7374 |
1990's | 60 (8.51) | 18.2507 |
2000's | 171 (24.26) | 29.6817 |
2010's | 191 (27.09) | 24.3611 |
2020's | 72 (10.21) | 2.80 |
Authors | Studies |
---|---|
Ma, Q | 1 |
Tong, H | 1 |
Jing, J | 1 |
Dhar, R | 1 |
SCHILLER, IW | 1 |
MICHELSON, AL | 1 |
FRIEDMAN, S | 1 |
KARLIN, H | 1 |
LEVY, DL | 1 |
UNGER, DL | 3 |
TOWNLEY, RG | 1 |
BRONSTEIN, SB | 1 |
LEVIN, SJ | 2 |
SCHERER, RA | 1 |
GHORY, JE | 1 |
BERNSTEIN, IL | 1 |
KREINDLER, L | 1 |
AUSDENMOORE, RW | 1 |
HEISEN, AJ | 1 |
HEISEN, A | 1 |
DAMRAU, F | 1 |
GROVER, FW | 1 |
WEISNAGEL, J | 1 |
Nguyen, TT | 1 |
Fallon, B | 1 |
Winfield, HN | 1 |
Unger, L | 2 |
Temple, DE | 2 |
Falliers, CJ | 1 |
Cato, AE | 1 |
Harris, JR | 1 |
Brandon, BM | 1 |
Stolley, PD | 1 |
West, SK | 1 |
Swartz, D | 1 |
Rumrill, R | 1 |
Heilborn, H | 1 |
Odeblad, E | 1 |
Kokkola, K | 1 |
Vaara, J | 1 |
Wójcicki, J | 1 |
Samochowiec, L | 1 |
Szwed, G | 1 |
Sawiński, J | 1 |
Fiedelman, W | 1 |
Martens, J | 1 |
Block, SH | 1 |
Parrillo, OJ | 1 |
Humoller, FL | 1 |
von Wichert, P | 1 |
Brechter, C | 1 |
Blumstein, CG | 1 |
Bürgi, H | 2 |
Radha, TC | 1 |
Venkatachalam, CG | 1 |
Viswanathan, R | 1 |
Taylor, WF | 1 |
Siegel, SC | 2 |
Busser, RJ | 1 |
Strick, L | 1 |
Heimlich, EM | 1 |
Pedersen, AT | 1 |
Batsakis, JG | 1 |
Vanselow, NA | 1 |
McLean, JA | 1 |
Nam, HH | 1 |
Lee, JH | 1 |
Ryu, SM | 1 |
Lee, S | 2 |
Yang, S | 1 |
Noh, P | 1 |
Moon, BC | 1 |
Kim, JS | 5 |
Seo, YS | 1 |
Lim, JO | 1 |
Lee, SJ | 2 |
Kim, WI | 2 |
Pak, SW | 2 |
Moon, C | 1 |
Shin, IS | 13 |
Heo, JD | 1 |
Ko, JW | 5 |
Kim, JC | 6 |
Kumar, SS | 1 |
Binu, A | 1 |
Devan, AR | 1 |
Nath, LR | 1 |
Ma, J | 2 |
Liu, MX | 1 |
Chen, LC | 1 |
Shen, JJ | 1 |
Kuo, ML | 1 |
Tajiri, T | 1 |
Matsumoto, H | 2 |
Jinnai, M | 1 |
Kanemitsu, Y | 1 |
Nagasaki, T | 1 |
Iwata, T | 1 |
Inoue, H | 3 |
Nakaji, H | 1 |
Oguma, T | 2 |
Ito, I | 1 |
Niimi, A | 1 |
Kubczak, M | 1 |
Michlewska, S | 1 |
Bryszewska, M | 1 |
Aigner, A | 1 |
Ionov, M | 1 |
Mummy, DG | 1 |
Dunican, EM | 5 |
Carey, KJ | 1 |
Evans, MD | 1 |
Elicker, BM | 3 |
Newell, JD | 3 |
Gierada, DS | 3 |
Nagle, SK | 2 |
Schiebler, ML | 4 |
Sorkness, RL | 1 |
Jarjour, NN | 3 |
Denlinger, LC | 2 |
Fahy, JV | 14 |
Fain, SB | 3 |
Hearn, AP | 1 |
Mak, MS | 1 |
Budaj, I | 1 |
Qurashi, N | 1 |
Snell, O | 1 |
Dhariwal, J | 1 |
Nanzer, AM | 1 |
Jackson, DJ | 1 |
Headland, SE | 1 |
Dengler, HS | 1 |
Xu, D | 2 |
Teng, G | 1 |
Everett, C | 1 |
Ratsimandresy, RA | 1 |
Yan, D | 1 |
Kang, J | 2 |
Ganeshan, K | 1 |
Nazarova, EV | 1 |
Gierke, S | 1 |
Wedeles, CJ | 1 |
Guidi, R | 1 |
DePianto, DJ | 1 |
Morshead, KB | 1 |
Huynh, A | 1 |
Mills, J | 1 |
Flanagan, S | 1 |
Hambro, S | 1 |
Nunez, V | 1 |
Klementowicz, JE | 1 |
Shi, Y | 3 |
Wang, J | 5 |
Bevers, J | 1 |
Ramirez-Carrozzi, V | 1 |
Pappu, R | 1 |
Abbas, A | 1 |
Vander Heiden, J | 1 |
Choy, DF | 1 |
Yadav, R | 1 |
Modrusan, Z | 1 |
Panettieri, RA | 1 |
Koziol-White, C | 1 |
Jester, WF | 1 |
Jenkins, BJ | 1 |
Cao, Y | 1 |
Clarke, C | 1 |
Austin, C | 1 |
Lafkas, D | 1 |
Xu, M | 1 |
Wolters, PJ | 1 |
Arron, JR | 1 |
West, NR | 1 |
Wilson, MS | 2 |
Wu, D | 2 |
Jiang, W | 1 |
Liu, C | 4 |
Liu, L | 3 |
Li, F | 1 |
Ma, X | 1 |
Pan, L | 1 |
Qu, X | 1 |
Liu, H | 3 |
Qin, X | 1 |
Xiang, Y | 1 |
Tang, M | 2 |
Henry, T | 1 |
Huang, BK | 1 |
Peters, MC | 3 |
Castro, M | 3 |
Hoffman, EA | 3 |
Ash, SY | 1 |
Choi, J | 1 |
Hall, C | 1 |
Phillips, BR | 2 |
Mauger, DT | 2 |
Israel, E | 2 |
Phipatanakul, W | 1 |
Levy, BD | 2 |
Wenzel, SE | 2 |
Bleecker, ER | 2 |
Woodruff, PG | 4 |
Ousingsawat, J | 3 |
Centeio, R | 3 |
Cabrita, I | 3 |
Talbi, K | 2 |
Zimmer, O | 1 |
Graf, M | 1 |
Göpferich, A | 1 |
Schreiber, R | 4 |
Kunzelmann, K | 4 |
Svenningsen, S | 6 |
Nair, P | 6 |
McIntosh, MJ | 2 |
Kooner, HK | 2 |
Eddy, RL | 3 |
Jeimy, S | 1 |
Licskai, C | 2 |
Mackenzie, CA | 2 |
Yamashita, C | 2 |
Parraga, G | 3 |
Sajuthi, SP | 2 |
Everman, JL | 2 |
Jackson, ND | 2 |
Saef, B | 1 |
Rios, CL | 2 |
Moore, CM | 1 |
Mak, ACY | 1 |
Eng, C | 2 |
Fairbanks-Mahnke, A | 1 |
Salazar, S | 1 |
Elhawary, J | 1 |
Huntsman, S | 1 |
Medina, V | 1 |
Nickerson, DA | 1 |
Germer, S | 1 |
Zody, MC | 1 |
Abecasis, G | 1 |
Kang, HM | 1 |
Rice, KM | 1 |
Kumar, R | 1 |
Zaitlen, NA | 1 |
Oh, S | 1 |
Rodríguez-Santana, J | 2 |
Burchard, EG | 2 |
Seibold, MA | 2 |
Mann, TS | 1 |
Larcombe, AN | 1 |
Wang, KCW | 1 |
Shamsuddin, D | 1 |
Landwehr, KR | 1 |
Noble, PB | 1 |
Henry, PJ | 1 |
Wang, Z | 3 |
Xin, L | 1 |
Zhang, W | 7 |
Tao, X | 1 |
Xia, J | 1 |
Zeng, P | 1 |
Wang, H | 4 |
Xie, Y | 1 |
Wang, C | 2 |
Cheng, Y | 1 |
Li, J | 4 |
Zhang, X | 3 |
Zhang, P | 1 |
Chen, S | 1 |
Yu, H | 2 |
Wu, H | 2 |
Wuniqiemu, T | 2 |
Teng, F | 2 |
Qin, J | 2 |
Lv, Y | 1 |
Nabijan, M | 1 |
Luo, Q | 1 |
Zhou, Y | 2 |
Cui, J | 2 |
Tang, W | 2 |
Zhu, X | 2 |
Wang, S | 8 |
Abduwaki, M | 1 |
Nurahmat, M | 1 |
Wei, Y | 2 |
Dong, JC | 1 |
Eddie, AM | 1 |
Chen, KW | 1 |
Schenkel, LB | 1 |
Swinger, KK | 1 |
Molina, JR | 1 |
Kunii, K | 1 |
Raybuck, AL | 1 |
Keilhack, H | 1 |
Gibson-Corley, KN | 1 |
Niepel, M | 1 |
Peebles, RS | 2 |
Boothby, MR | 1 |
Cho, SH | 1 |
Peng, JQ | 1 |
Wang, P | 3 |
Gao, YX | 1 |
DU, Y | 1 |
Chen, XX | 1 |
Yu, QY | 1 |
Ren, JG | 1 |
Liu, JX | 1 |
Virmani, T | 1 |
Kumar, G | 1 |
Virmani, R | 1 |
Sharma, A | 2 |
Pathak, K | 1 |
Zhi, W | 1 |
Jiang, S | 2 |
Xu, Z | 3 |
An, Y | 1 |
Chen, J | 1 |
Li, Y | 5 |
Liu, Y | 6 |
Zhang, H | 2 |
Pieper, M | 1 |
Schulz-Hildebrandt, H | 1 |
Schmudde, I | 1 |
Quell, KM | 1 |
Laumonnier, Y | 1 |
Hüttmann, G | 1 |
König, P | 1 |
Sun, Y | 3 |
Miao, X | 1 |
Zhu, L | 1 |
Liu, J | 3 |
Lin, Y | 2 |
Xiang, G | 1 |
Wu, X | 1 |
Wang, X | 8 |
Ni, Z | 1 |
Li, S | 1 |
Chang, C | 1 |
Wu, JW | 1 |
Peng, YS | 1 |
Liu, KX | 1 |
Tran, C | 1 |
Singh, GV | 1 |
Haider, E | 3 |
Boylan, C | 3 |
Venegas, C | 2 |
Riaz, S | 1 |
Al Duwaiki, S | 1 |
Yehia, M | 1 |
Ho, T | 1 |
Kirby, M | 2 |
Aegerter, H | 2 |
Lambrecht, BN | 4 |
Lu, X | 1 |
Tan, ZX | 1 |
Wang, WJ | 1 |
Zhan, P | 1 |
Wang, Y | 7 |
Fu, L | 1 |
Gao, L | 1 |
Zhao, H | 2 |
Xu, DX | 1 |
Oguma, A | 3 |
Shimizu, K | 3 |
Kimura, H | 3 |
Tanabe, N | 3 |
Sato, S | 3 |
Yokota, I | 3 |
Takimoto-Sato, M | 3 |
Matsumoto-Sasaki, M | 3 |
Abe, Y | 3 |
Takei, N | 3 |
Goudarzi, H | 3 |
Suzuki, M | 3 |
Makita, H | 3 |
Hirai, T | 4 |
Nishimura, M | 4 |
Konno, S | 3 |
Pangeni, R | 1 |
Meng, T | 1 |
Poudel, S | 1 |
Sharma, D | 1 |
Hutsell, H | 1 |
Rubin, BK | 10 |
Longest, W | 1 |
Hindle, M | 1 |
Xu, Q | 1 |
Wilson, A | 1 |
Serajeddini, H | 1 |
Bhalla, A | 1 |
Nomura, N | 1 |
Sunadome, H | 1 |
Wei, L | 2 |
Hongping, H | 1 |
Chufang, L | 1 |
Cuomu, M | 1 |
Jintao, L | 1 |
Kaiyin, C | 1 |
Lvyi, C | 1 |
Weiwu, C | 1 |
Zuguang, Y | 1 |
Nanshan, Z | 1 |
Sakai, N | 1 |
Koya, T | 1 |
Murai, Y | 1 |
Tsubokawa, F | 1 |
Tanaka, K | 1 |
Naramoto, S | 1 |
Aoki, A | 1 |
Shima, K | 1 |
Kimura, Y | 1 |
Watanabe, S | 1 |
Hasegawa, T | 1 |
Kikuchi, T | 1 |
Tsuchiya, N | 1 |
Hahn, A | 1 |
Fain, S | 1 |
Denlinger, L | 1 |
Jarjour, N | 1 |
Chan, R | 1 |
Duraikannu, C | 1 |
Thouseef, MJ | 1 |
Lipworth, B | 1 |
Hou, Y | 1 |
Zheng, S | 1 |
Zou, F | 1 |
Wang, D | 3 |
Da, H | 1 |
Fan, X | 1 |
He, J | 1 |
Li, H | 3 |
Sun, X | 1 |
Kjarsgaard, M | 1 |
Konyer, N | 1 |
Friedlander, Y | 1 |
Nasir, N | 1 |
Wang, BH | 1 |
Tang, LL | 1 |
Sun, XH | 1 |
Zhang, Q | 2 |
Liu, CY | 1 |
Zhang, XN | 1 |
Yu, KY | 1 |
Yang, Y | 2 |
Hu, J | 2 |
Shi, XL | 1 |
Lee, IS | 1 |
Yang, YG | 1 |
Kim, T | 1 |
Benedetto, R | 2 |
Lu, C | 2 |
Zhang, B | 2 |
Xu, T | 2 |
Bai, B | 1 |
Xiao, Z | 2 |
Wu, L | 2 |
Liang, G | 2 |
Zhang, Y | 10 |
Dai, Y | 3 |
Yao, N | 1 |
Fu, X | 1 |
Ding, M | 1 |
Pang, Y | 1 |
Liu, D | 1 |
Ren, Y | 1 |
Guo, M | 1 |
Tasena, H | 3 |
Boudewijn, IM | 1 |
Faiz, A | 2 |
Timens, W | 1 |
Hylkema, MN | 1 |
Berg, M | 1 |
Ten Hacken, NHT | 2 |
Brandsma, CA | 1 |
Heijink, IH | 2 |
van den Berge, M | 3 |
Okauchi, S | 1 |
Yamada, H | 1 |
Satoh, H | 2 |
Koch, S | 1 |
Knipfer, L | 1 |
Kölle, J | 1 |
Mirzakhani, H | 1 |
Graser, A | 1 |
Zimmermann, T | 1 |
Kiefer, A | 1 |
Melichar, VO | 1 |
Rascher, W | 1 |
Papadopoulos, NG | 1 |
Rieker, RJ | 1 |
Raby, BA | 1 |
Weiss, ST | 2 |
Wirtz, S | 1 |
Finotto, S | 1 |
Ge, X | 1 |
Dai, W | 1 |
Chen, H | 1 |
Ying, S | 2 |
Kwon, HJ | 4 |
Seo, CS | 6 |
Choi, SJ | 1 |
Shin, NR | 7 |
Kim, SH | 3 |
Kim, YH | 1 |
Kim, MS | 1 |
Zhang, T | 2 |
Peng, L | 1 |
Zhou, L | 1 |
Matias, J | 1 |
Gaspar, A | 1 |
Borrego, LM | 1 |
Piedade, S | 1 |
Pires, G | 1 |
Arede, C | 1 |
Sampaio, G | 1 |
Morais Almeida, M | 1 |
Yoshida, Y | 1 |
Takaku, Y | 1 |
Nakamoto, Y | 1 |
Takayanagi, N | 1 |
Yanagisawa, T | 1 |
Takizawa, H | 1 |
Kurashima, K | 1 |
Frey, A | 1 |
Lunding, LP | 2 |
Ehlers, JC | 1 |
Weckmann, M | 2 |
Zissler, UM | 1 |
Wegmann, M | 2 |
Cavalcanti, RFP | 1 |
Gadelha, FAAF | 1 |
de Jesus, TG | 1 |
Cavalcante-Silva, LHA | 1 |
Paiva Ferreira, LKD | 2 |
Paiva Ferreira, LAM | 1 |
Vieira, GC | 1 |
Piuvezam, MR | 3 |
Chioccioli, M | 1 |
Feriani, L | 1 |
Goldfarbmuren, KC | 1 |
Powell, R | 1 |
Armstrong, M | 1 |
Gomez, J | 1 |
Michel, C | 1 |
Oh, SS | 1 |
Cicuta, P | 1 |
Reisdorph, N | 1 |
Xue, K | 1 |
Ruan, L | 1 |
Fu, Z | 2 |
Tian, D | 2 |
Zou, W | 2 |
Yan, P | 1 |
Su, Y | 1 |
Shang, C | 1 |
Zhou, X | 3 |
An, W | 2 |
Yu, C | 3 |
Dai, GM | 1 |
Wang, JJ | 1 |
Chen, ZH | 2 |
Ran, YJ | 1 |
Deng, HJ | 1 |
Mao, RL | 1 |
Zhu, T | 3 |
Bezerra Barros, GC | 1 |
Ferreira, LAMP | 1 |
Mozzini Monteiro, T | 1 |
Alves, AF | 1 |
Pereira, RA | 1 |
Rao, SP | 1 |
Rastle-Simpson, S | 1 |
Dileepan, M | 1 |
Sriramarao, P | 1 |
Dong, M | 1 |
Wang, W | 2 |
Dong, J | 1 |
Morgan, LE | 1 |
Jaramillo, AM | 1 |
Shenoy, SK | 1 |
Raclawska, D | 1 |
Emezienna, NA | 1 |
Richardson, VL | 1 |
Hara, N | 1 |
Harder, AQ | 1 |
NeeDell, JC | 1 |
Hennessy, CE | 1 |
El-Batal, HM | 1 |
Magin, CM | 1 |
Grove Villalon, DE | 1 |
Duncan, G | 1 |
Hanes, JS | 1 |
Suk, JS | 1 |
Thornton, DJ | 5 |
Holguin, F | 1 |
Janssen, WJ | 2 |
Thelin, WR | 2 |
Evans, CM | 3 |
Huang, W | 1 |
Liang, S | 1 |
Zhou, Z | 2 |
Liu, A | 1 |
Cai, S | 2 |
Siddiqui, S | 2 |
Johansson, K | 1 |
Joo, A | 1 |
Bonser, LR | 3 |
Koh, KD | 1 |
Le Tonqueze, O | 1 |
Bolourchi, S | 1 |
Bautista, RA | 1 |
Zlock, L | 2 |
Roth, TL | 1 |
Marson, A | 1 |
Bhakta, NR | 1 |
Ansel, KM | 1 |
Finkbeiner, WE | 3 |
Erle, DJ | 5 |
Johnathan, M | 1 |
Muhamad, SA | 1 |
Gan, SH | 1 |
Stanslas, J | 1 |
Mohd Fuad, WE | 1 |
Hussain, FA | 1 |
Wan Ahmad, WAN | 1 |
Nurul, AA | 1 |
Song, D | 1 |
Iverson, E | 1 |
Kaler, L | 1 |
Bader, S | 1 |
Scull, MA | 1 |
Duncan, GA | 1 |
Fang, L | 3 |
Yan, Y | 1 |
He, Z | 1 |
Zhou, S | 1 |
Jiang, X | 1 |
Wu, F | 1 |
Yuan, X | 3 |
Yu, D | 1 |
Yoshida, M | 1 |
Miyahara, Y | 1 |
Orimo, K | 1 |
Kono, N | 1 |
Narita, M | 1 |
Ohya, Y | 1 |
Matsumoto, K | 3 |
Nakagawa, S | 1 |
Ueki, S | 1 |
Morita, H | 2 |
Miyairi, I | 1 |
Xie, J | 1 |
Sun, H | 1 |
Wei, Q | 1 |
Nong, G | 1 |
Corcoran, TE | 1 |
Huber, AS | 1 |
Hill, SL | 1 |
Locke, LW | 1 |
Weber, L | 1 |
Muthukrishnan, A | 1 |
Heidrich, EM | 1 |
Wenzel, S | 1 |
Myerburg, MM | 2 |
Bhatt, R | 1 |
Ghosh, S | 1 |
Handa, N | 1 |
Tale, S | 1 |
Piao, X | 1 |
Jiang, SH | 1 |
Wang, JN | 1 |
Wu, J | 2 |
Xu, WC | 1 |
Li, LQ | 1 |
Xue, Z | 1 |
Yu, JE | 1 |
Crespo-Lessmann, A | 1 |
Bernal, S | 1 |
Del Río, E | 1 |
Rojas, E | 1 |
Martínez-Rivera, C | 2 |
Marina, N | 1 |
Pallarés-Sanmartín, A | 2 |
Pascual, S | 1 |
García-Rivero, JL | 2 |
Padilla-Galo, A | 1 |
Curto, E | 1 |
Cisneros, C | 1 |
Serrano, J | 1 |
Baiget, M | 1 |
Plaza, V | 2 |
Steele, H | 1 |
Sachen, K | 1 |
McKnight, AJ | 1 |
Soloff, R | 1 |
Herro, R | 1 |
Doušová, T | 1 |
Verbeken, EK | 1 |
De Boeck, K | 1 |
Cohen, I | 1 |
Cloots, E | 1 |
Debeuf, N | 1 |
Deswarte, K | 2 |
Fayazpour, F | 1 |
Vanheerswynghels, M | 1 |
De Wolf, C | 1 |
Van De Velde, E | 1 |
Hammad, H | 3 |
Eyckerman, S | 1 |
Janssens, S | 1 |
Takabayashi, T | 1 |
Imoto, Y | 1 |
Sakashita, M | 1 |
Kato, Y | 1 |
Tokunaga, T | 1 |
Yoshida, K | 1 |
Narita, N | 1 |
Ishizuka, T | 1 |
Fujieda, S | 1 |
Sugita, K | 1 |
Steer, CA | 1 |
Martinez-Gonzalez, I | 1 |
Altunbulakli, C | 1 |
Castro-Giner, F | 1 |
Kubo, T | 1 |
Wawrzyniak, P | 1 |
Rückert, B | 1 |
Sudo, K | 1 |
Nakae, S | 1 |
O'Mahony, L | 1 |
Akdis, M | 2 |
Takei, F | 2 |
Akdis, CA | 2 |
Xu, B | 1 |
Huang, S | 2 |
Fang, S | 1 |
Sharma, P | 1 |
Yi, R | 1 |
Nayak, AP | 1 |
Wang, N | 1 |
Tang, F | 1 |
Knight, MJ | 1 |
Pan, S | 1 |
Oliver, B | 1 |
Deshpande, DA | 1 |
Ehlers, A | 1 |
Xie, W | 1 |
Agapov, E | 1 |
Brown, S | 1 |
Steinberg, D | 1 |
Tidwell, R | 1 |
Sajol, G | 1 |
Schutz, R | 1 |
Weaver, R | 1 |
Bacharier, LB | 1 |
Holtzman, MJ | 1 |
Haspel, JA | 1 |
Huang, R | 1 |
Yao, R | 1 |
Yang, A | 1 |
Wijerathne, CUB | 1 |
Song, JW | 1 |
Park, HS | 1 |
Moon, OS | 1 |
Won, YS | 1 |
Son, HY | 1 |
Carraro, G | 1 |
Stripp, BR | 1 |
Welsh, KG | 1 |
Rousseau, K | 1 |
Fisher, G | 1 |
Bradding, P | 1 |
Brightling, CE | 1 |
Gaillard, EA | 1 |
Corthésy, B | 1 |
Bioley, G | 1 |
Fu, LQ | 1 |
Li, YL | 1 |
Fu, AK | 1 |
Wu, YP | 1 |
Wang, YY | 1 |
Hu, SL | 1 |
Li, WF | 1 |
Ryu, HW | 1 |
Park, SH | 2 |
Yuk, HJ | 1 |
Kim, HJ | 1 |
Jeong, SH | 1 |
Hao, W | 1 |
Sun, L | 1 |
Han, W | 1 |
Agarwal, R | 1 |
Sehgal, IS | 1 |
Dhooria, S | 1 |
Garg, M | 1 |
Xiong, J | 1 |
Zhao, WQ | 1 |
Huang, GH | 1 |
Yao, LH | 1 |
Dong, HM | 1 |
Yu, CH | 1 |
Zhao, HJ | 1 |
Cai, SX | 1 |
Saco, TV | 1 |
Breitzig, MT | 1 |
Lockey, RF | 1 |
Kolliputi, N | 1 |
Akaba, T | 1 |
Komiya, K | 1 |
Suzaki, I | 1 |
Kozaki, Y | 1 |
Tamaoki, J | 5 |
Verma, M | 1 |
Liu, S | 1 |
Michalec, L | 1 |
Sripada, A | 1 |
Gorska, MM | 2 |
Alam, R | 2 |
Deng, Y | 2 |
Yang, H | 1 |
Zhang, L | 3 |
Toki, S | 1 |
Goleniewska, K | 1 |
Reiss, S | 1 |
Zhang, J | 4 |
Bloodworth, MH | 1 |
Stier, MT | 2 |
Zhou, W | 1 |
Newcomb, DC | 1 |
Ware, LB | 1 |
Stanwood, GD | 1 |
Galli, A | 1 |
Boyd, KL | 1 |
Niswender, KD | 1 |
Georas, SN | 1 |
Raymond, WW | 1 |
Lachowicz-Scroggins, ME | 2 |
Di Maio, S | 1 |
Erzurum, SC | 1 |
Meyers, DA | 1 |
Gordon, ED | 1 |
Khelloufi, MK | 1 |
Loiseau, E | 1 |
Jaeger, M | 1 |
Molinari, N | 1 |
Chanez, P | 4 |
Gras, D | 3 |
Viallat, A | 1 |
Crespo, A | 1 |
Pinedo-Sierra, C | 1 |
Marina-Malanda, N | 1 |
Pascual-Erquicia, S | 1 |
Padilla, A | 1 |
Mayoralas-Alises, S | 1 |
López-Viña, A | 1 |
Picado, C | 1 |
Shen, Y | 3 |
Lin, J | 1 |
Lai, K | 1 |
Xiao, W | 1 |
Yang, L | 2 |
Yao, W | 1 |
Huang, K | 1 |
Wen, F | 1 |
Bao, W | 1 |
Zhang, M | 2 |
Bao, A | 1 |
Fei, X | 1 |
Ding, F | 1 |
Liu, B | 1 |
Li, Q | 1 |
Dai, J | 1 |
Luo, Z | 1 |
Abreu, SC | 1 |
Lopes-Pacheco, M | 1 |
da Silva, AL | 1 |
Xisto, DG | 1 |
de Oliveira, TB | 1 |
Kitoko, JZ | 1 |
de Castro, LL | 1 |
Amorim, NR | 1 |
Martins, V | 1 |
Silva, LHA | 1 |
Gonçalves-de-Albuquerque, CF | 1 |
de Castro Faria-Neto, HC | 1 |
Olsen, PC | 2 |
Weiss, DJ | 1 |
Morales, MM | 1 |
Diaz, BL | 1 |
Rocco, PRM | 1 |
Vermeulen, CJ | 1 |
Halayko, AJ | 3 |
Ward, JPT | 1 |
Lee, TH | 1 |
Tjin, G | 1 |
Black, JL | 1 |
Haghi, M | 1 |
Xu, CJ | 1 |
King, GG | 2 |
Farah, CS | 1 |
Oliver, BG | 1 |
Burgess, JK | 1 |
Atanasova, KR | 1 |
Reznikov, LR | 1 |
Martin, JG | 3 |
Patel, DF | 1 |
Peiró, T | 1 |
Shoemark, A | 1 |
Akthar, S | 1 |
Walker, SA | 1 |
Grabiec, AM | 1 |
Jackson, PL | 1 |
Hussell, T | 1 |
Gaggar, A | 1 |
Xu, X | 1 |
Trevor, JL | 1 |
Steele, C | 1 |
Tavernier, G | 1 |
Blalock, JE | 1 |
Niven, RM | 1 |
Gregory, LG | 1 |
Simpson, A | 1 |
Lloyd, CM | 4 |
Snelgrove, RJ | 1 |
Ehre, C | 1 |
Rushton, ZL | 1 |
Wang, B | 1 |
Hothem, LN | 1 |
Morrison, CB | 1 |
Fontana, NC | 1 |
Markovetz, MR | 1 |
Delion, MF | 1 |
Kato, T | 1 |
Villalon, D | 1 |
Esther, CR | 1 |
Hill, DB | 1 |
Grubb, BR | 1 |
Livraghi-Butrico, A | 1 |
Donaldson, SH | 1 |
Boucher, RC | 1 |
Gungl, A | 1 |
Biasin, V | 1 |
Wilhelm, J | 1 |
Olschewski, A | 1 |
Kwapiszewska, G | 1 |
Marsh, LM | 1 |
Rosa, MPG | 1 |
Jose, MMF | 1 |
Watchorn, DC | 1 |
Barrios, J | 1 |
Kho, AT | 1 |
Aven, L | 1 |
Mitchel, JA | 1 |
Park, JA | 1 |
Randell, SH | 1 |
Miller, LA | 1 |
Tantisira, KG | 1 |
Ai, X | 1 |
Lee, IC | 2 |
Nagano, N | 1 |
Iikura, M | 1 |
Ito, A | 1 |
Miyawaki, E | 1 |
Hashimoto, M | 1 |
Sugiyama, H | 1 |
Rojas, DA | 1 |
Iturra, PA | 1 |
Méndez, A | 1 |
Ponce, CA | 1 |
Bustamante, R | 1 |
Gallo, M | 1 |
Bórquez, P | 1 |
Vargas, SL | 1 |
Feldman, MB | 1 |
Wood, M | 1 |
Lapey, A | 1 |
Mou, H | 1 |
Mukherjee, M | 1 |
Capaldi, DPI | 1 |
Perkins, TN | 1 |
Oczypok, EA | 1 |
Dutz, RE | 1 |
Donnell, ML | 1 |
Oury, TD | 1 |
Reddehase, MJ | 1 |
Persson, EK | 1 |
Verstraete, K | 1 |
Heyndrickx, I | 1 |
Gevaert, E | 1 |
Percier, JM | 1 |
Verschueren, KHG | 1 |
Dansercoer, A | 1 |
Bachert, C | 1 |
Gonçalves, A | 1 |
Van Gorp, H | 1 |
De Haard, H | 1 |
Blanchetot, C | 1 |
Saunders, M | 1 |
Savvides, SN | 1 |
Li, X | 1 |
Shi, J | 2 |
Cheng, Z | 1 |
Cerqueira, JV | 1 |
Meira, CS | 1 |
Santos, ES | 1 |
de Aragão França, LS | 1 |
Vasconcelos, JF | 1 |
Nonaka, CKV | 1 |
de Melo, TL | 1 |
Dos Santos Filho, JM | 1 |
Moreira, DRM | 1 |
Soares, MBP | 1 |
Mainguy-Seers, S | 1 |
Vargas, A | 1 |
Labrecque, O | 1 |
Bédard, C | 1 |
Hélie, P | 1 |
Lavoie, JP | 1 |
Lee, MY | 11 |
Jeon, WY | 4 |
Ha, H | 3 |
Biffi, S | 1 |
Dal Monego, S | 1 |
Dullin, C | 1 |
Garrovo, C | 1 |
Bosnjak, B | 2 |
Licha, K | 1 |
Welker, P | 1 |
Epstein, MM | 5 |
Alves, F | 1 |
Yadav, UC | 1 |
Naura, AS | 2 |
Aguilera-Aguirre, L | 1 |
Boldogh, I | 1 |
Boulares, HA | 1 |
Calhoun, WJ | 1 |
Ramana, KV | 1 |
Srivastava, SK | 1 |
Lim, HS | 1 |
Kim, JH | 6 |
Wei, M | 1 |
Xie, X | 1 |
Chu, X | 1 |
Yang, X | 8 |
Guan, M | 1 |
Thomson, NC | 1 |
Chaudhuri, R | 1 |
Messow, CM | 1 |
Spears, M | 1 |
MacNee, W | 1 |
Connell, M | 1 |
Murchison, JT | 1 |
Sproule, M | 1 |
McSharry, C | 1 |
Zhu, W | 1 |
Bi, M | 1 |
Pan, F | 1 |
Qiu, L | 1 |
Guo, A | 1 |
Lv, H | 1 |
Yao, P | 1 |
Zhang, N | 1 |
Tilp, C | 1 |
Tomsic, C | 1 |
Dekan, G | 4 |
Pieper, MP | 1 |
Erb, KJ | 1 |
Shin, HK | 5 |
de Boer, JD | 1 |
Yang, J | 3 |
van den Boogaard, FE | 1 |
Hoogendijk, AJ | 2 |
de Beer, R | 2 |
van der Zee, JS | 2 |
Roelofs, JJ | 2 |
van 't Veer, C | 1 |
de Vos, AF | 2 |
van der Poll, T | 2 |
Saravia, J | 3 |
You, D | 1 |
Thevenot, P | 1 |
Lee, GI | 1 |
Shrestha, B | 1 |
Lomnicki, S | 1 |
Cormier, SA | 4 |
Usta Guc, B | 1 |
Asilsoy, S | 1 |
Durmaz, C | 1 |
Tan, Y | 1 |
Mao, S | 1 |
Gu, W | 1 |
Shin, N | 1 |
Yan, F | 1 |
Li, W | 2 |
Zhou, H | 1 |
Wu, Y | 1 |
Chen, Z | 4 |
Shen, H | 1 |
Jakiela, B | 1 |
Gielicz, A | 1 |
Plutecka, H | 1 |
Hubalewska-Mazgaj, M | 1 |
Mastalerz, L | 1 |
Bochenek, G | 1 |
Soja, J | 1 |
Januszek, R | 1 |
Aab, A | 1 |
Musial, J | 1 |
Sanak, M | 1 |
Kerr, SC | 2 |
Carrington, SD | 2 |
Oscarson, S | 1 |
Gallagher, ME | 1 |
Solon, M | 1 |
Yuan, S | 2 |
Ahn, JN | 1 |
Dougherty, RH | 1 |
Lin, CH | 2 |
Shen, ML | 2 |
Zhou, N | 2 |
Lee, CC | 2 |
Kao, ST | 2 |
Wu, DC | 2 |
Staab, EB | 1 |
Sanderson, SD | 1 |
Wells, SM | 1 |
Poole, JA | 1 |
Hoppin, JA | 1 |
Umbach, DM | 1 |
Long, S | 1 |
Rinsky, JL | 1 |
Henneberger, PK | 1 |
Salo, PM | 1 |
Zeldin, DC | 1 |
London, SJ | 1 |
Alavanja, MC | 1 |
Blair, A | 1 |
Beane Freeman, LE | 1 |
Sandler, DP | 1 |
Qiao, M | 1 |
Wong, EH | 1 |
Porter, JD | 1 |
Edwards, MR | 1 |
Johnston, SL | 1 |
Jeon, CM | 3 |
Hong, JM | 1 |
Kwon, OK | 8 |
Kim, HS | 3 |
Oh, SR | 8 |
Myung, PK | 1 |
Ahn, KS | 6 |
Reiner, D | 1 |
Lee, RY | 1 |
Priftis, KN | 1 |
Schmidt, HJ | 2 |
Henke, MO | 1 |
Zhong, B | 1 |
Sun, Q | 1 |
Lan, X | 1 |
Tian, J | 1 |
He, Q | 1 |
Hou, W | 1 |
Jiang, C | 1 |
Gao, N | 1 |
Lu, S | 1 |
Silva, RA | 1 |
Almeida, FM | 1 |
Olivo, CR | 1 |
Saraiva-Romanholo, BM | 1 |
Martins, MA | 3 |
Carvalho, CR | 1 |
Park, JW | 2 |
Currie, LL | 1 |
Medford, AR | 1 |
Shen, QY | 2 |
Wu, HM | 2 |
He, F | 1 |
Ding, PS | 1 |
Liu, RY | 2 |
Nau, F | 1 |
Miller, J | 1 |
Ahlert, T | 1 |
Yu, B | 1 |
Happel, KI | 1 |
Nichols, CD | 1 |
Chen, M | 2 |
Lv, Z | 1 |
Huang, L | 1 |
Lin, X | 1 |
Liang, R | 1 |
Yayan, J | 1 |
Potter, PC | 1 |
Ehrlich, R | 1 |
van Rooyen, C | 1 |
Fenemore, B | 1 |
Raclawska, DS | 1 |
Ttofali, F | 1 |
Liptzin, DR | 1 |
Fletcher, AA | 1 |
Harper, DN | 1 |
McGing, MA | 1 |
McElwee, MM | 1 |
Williams, OW | 1 |
Sanchez, E | 1 |
Roy, MG | 1 |
Kindrachuk, KN | 1 |
Wynn, TA | 2 |
Eltzschig, HK | 1 |
Blackburn, MR | 1 |
Tuvim, MJ | 2 |
Schwartz, DA | 1 |
Dickey, BF | 3 |
Vock, C | 1 |
Yildirim, AÖ | 1 |
Wagner, C | 1 |
Schlick, S | 1 |
Lee, CG | 3 |
Elias, JA | 4 |
Fehrenbach, H | 1 |
Weir, D | 1 |
Busse, P | 1 |
Yang, N | 1 |
Emala, C | 1 |
Li, XM | 3 |
Andemariam, B | 1 |
Adami, AJ | 1 |
Singh, A | 1 |
McNamara, JT | 1 |
Secor, ER | 1 |
Guernsey, LA | 1 |
Thrall, RS | 2 |
He, Y | 1 |
Li, T | 1 |
Wei, J | 1 |
Lin, R | 1 |
Santos Serafim Machado, M | 1 |
Ferreira Silva, HB | 1 |
Rios, R | 1 |
Pires de Oliveira, A | 1 |
Vilany Queiroz Carneiro, N | 1 |
Santos Costa, R | 1 |
Santos Alves, W | 1 |
Meneses Souza, FL | 1 |
da Silva Velozo, E | 1 |
Alves de Souza, S | 1 |
Sarmento Silva, TM | 1 |
Silva, ML | 1 |
Pontes-de-Carvalho, LC | 1 |
Alcântara-Neves, NM | 1 |
Figueiredo, CA | 1 |
Jaligama, S | 1 |
Yadav, N | 1 |
Lomnicki, SM | 1 |
Dugas, TR | 1 |
Ghonim, MA | 1 |
Pyakurel, K | 1 |
Ibba, SV | 1 |
Al-Khami, AA | 1 |
Rodriguez, P | 1 |
Rady, HF | 1 |
El-Bahrawy, AH | 1 |
Lammi, MR | 1 |
Mansy, MS | 1 |
Al-Ghareeb, K | 1 |
Ramsay, A | 1 |
Ochoa, A | 1 |
Boulares, AH | 1 |
Xie, T | 1 |
Luo, G | 1 |
Wu, M | 2 |
Li, G | 2 |
Aihua, B | 1 |
Yuqing, C | 1 |
Feng, L | 1 |
Xin, Z | 1 |
Prazma, CM | 1 |
Gern, JE | 1 |
Weinstein, SF | 1 |
Prillaman, BA | 1 |
Stempel, DA | 1 |
Brett, TJ | 1 |
Wu, XL | 1 |
Xiao, M | 1 |
Ni, ZH | 1 |
Tang, JH | 1 |
Chen, G | 1 |
Lai, YM | 1 |
Chen, QG | 1 |
Li, Z | 1 |
Yang, W | 1 |
Luo, XM | 1 |
Wang, XB | 1 |
Nagai, A | 2 |
Son, Y | 1 |
Bae, MJ | 1 |
Lee, SS | 1 |
Lee, HJ | 1 |
Lee, SI | 1 |
Kim, SD | 1 |
Jo, WS | 1 |
Ha, EV | 1 |
Rogers, DF | 12 |
Akata, K | 1 |
Yatera, K | 1 |
Wang, KY | 1 |
Naito, K | 1 |
Ogoshi, T | 1 |
Noguchi, S | 1 |
Kido, T | 1 |
Toyohira, Y | 1 |
Shimokawa, H | 1 |
Yanagihara, N | 1 |
Tsutsui, M | 1 |
Mukae, H | 1 |
Manni, ML | 1 |
Mandalapu, S | 1 |
McHugh, KJ | 1 |
Elloso, MM | 1 |
Dudas, PL | 1 |
Alcorn, JF | 1 |
Gurusamy, M | 1 |
Nasseri, S | 1 |
Lee, H | 2 |
Jung, B | 1 |
Lee, D | 1 |
Khang, G | 1 |
Abraham, WM | 3 |
Doods, H | 1 |
Zhang, C | 1 |
Zhang, LH | 1 |
Wu, YF | 1 |
Lai, TW | 1 |
Wang, HS | 1 |
Xiao, H | 1 |
Che, LQ | 1 |
Ying, SM | 1 |
Shen, HH | 3 |
Forkuo, GS | 1 |
Kim, H | 1 |
Thanawala, VJ | 1 |
Al-Sawalha, N | 1 |
Valdez, D | 1 |
Joshi, R | 1 |
Parra, S | 1 |
Pera, T | 1 |
Gonnella, PA | 1 |
Knoll, BJ | 1 |
Walker, JK | 1 |
Penn, RB | 1 |
Bond, RA | 1 |
Lee, YL | 1 |
Wang, CN | 1 |
Tsai, HC | 1 |
Chiu, CL | 1 |
Liu, LF | 1 |
Lin, HY | 1 |
Wu, R | 1 |
da Cunha, AA | 1 |
Nuñez, NK | 1 |
de Souza, RG | 1 |
Moraes Vargas, MH | 1 |
Silveira, JS | 1 |
Antunes, GL | 1 |
Durante, Lda S | 1 |
Porto, BN | 1 |
Marczak, ES | 1 |
Jones, MH | 1 |
Pitrez, PM | 1 |
Finkbeiner, W | 1 |
Reuter, S | 1 |
Maxeiner, J | 1 |
Meyer-Martin, H | 1 |
Michel, A | 1 |
Baars, P | 1 |
Bopp, T | 1 |
Waisman, A | 1 |
Reissig, S | 1 |
Wehler, TC | 1 |
Schild, H | 1 |
Taube, C | 1 |
Stassen, M | 1 |
Becker, M | 1 |
Balhara, J | 1 |
Shan, L | 1 |
Muhuri, A | 1 |
Almiski, MS | 1 |
Doeing, D | 1 |
McConville, J | 1 |
Matzuk, MM | 1 |
Gounni, AS | 1 |
Wang, CH | 1 |
Lu, Y | 1 |
Xing, QQ | 1 |
Xu, JY | 1 |
Ding, D | 1 |
Zhao, X | 1 |
Han, M | 1 |
Hong, JY | 1 |
Jaipalli, S | 1 |
Rajput, C | 1 |
Lei, J | 1 |
Hinde, JL | 1 |
Chen, Q | 2 |
Hershenson, NM | 1 |
Bentley, JK | 1 |
Hershenson, MB | 1 |
Cho, JL | 1 |
Ling, MF | 1 |
Adams, DC | 1 |
Faustino, L | 2 |
Islam, SA | 1 |
Afshar, R | 1 |
Griffith, JW | 1 |
Harris, RS | 1 |
Ng, A | 1 |
Radicioni, G | 1 |
Ford, AA | 1 |
Han, AK | 1 |
Xavier, R | 1 |
Kwok, WW | 1 |
Boucher, R | 1 |
Moon, JJ | 1 |
Hamilos, DL | 2 |
Kesimer, M | 1 |
Suter, MJ | 1 |
Medoff, BD | 2 |
Luster, AD | 2 |
Yu, M | 1 |
Yokota, M | 1 |
Tamachi, T | 1 |
Yokoyama, Y | 1 |
Maezawa, Y | 1 |
Takatori, H | 1 |
Suto, A | 2 |
Suzuki, K | 2 |
Hirose, K | 2 |
Takeda, K | 1 |
Nakajima, H | 2 |
Lee, AR | 1 |
Chun, JM | 1 |
Lee, AY | 1 |
Gu, GJ | 1 |
Kwon, BI | 1 |
Dai, X | 1 |
Niu, B | 1 |
Xiong, A | 1 |
Liu, Z | 1 |
Zhong, N | 1 |
Eid, R | 1 |
Bickel, S | 1 |
Eid, N | 1 |
Piñeiro-Hermida, S | 1 |
Gregory, JA | 1 |
López, IP | 1 |
Torrens, R | 1 |
Ruíz-Martínez, C | 1 |
Adner, M | 1 |
Pichel, JG | 1 |
Tsuchiya, K | 1 |
Isogai, S | 1 |
Tamaoka, M | 1 |
Inase, N | 1 |
Akashi, T | 1 |
Yoshizawa, Y | 1 |
Du, Q | 1 |
Zhou, LF | 1 |
Huang, M | 1 |
Yin, KS | 1 |
Wakashin, H | 1 |
Oki, M | 1 |
Kagami, S | 1 |
Ikeda, K | 1 |
Watanabe, N | 1 |
Iwamoto, I | 1 |
Furuichi, Y | 1 |
Kearley, J | 1 |
Robinson, DS | 1 |
Tsuchida, H | 1 |
Takahashi, S | 1 |
Nosaka, E | 1 |
Kuraya, T | 1 |
Yamashita, M | 1 |
Morimoto, K | 1 |
Shi, L | 1 |
Leu, SW | 1 |
Xu, F | 2 |
Yin, H | 1 |
Cai, L | 1 |
Landgraf, RG | 1 |
Jancar, S | 1 |
Khemiri, M | 1 |
Hammami, O | 1 |
Zouari, S | 1 |
Khaldi, F | 1 |
Barsaoui, S | 1 |
Agrawal, A | 3 |
Mabalirajan, U | 2 |
Ram, A | 1 |
Ghosh, B | 2 |
Kim, K | 1 |
Kim, SY | 1 |
Park, BY | 2 |
Kim, MK | 2 |
Lee, IY | 2 |
Lee, HK | 7 |
Lee, M | 1 |
Kim, S | 1 |
Ahn, K | 2 |
Voynow, JA | 2 |
Yang, EJ | 2 |
Song, GY | 1 |
Lee, JS | 2 |
Yun, CY | 2 |
Kim, IS | 2 |
Dong, L | 1 |
Kurt, E | 1 |
Ozkan, R | 1 |
Orman, A | 1 |
Calisir, C | 1 |
Metintas, M | 1 |
Tumes, DJ | 1 |
Connolly, A | 1 |
Dent, LA | 1 |
Lu, WY | 2 |
Inman, MD | 2 |
Song, DJ | 2 |
Min, MG | 2 |
Miller, M | 4 |
Cho, JY | 4 |
Broide, DH | 4 |
Park, SW | 1 |
Verhaeghe, C | 1 |
Nguyenvu, LT | 1 |
Barbeau, R | 1 |
Eisley, CJ | 1 |
Nakagami, Y | 1 |
Huang, X | 4 |
Izuhara, K | 2 |
Ohta, S | 2 |
Shiraishi, H | 1 |
Suzuki, S | 1 |
Taniguchi, K | 1 |
Toda, S | 2 |
Tanabe, T | 1 |
Yasuo, M | 1 |
Kubo, K | 1 |
Hoshino, T | 2 |
Aizawa, H | 4 |
Medeiros, KC | 1 |
Borduchi, E | 1 |
Nascimento, RJ | 1 |
Silva, TM | 1 |
Gomes, E | 2 |
Russo, M | 3 |
Yuk, JE | 1 |
Brattström, A | 2 |
Schapowal, A | 2 |
Maillet, I | 2 |
Schnyder, B | 1 |
Ryffel, B | 2 |
Moser, R | 2 |
Lai, HY | 1 |
Bartley, J | 1 |
McGlashan, SR | 1 |
Green, FH | 2 |
Williams, DJ | 1 |
James, A | 2 |
McPhee, LJ | 1 |
Mitchell, I | 1 |
Mauad, T | 1 |
Smith, JA | 1 |
Ramaprakash, H | 1 |
Hogaboam, CM | 1 |
Liu, P | 1 |
Zhu, Y | 1 |
Wu, Z | 1 |
Liu, X | 2 |
An, G | 1 |
Ji, W | 1 |
Gao, W | 1 |
Kamal, MA | 1 |
Lee, NH | 3 |
Jung, D | 1 |
Lee, JA | 3 |
Goplen, N | 1 |
Liang, Q | 1 |
Larsen, ST | 1 |
Matsubara, S | 1 |
McConville, G | 1 |
Poulsen, SS | 1 |
Gelfand, EW | 1 |
Bhandari, V | 2 |
Bhandari, A | 1 |
Davies, J | 1 |
Marshall, BC | 1 |
Praud, JP | 1 |
Zar, HJ | 1 |
Anagnostopoulou, P | 2 |
Dai, L | 1 |
Schatterny, J | 2 |
Hirtz, S | 1 |
Duerr, J | 2 |
Mall, MA | 2 |
Halwani, R | 1 |
Al-Muhsen, S | 1 |
Al-Jahdali, H | 1 |
Hamid, Q | 4 |
Wang, Q | 1 |
Yao, Y | 1 |
Xia, D | 1 |
Zhou, J | 1 |
Jin, M | 1 |
Bai, C | 2 |
Ahmad, T | 1 |
Aich, J | 1 |
Makhija, L | 1 |
Jung, DY | 2 |
Song, BB | 1 |
Kim, DH | 1 |
Harmsen, L | 1 |
Thomsen, SF | 1 |
Ingebrigtsen, T | 1 |
Steffensen, IE | 1 |
Skadhauge, LR | 1 |
Kyvik, KO | 1 |
Backer, V | 2 |
Oh, SW | 2 |
Cha, JY | 1 |
Jung, JE | 1 |
Chang, BC | 1 |
Lee, BR | 1 |
Kim, DY | 2 |
Lai, H | 1 |
Hackenberg, S | 1 |
Hacki, T | 1 |
Hagen, R | 1 |
Kleinsasser, NH | 1 |
Sun, S | 1 |
Sivaprasad, U | 1 |
Askew, DJ | 1 |
Ericksen, MB | 1 |
Gibson, AM | 1 |
Brandt, EB | 1 |
Bass, SA | 1 |
Daines, MO | 1 |
Chakir, J | 1 |
Stringer, KF | 1 |
Wert, SE | 1 |
Whitsett, JA | 2 |
Le Cras, TD | 1 |
Wills-Karp, M | 6 |
Silverman, GA | 1 |
Khurana Hershey, GK | 1 |
Merrien, J | 1 |
Robert, P | 1 |
Bao, ZS | 1 |
Hong, L | 1 |
Guan, Y | 1 |
Dong, XW | 1 |
Zheng, HS | 1 |
Tan, GL | 1 |
Xie, QM | 1 |
Pham, A | 1 |
Rosenthal, P | 1 |
Doherty, T | 1 |
Hirano, Y | 1 |
Shichijo, M | 1 |
Ikeda, M | 1 |
Kitaura, M | 1 |
Tsuchida, J | 1 |
Asanuma, F | 1 |
Yanagimoto, T | 1 |
Furue, Y | 1 |
Imura, K | 1 |
Yasui, K | 1 |
Arimura, A | 1 |
Lay, JC | 1 |
Peden, DB | 1 |
Alexis, NE | 1 |
Henderson, WR | 8 |
Oslund, RC | 1 |
Bollinger, JG | 1 |
Ye, X | 1 |
Tien, YT | 2 |
Xue, J | 1 |
Gelb, MH | 1 |
Holgate, ST | 3 |
Cheng, C | 2 |
Ho, WE | 1 |
Goh, FY | 2 |
Guan, SP | 1 |
Kong, LR | 1 |
Lai, WQ | 1 |
Leung, BP | 6 |
Wong, WS | 6 |
Nofziger, C | 1 |
Vezzoli, V | 1 |
Dossena, S | 1 |
Schönherr, T | 1 |
Studnicka, J | 1 |
Nofziger, J | 1 |
Vanoni, S | 1 |
Stephan, S | 1 |
Silva, ME | 1 |
Meyer, G | 1 |
Paulmichl, M | 1 |
Mitchell, VL | 1 |
Van Winkle, LS | 1 |
Gershwin, LJ | 1 |
Birben, E | 1 |
Sackesen, C | 1 |
Turgutoğlu, N | 1 |
Kalayci, O | 1 |
Khakzad, MR | 1 |
Mirsadraee, M | 1 |
Mohammadpour, A | 1 |
Ghafarzadegan, K | 1 |
Hadi, R | 1 |
Saghari, M | 1 |
Meshkat, M | 1 |
Miravitlles, M | 1 |
Calle, M | 1 |
Soler-Cataluña, JJ | 1 |
Upton, N | 1 |
Guan, S | 1 |
Shanmugam, MK | 1 |
Sethi, G | 1 |
Thiara, G | 1 |
Goldman, RD | 1 |
Halim, TY | 1 |
Krauss, RH | 1 |
Sun, AC | 1 |
Thorburn, AN | 1 |
Foster, PS | 2 |
Gibson, PG | 2 |
Hansbro, PM | 2 |
Behrendt, AK | 1 |
Meyer-Bahlburg, A | 1 |
Hansen, G | 2 |
Petersen, BC | 1 |
Lukacs, NW | 3 |
Wang, DX | 1 |
Huang, NW | 1 |
Bo, H | 1 |
Deng, W | 1 |
Deng, J | 1 |
Wang, G | 1 |
Wang, R | 1 |
Al-Hijji, M | 1 |
Salit, J | 1 |
Strulovici-Barel, Y | 1 |
Tilley, AE | 1 |
Mezey, JG | 1 |
Crystal, RG | 1 |
Li, K | 2 |
Bing Ma, L | 1 |
Gong, SB | 1 |
Wang, GY | 1 |
Ji, XY | 1 |
Xu, L | 1 |
Liu, SK | 1 |
Chen, P | 1 |
Ouyang, RY | 1 |
Xiang, XD | 1 |
Serra, MF | 1 |
Anjos-Valotta, EA | 1 |
Couto, GC | 1 |
Jurgilas, PB | 1 |
Cotias, AC | 1 |
Pão, CR | 1 |
Ferreira, TP | 1 |
Arantes, AC | 1 |
Pires, AL | 2 |
Cordeiro, RS | 1 |
Silva, PM | 1 |
Riederer, B | 1 |
Michel, S | 1 |
Binia, A | 1 |
Agrawal, R | 1 |
Kalitzki, K | 1 |
Xiao, F | 1 |
Hartmann, D | 1 |
Thum, T | 1 |
Kabesch, M | 1 |
Soleimani, M | 1 |
Seidler, U | 1 |
Lewkowich, IP | 2 |
Lajoie, S | 1 |
Stoffers, SL | 1 |
Suzuki, Y | 1 |
Richgels, PK | 1 |
Dienger, K | 1 |
Sproles, AA | 2 |
Yagita, H | 1 |
Reber, LL | 1 |
Daubeuf, F | 1 |
Nemska, S | 1 |
Frossard, N | 2 |
Daan de Boer, J | 1 |
Schouten, M | 1 |
Hommes, TJ | 1 |
de Boer, OJ | 1 |
Stroo, I | 1 |
Veer, CV | 1 |
Chen, CG | 1 |
Wang, HY | 1 |
Wang, JL | 1 |
Xu, WH | 2 |
Kondo, M | 2 |
Zhou, M | 1 |
Chen, HL | 1 |
Cheng, S | 1 |
Mei, L | 1 |
Zhang, HL | 3 |
Xie, M | 1 |
Xiong, WN | 1 |
Xu, YJ | 3 |
Carroll, NG | 1 |
Mutavdzic, S | 1 |
James, AL | 2 |
Mojtabavi, N | 1 |
Stingl, G | 2 |
Chi, EY | 6 |
Teo, JL | 1 |
Nguyen, C | 1 |
Kahn, M | 2 |
Widdicombe, JH | 2 |
Basbaum, C | 1 |
Salathe, M | 1 |
Forteza, R | 1 |
Conner, GE | 1 |
Cohn, L | 4 |
Whittaker, L | 1 |
Niu, N | 2 |
Homer, RJ | 5 |
Barnes, PJ | 3 |
Wray, BB | 1 |
McCann, W | 1 |
Rodríguez, D | 2 |
Keller, AC | 1 |
Faquim-Mauro, EL | 1 |
de Macedo, MS | 1 |
Cunha, FQ | 1 |
Lefort, J | 3 |
Vargaftig, BB | 4 |
Kuyper, LM | 1 |
Paré, PD | 1 |
Hogg, JC | 3 |
Lambert, RK | 1 |
Ionescu, D | 1 |
Woods, R | 1 |
Bai, TR | 2 |
Hays, SR | 1 |
ALBERICI, RA | 3 |
HAJOS, K | 2 |
HAJOS, M | 2 |
TURIAF, J | 1 |
BASSET, G | 1 |
BASSET, F | 1 |
BISERTE, G | 1 |
HAVEZ, R | 1 |
CUVELIER, R | 1 |
SMITH, WG | 1 |
CLARK, FJ | 1 |
WILSON, W | 1 |
WEBB, WR | 1 |
WALDBOTT, GL | 1 |
PRICKMAN, LE | 1 |
REID, L | 5 |
SANERKIN, NG | 2 |
EVANS, DM | 1 |
Groneberg, DA | 2 |
Wagner, U | 1 |
Chung, KF | 1 |
Singer, M | 1 |
Martin, LD | 1 |
Park, J | 1 |
Gruber, AD | 1 |
Adler, KB | 2 |
Araujo, LM | 1 |
Nahori, MA | 2 |
Diem, S | 1 |
Zhu, R | 1 |
Dy, M | 1 |
Leite-de-Moraes, MC | 1 |
Bach, JF | 1 |
Herbelin, A | 1 |
Jungsuwadee, P | 1 |
Laufs, J | 1 |
Andrason, H | 1 |
Sigvaldason, A | 1 |
Halapi, E | 1 |
Thorsteinsson, L | 1 |
Jónasson, K | 1 |
Söebech, E | 1 |
Gislason, T | 1 |
Gulcher, JR | 1 |
Stefansson, K | 1 |
Hakonarson, H | 1 |
Duan, W | 3 |
Chan, JH | 2 |
Wong, CH | 1 |
Shale, DJ | 1 |
Ionescu, AA | 1 |
Hoshino, A | 1 |
Tsuji, T | 1 |
Matsuzaki, J | 1 |
Jinushi, T | 1 |
Ashino, S | 1 |
Teramura, T | 1 |
Chamoto, K | 1 |
Tanaka, Y | 1 |
Asakura, Y | 1 |
Sakurai, T | 1 |
Mita, Y | 1 |
Takaoka, A | 1 |
Nakaike, S | 1 |
Takeshima, T | 1 |
Ikeda, H | 1 |
Nishimura, T | 1 |
Karp, CL | 1 |
Lee, JJ | 2 |
Dimina, D | 1 |
Macias, MP | 1 |
Ochkur, SI | 1 |
McGarry, MP | 1 |
O'Neill, KR | 1 |
Protheroe, C | 1 |
Pero, R | 1 |
Nguyen, T | 1 |
Lenkiewicz, E | 1 |
Colbert, D | 1 |
Rinaldi, L | 1 |
Ackerman, SJ | 1 |
Irvin, CG | 1 |
Lee, NA | 2 |
Humbles, AA | 2 |
McMillan, SJ | 2 |
Friend, DS | 1 |
Xanthou, G | 2 |
McKenna, EE | 1 |
Ghiran, S | 1 |
Gerard, NP | 1 |
Orkin, SH | 1 |
Gerard, C | 2 |
Desmet, C | 1 |
Gosset, P | 1 |
Pajak, B | 1 |
Cataldo, D | 1 |
Bentires-Alj, M | 1 |
Lekeux, P | 1 |
Bureau, F | 1 |
McKay, K | 2 |
Crosby, JR | 2 |
Choo, HH | 1 |
Karras, JG | 2 |
Morice, AH | 1 |
Nagata, K | 1 |
Iwasaki, Y | 1 |
Yamada, T | 1 |
Yuba, T | 1 |
Kohno, K | 1 |
Hosogi, S | 1 |
Ohsugi, S | 1 |
Kuwahara, H | 1 |
Yokomura, I | 1 |
Scherf, W | 1 |
Burdach, S | 1 |
John, AE | 1 |
Gerard, CJ | 1 |
Schaller, M | 2 |
Miller, AL | 1 |
Berlin, AA | 1 |
Yang, G | 1 |
Li, L | 1 |
Volk, A | 1 |
Emmell, E | 1 |
Petley, T | 1 |
Giles-Komar, J | 1 |
Rafferty, P | 1 |
Lakshminarayanan, M | 1 |
Griswold, DE | 1 |
Bugelski, PJ | 1 |
Das, AM | 1 |
Maeda, Y | 1 |
Hizawa, N | 1 |
Fukui, Y | 1 |
Nagai, K | 1 |
Kikuchi, E | 1 |
Takahashi, D | 1 |
Harada, T | 1 |
Suko, N | 1 |
Aguinaldo Datiles, AM | 1 |
Vlahos, CJ | 1 |
Liu, JB | 2 |
Zhang, ZX | 2 |
Xing, LH | 2 |
Parnham, MJ | 1 |
Zhang, GS | 2 |
Naito, A | 1 |
Ohtsuka, M | 1 |
Sekizawa, K | 2 |
Knight, DA | 1 |
Ko, FW | 1 |
Diba, C | 1 |
Roth, M | 1 |
Johnson, PR | 1 |
Salome, C | 1 |
Robichaud, A | 1 |
Tuck, SA | 1 |
Kargman, S | 1 |
Tam, J | 1 |
Wong, E | 1 |
Abramovitz, M | 1 |
Mortimer, JR | 2 |
Mortimer, J | 1 |
Burston, HE | 1 |
Masson, P | 1 |
Hirota, J | 1 |
Slipetz, D | 1 |
Kennedy, B | 1 |
O'Neill, G | 1 |
Xanthoudakis, S | 1 |
Banerjee, ER | 1 |
Ohki, Y | 2 |
Tokuyama, K | 2 |
Mayuzumi, H | 2 |
Sato, A | 1 |
Koyama, H | 2 |
Takizawa, T | 2 |
Arakawa, H | 2 |
Mochizuki, H | 2 |
Morikawa, A | 2 |
Tager, AM | 1 |
Jackobek, R | 1 |
Means, TK | 1 |
Wang, L | 2 |
Elliot, JG | 1 |
Abramson, MJ | 1 |
Walters, EH | 1 |
Kuperman, DA | 2 |
Nguyenvu, L | 1 |
Hölscher, C | 1 |
Brombacher, F | 2 |
O'Hara, J | 1 |
Jones, NS | 1 |
Nishimura, H | 1 |
Mizuno, T | 1 |
Ulrik, CS | 1 |
von Linstow, ML | 1 |
Nepper-Christensen, S | 1 |
Porsbjerg, C | 1 |
Busse, PJ | 2 |
Zhang, TF | 2 |
Srivastava, K | 2 |
Lin, BP | 1 |
Schofield, B | 2 |
Sealfon, SC | 1 |
Encinas, JA | 1 |
Janssen, EM | 1 |
Weiner, DB | 1 |
Calarota, SA | 1 |
Nieto, D | 1 |
Moll, T | 1 |
Carlo, DJ | 1 |
Moss, RB | 1 |
Morcillo, EJ | 1 |
Cortijo, J | 1 |
Wüthrich, B | 1 |
Schmid, A | 1 |
Walther, B | 1 |
Sieber, R | 1 |
Gendler, SJ | 1 |
Rose, MC | 1 |
Rabe, KF | 1 |
Fischer, A | 1 |
Lee, KS | 1 |
Hayflick, JS | 1 |
Lee, YC | 1 |
Puri, KD | 1 |
Köhl, J | 1 |
Baelder, R | 1 |
Pandey, MK | 1 |
Hawlisch, H | 1 |
Best, J | 1 |
Herman, NS | 1 |
Zwirner, J | 1 |
Sfyroera, G | 1 |
Lambris, JD | 1 |
Nakano, T | 1 |
Fukuyama, S | 1 |
Matsumura, M | 1 |
Tsuda, M | 1 |
Matsumoto, T | 1 |
Nakanishi, Y | 1 |
Ishikawa, Y | 1 |
Yoshimoto, T | 1 |
Nakanishi, K | 1 |
Alessandrini, F | 1 |
Schulz, H | 1 |
Takenaka, S | 1 |
Lentner, B | 1 |
Karg, E | 1 |
Behrendt, H | 1 |
Jakob, T | 1 |
Joung, H | 1 |
Lee, J | 1 |
Louis, R | 1 |
Djukanovic, R | 1 |
Muz, MH | 1 |
Deveci, F | 1 |
Bulut, Y | 1 |
Ilhan, N | 1 |
Yekeler, H | 1 |
Turgut, T | 1 |
Gosens, R | 1 |
Zaagsma, J | 1 |
Meurs, H | 1 |
Venkataraman, C | 1 |
Justen, K | 1 |
Zhao, J | 1 |
Galbreath, E | 1 |
Na, S | 1 |
Choo-Wing, R | 1 |
Chapoval, SP | 1 |
Tang, C | 1 |
Kim, YK | 1 |
Ma, B | 1 |
Baluk, P | 1 |
Lin, MI | 1 |
McDonald, DM | 1 |
Sessa, WC | 1 |
Hardy, CL | 1 |
O'Connor, AE | 1 |
Yao, J | 1 |
Sebire, K | 1 |
de Kretser, DM | 1 |
Rolland, JM | 1 |
Anderson, GP | 1 |
Phillips, DJ | 1 |
O'Hehir, RE | 1 |
Chen, C | 1 |
Sheppard, D | 2 |
Okamoto, K | 1 |
Wark, PA | 1 |
Wang, SB | 1 |
Fulkerson, PC | 1 |
Fischetti, CA | 1 |
Rothenberg, ME | 1 |
Sharkhuu, T | 1 |
Matthaei, KI | 1 |
Forbes, E | 1 |
Mahalingam, S | 1 |
Hogan, SP | 1 |
Steenwinckel, V | 1 |
Louahed, J | 2 |
Orabona, C | 1 |
Huaux, F | 1 |
Warnier, G | 1 |
McKenzie, A | 1 |
Lison, D | 1 |
Levitt, R | 1 |
Renauld, JC | 2 |
Magalhães, ES | 1 |
Mourao-Sa, DS | 1 |
Vieira-de-Abreu, A | 1 |
Figueiredo, RT | 1 |
Farias-Filho, FA | 1 |
Fonseca, BP | 1 |
Viola, JP | 1 |
Metz, C | 1 |
Castro-Faria-Neto, HC | 1 |
Bozza, PT | 1 |
Bozza, MT | 1 |
Guha, M | 1 |
Tung, D | 1 |
Miller, DA | 1 |
Bender, B | 1 |
Condon, TP | 1 |
York-DeFalco, C | 1 |
Geary, RS | 1 |
Monia, BP | 1 |
Gregory, SA | 1 |
McElwain, S | 1 |
Ferguson, P | 1 |
Fink, JB | 1 |
Paveglio, SA | 1 |
Allard, J | 1 |
Mayette, J | 1 |
Whittaker, LA | 1 |
Juncadella, I | 1 |
Anguita, J | 1 |
Poynter, ME | 1 |
Swaisgood, CM | 1 |
Aronica, MA | 1 |
Swaidani, S | 1 |
Plow, EF | 1 |
Bao, Z | 1 |
Lim, S | 1 |
Liao, W | 1 |
Thiemermann, C | 1 |
Xiang, YY | 1 |
Liu, M | 1 |
Hirota, JA | 1 |
Ju, W | 1 |
Fan, Y | 2 |
Kelly, MM | 1 |
Ye, B | 1 |
Orser, B | 1 |
O'Byrne, PM | 1 |
Corry, DB | 2 |
Kheradmand, F | 2 |
McCusker, CT | 1 |
Shan, J | 1 |
Kinyanjui, MW | 1 |
Villeneuve, A | 1 |
Michael, H | 1 |
Fixman, ED | 1 |
Smit, J | 1 |
Lindell, D | 1 |
Wang, K | 1 |
Wen, FQ | 1 |
Feng, YL | 1 |
Ou, XM | 1 |
Deng, ZP | 1 |
Kim, MJ | 1 |
Daviskas, E | 1 |
Anderson, SD | 1 |
Young, IH | 1 |
Ohwada, K | 1 |
Watanabe, K | 1 |
Okuyama, K | 1 |
Ohkawara, Y | 1 |
Sugaya, T | 1 |
Takayanagi, M | 1 |
Ohno, I | 1 |
Elnekave, E | 1 |
Mentink-Kane, MM | 1 |
Hodges, MG | 1 |
Pesce, JT | 1 |
Ramalingam, TR | 1 |
Thompson, RW | 1 |
Kamanaka, M | 1 |
Flavell, RA | 1 |
Keane-Myers, A | 1 |
Cheever, AW | 1 |
Ko, HM | 1 |
Kang, NI | 1 |
Kim, YS | 1 |
Lee, YM | 1 |
Jin, ZW | 1 |
Jung, YJ | 1 |
Im, SY | 1 |
Shin, YH | 1 |
Cho, BH | 1 |
López-Boado, YS | 1 |
Nakao, I | 1 |
Kanaji, S | 1 |
Matsushita, H | 1 |
Arima, K | 1 |
Yuyama, N | 1 |
Yamaya, M | 1 |
Nakayama, K | 1 |
Kubo, H | 1 |
Watanabe, M | 1 |
Sagara, H | 1 |
Sugiyama, K | 1 |
Tanaka, H | 2 |
Hayashi, H | 1 |
Shiraki, A | 1 |
Inoue, M | 1 |
Okinami, S | 1 |
Nagai, H | 2 |
Hasegawa, M | 1 |
Fukuda, T | 1 |
Green, ED | 1 |
Hauber, HP | 1 |
Zabel, P | 1 |
Kasaian, MT | 1 |
Miller, DK | 1 |
Lewis, JF | 1 |
Wasserman, SI | 1 |
Ramsdell, JW | 1 |
Smith, B | 1 |
Robertson, RM | 1 |
Robertson, D | 1 |
Pavia, D | 6 |
Lopez-Vidriero, MT | 3 |
Sutton, PP | 2 |
Clarke, SW | 6 |
Shimura, S | 4 |
Takishima, T | 3 |
Nowak, RM | 1 |
Filley, WV | 1 |
Holley, KE | 1 |
Kephart, GM | 1 |
Gleich, GJ | 1 |
Bell, JA | 1 |
Bluestein, BM | 1 |
Danta, I | 1 |
Wanner, A | 11 |
Phipps, RJ | 1 |
Casale, TB | 1 |
Marom, Z | 5 |
Kaliner, M | 5 |
Diaz, P | 1 |
Galleguillos, FR | 1 |
Gonzalez, MC | 1 |
Pantin, CF | 1 |
Kay, AB | 1 |
Muers, MF | 1 |
Morley, J | 2 |
Lewis, M | 1 |
Kallenbach, J | 1 |
Zaltzman, M | 1 |
Hurwitz, M | 1 |
Shapiro, T | 1 |
Zwi, S | 1 |
Agnew, JE | 5 |
Bateman, JR | 3 |
Jones, RS | 1 |
Millman, M | 4 |
Goodman, AH | 1 |
Goldstein, IM | 2 |
Millman, FM | 2 |
Van Campen, SS | 1 |
Bhaskar, K | 1 |
Coles, S | 1 |
Jelihovsky, T | 1 |
Fanta, CH | 2 |
Drazen, JM | 2 |
Sheahan, NF | 2 |
Komarov, FI | 1 |
Daniliak, IG | 1 |
Guliaeva, FE | 1 |
Mindlina, GI | 1 |
Zhukova, AV | 1 |
Middleton, E | 1 |
Atkins, FM | 1 |
Fanning, M | 1 |
Georgitis, JW | 1 |
Simonsson, BG | 1 |
Fruchter, L | 1 |
Gorvoy, J | 1 |
Abramson, A | 1 |
Wind, E | 1 |
Shelhamer, JH | 4 |
Bach, MK | 1 |
Morton, DR | 1 |
Foster, WM | 2 |
Langenback, EG | 1 |
Bergofsky, EH | 3 |
Imhof-Burgener, M | 1 |
de Weck, A | 1 |
Bachofen, H | 1 |
Scherrer, M | 1 |
Bhaskar, KR | 2 |
Ahmed, T | 1 |
Greenblatt, DW | 1 |
Birch, S | 1 |
Marchette, B | 1 |
Häcki, M | 1 |
Brändli, O | 1 |
Bookman, R | 2 |
Medici, TC | 2 |
Radielovic, P | 2 |
Juniper, CP | 1 |
Bonet Agustí, M | 1 |
Casan Clarà, P | 1 |
Savoie, C | 1 |
Plant, M | 1 |
Zwikker, M | 1 |
van Staden, CJ | 1 |
Boulet, L | 1 |
Chan, CC | 1 |
Rodger, IW | 1 |
Pon, DJ | 1 |
Ernst, P | 1 |
Demissie, K | 1 |
Joseph, L | 1 |
Locher, U | 1 |
Becklake, MR | 1 |
Lundgren, JD | 4 |
Vestbo, J | 1 |
Carroll, N | 1 |
Vignola, AM | 1 |
Campbell, AM | 1 |
Fournier, M | 1 |
Godard, P | 1 |
Devine, PL | 1 |
Hanski, C | 1 |
Howard, M | 2 |
Sheehan, JK | 3 |
Kimura, I | 3 |
Tada, S | 2 |
Michoud, MC | 1 |
Fajac, I | 1 |
Pradalier, A | 1 |
Saito, M | 1 |
Fujimura, M | 1 |
Yasui, M | 1 |
Niitani, H | 1 |
Matsuda, T | 1 |
Iken, K | 1 |
Morishita, D | 1 |
Nakamura, Y | 1 |
Murata, Y | 1 |
Fujioka, M | 1 |
Tanizaki, Y | 2 |
Kitani, H | 2 |
Okazaki, M | 2 |
Mifune, T | 2 |
Mitsunobu, F | 2 |
Soda, R | 1 |
Takahashi, K | 1 |
Everard, M | 1 |
Steiger, DJ | 1 |
Basbaum, CB | 1 |
Boushey, HA | 4 |
Grenier, P | 1 |
Mourey-Gerosa, I | 1 |
Benali, K | 1 |
Brauner, MW | 1 |
Leung, AN | 1 |
Lenoir, S | 1 |
Cordeau, MP | 1 |
Mazoyer, B | 1 |
Sagai, M | 2 |
Furuyama, A | 1 |
Ichinose, T | 1 |
Andoh, Y | 1 |
Haraguchi, M | 1 |
Shirato, K | 1 |
Lewis, DB | 1 |
Albert, RK | 1 |
Lamm, WJ | 1 |
Chiang, GK | 2 |
Jones, F | 2 |
Eriksen, P | 1 |
Jonas, M | 1 |
Cambach, W | 1 |
Chadwick-Straver, RV | 1 |
Wagenaar, RC | 1 |
van Keimpema, AR | 1 |
Kemper, HC | 1 |
Nakata, J | 2 |
Takeyama, K | 4 |
Chiyotani, A | 1 |
Konno, K | 1 |
Matsuo, K | 1 |
Araki, M | 1 |
Watanabe, Y | 1 |
Hiraki, S | 1 |
Persson, CG | 1 |
Erjefält, JS | 1 |
Greiff, L | 1 |
Andersson, M | 1 |
Erjefält, I | 1 |
Godfrey, RW | 1 |
Korsgren, M | 1 |
Linden, M | 1 |
Sundler, F | 1 |
Svensson, C | 1 |
Agusti, C | 1 |
Cardell, LO | 1 |
Ueki, I | 1 |
Lausier, J | 1 |
Lou, YP | 1 |
Nadel, JA | 5 |
Jean, R | 1 |
Rufin, P | 1 |
Pfister, A | 1 |
Landais, P | 1 |
Waernessyckle, S | 1 |
de Blic, J | 1 |
Scheinmann, P | 1 |
Takeda, Y | 1 |
Yamawaki, I | 1 |
Richardson, PS | 2 |
Longwill, T | 1 |
Cockrill, BA | 1 |
Hales, CA | 1 |
Zhu, Z | 2 |
Geba, GP | 1 |
Wright, CD | 1 |
Havill, AM | 1 |
Middleton, SC | 1 |
Kashem, MA | 1 |
Lee, PA | 1 |
Dripps, DJ | 1 |
O'Riordan, TG | 2 |
Bevilacqua, MP | 1 |
MacLeod, H | 1 |
Mohrs, M | 1 |
Bottomly, K | 2 |
Misson, J | 1 |
Clark, W | 1 |
Kendall, MJ | 1 |
Mc Ilraith, TB | 1 |
Noskin, GA | 1 |
Corbridge, TC | 1 |
Zhang, DH | 1 |
Parkyn, L | 1 |
Homer, R | 1 |
Ray, P | 1 |
Ray, A | 1 |
Maliszewski, CR | 1 |
Banerjee, R | 1 |
Puniyani, RR | 1 |
Lu, J | 1 |
Poole, KM | 1 |
Dietsch, GN | 1 |
Matsuoka, T | 1 |
Hirata, M | 1 |
Takahashi, Y | 1 |
Murata, T | 1 |
Kabashima, K | 1 |
Sugimoto, Y | 1 |
Kobayashi, T | 1 |
Ushikubi, F | 1 |
Aze, Y | 1 |
Eguchi, N | 1 |
Urade, Y | 1 |
Yoshida, N | 1 |
Kimura, K | 1 |
Mizoguchi, A | 1 |
Honda, Y | 1 |
Narumiya, S | 1 |
Mitchell, TA | 1 |
Lynch, DA | 1 |
Ordoñez, CL | 1 |
Shaughnessy, TE | 1 |
Matthay, MA | 1 |
Toda, M | 2 |
Jen, J | 1 |
Levitt, RC | 2 |
Nicolaides, NC | 1 |
Avila, PC | 1 |
Chu, HW | 1 |
Kraft, M | 1 |
Krause, JE | 1 |
Rex, MD | 1 |
Martin, RJ | 1 |
Del Donno, M | 1 |
Bittesnich, D | 1 |
Chetta, A | 1 |
Olivieri, D | 2 |
Jeffery, PK | 2 |
Laitinen, A | 1 |
Venge, P | 1 |
Trifilieff, A | 1 |
El-Hashim, A | 1 |
Bertrand, C | 1 |
Nicosia, S | 1 |
Capra, V | 1 |
Rovati, GE | 1 |
Bitsori, M | 1 |
Galanakis, E | 1 |
Paraskakis, E | 1 |
Papadakis, CE | 1 |
Kokori, H | 1 |
Sbyrakis, S | 1 |
Blyth, DI | 1 |
Nakanishi, A | 2 |
Morita, S | 2 |
Iwashita, H | 2 |
Sagiya, Y | 2 |
Ashida, Y | 2 |
Shirafuji, H | 1 |
Fujisawa, Y | 2 |
Nishimura, O | 2 |
Fujino, M | 2 |
de Castro Keller, A | 1 |
Ribeiro, OG | 1 |
Adriouch, S | 1 |
Gallois, V | 1 |
de Faria, AM | 1 |
O'Neill, L | 1 |
Sledziewska, J | 1 |
Załeska, J | 1 |
Wiatr, E | 1 |
Płodziszewska, M | 1 |
Załeska, M | 1 |
Pirozynski, M | 1 |
Bestry, I | 1 |
Rowińska-Zakrzewska, E | 1 |
Wu, CA | 1 |
Puddington, L | 1 |
Whiteley, HE | 1 |
Yiamouyiannis, CA | 1 |
Schramm, CM | 1 |
Mohammadu, F | 1 |
Baek, KJ | 1 |
Castaneda, D | 1 |
Nayar, J | 1 |
Roman, M | 1 |
Raz, E | 1 |
Hashimoto, K | 1 |
Ishii, Y | 1 |
Uchida, Y | 1 |
Kimura, T | 1 |
Masuyama, K | 1 |
Morishima, Y | 1 |
Hirano, K | 1 |
Nomura, A | 1 |
Sakamoto, T | 1 |
Takano, H | 1 |
Kirkham, S | 1 |
Knight, D | 1 |
Pae, CI | 1 |
Lee, DK | 1 |
Kim, HO | 1 |
Moon, SH | 1 |
Cao, B | 1 |
Ogbu, C | 1 |
Jeong, KW | 1 |
Kozu, G | 1 |
Nakanishi, H | 1 |
Tulic, MK | 1 |
Tomkiewicz, R | 1 |
Tigani, B | 1 |
Schaeublin, E | 1 |
Sugar, R | 1 |
Jackson, AD | 1 |
Fozard, JR | 1 |
Beckmann, N | 1 |
Evans, C | 1 |
Corry, D | 1 |
Tuvim, M | 1 |
Densmore, C | 1 |
Waldrep, C | 1 |
Knight, V | 1 |
Dickey, B | 1 |
Han, X | 1 |
Bilenki, L | 1 |
Chen, L | 1 |
Justice, JP | 1 |
Crosby, J | 1 |
Borchers, MT | 1 |
Tomkinson, A | 1 |
Hoshino, M | 1 |
Nagi, T | 1 |
Melton, L | 1 |
Koth, LL | 1 |
Chang, GH | 1 |
Dolganov, GM | 1 |
Blasi, A | 1 |
Marzo, C | 1 |
Göbel, P | 1 |
Masala, C | 1 |
Amendolea, MA | 1 |
Bonini, S | 1 |
Foltinová, J | 1 |
Mikulíková, K | 1 |
Soltés, L | 1 |
Widdicombe, JG | 2 |
Mossberg, B | 1 |
Poirier, P | 1 |
Bettendorf, A | 1 |
Garbe, L | 1 |
Casanova, P | 1 |
Kleinsbauer, JP | 1 |
Laval, P | 2 |
Mélon, J | 1 |
Geubelle, F | 1 |
Lambrechts, L | 1 |
Leclercq-Fourcart, J | 1 |
Maréchal, J | 1 |
Eggleston, PA | 1 |
Hendley, JO | 1 |
Gwaltney, JM | 1 |
Eggleston, AW | 1 |
Leavell, BS | 1 |
Powers, RJ | 1 |
Cutz, E | 1 |
Levison, H | 1 |
Cooper, DM | 1 |
Blair, H | 1 |
Viner, AS | 1 |
Zarzecki, S | 2 |
Hirsch, J | 2 |
Epstein, S | 2 |
Ivanova, LA | 1 |
Ketiladze, ES | 1 |
Naumova, VK | 1 |
Rodov, MN | 1 |
Mue, S | 1 |
Ise, T | 1 |
Ono, Y | 1 |
Akasaka, K | 1 |
Nyiredy, G | 1 |
Ferenczy, S | 1 |
Gamble, JE | 1 |
Bizal, JA | 1 |
Daetwyler, EP | 1 |
Sperber, K | 1 |
Gollub, E | 1 |
Goswami, S | 1 |
Kalb, TH | 1 |
Mayer, L | 1 |
Szelenyi, I | 1 |
Achterrath-Tuckermann, U | 1 |
Schmidt, J | 1 |
Minker, E | 1 |
Paegelow, I | 1 |
Werner, H | 1 |
Sasaki, T | 2 |
Ishihara, H | 1 |
Satoh, M | 1 |
Masuda, T | 1 |
Sasaki, H | 2 |
Marom, ZM | 1 |
Lang, DM | 1 |
Simon, RA | 1 |
Mathison, DA | 2 |
Timms, RM | 1 |
Stevenson, DD | 2 |
Tollerud, DJ | 1 |
O'Connor, GT | 1 |
Sparrow, D | 1 |
Haas, F | 1 |
Bishop, MC | 1 |
Salazar-Schicchi, J | 1 |
Axen, KV | 1 |
Lieberman, D | 1 |
Axen, K | 1 |
Garvin, JM | 1 |
Davey, RT | 1 |
Lundgren, B | 1 |
Mullol, J | 1 |
Logun, C | 1 |
Baraniuk, J | 1 |
Kaliner, MA | 4 |
Piacentini, GL | 1 |
Messina, MS | 1 |
Smaldone, GC | 1 |
Hasani, A | 1 |
Irwin, RS | 2 |
Curley, FJ | 1 |
French, CL | 1 |
Anderson, WM | 1 |
Pauwels, R | 1 |
O'Sullivan, DD | 1 |
Coles, SJ | 1 |
Kozakewich, H | 1 |
Vawter, GP | 1 |
Reid, LM | 3 |
Mann, JS | 1 |
George, CF | 1 |
Löfdahl, CG | 1 |
Tomioka, H | 1 |
Leitch, AG | 1 |
Davis, PB | 1 |
Hanley, SP | 1 |
Strachan, DP | 1 |
Anderson, HR | 1 |
Bland, JM | 1 |
Peckham, C | 1 |
Basterra, J | 1 |
Matoses, F | 1 |
Latorre, E | 1 |
Ferrando, C | 1 |
Ziment, I | 1 |
Pride, NB | 1 |
Lang, M | 1 |
Hansen, D | 1 |
Hahn, HL | 1 |
Kneussl, M | 1 |
Varonier, HS | 1 |
O'Byrne, P | 1 |
Valentine, M | 1 |
Woolcock, A | 1 |
Geddes, DM | 1 |
Page, CP | 1 |
Bowen, A | 1 |
Oudjhane, K | 1 |
Odagiri, K | 1 |
Liston, SL | 1 |
Cumming, WA | 1 |
Oh, KS | 1 |
Rachelefsky, GS | 1 |
Niederman, MS | 1 |
Gambino, A | 1 |
Lichter, J | 1 |
Weinblatt, M | 1 |
Fein, AM | 1 |
Schlesinger, RB | 1 |
Suez, D | 1 |
Szefler, SJ | 1 |
DeLuca, SA | 1 |
Mercandetti, AJ | 1 |
Stanley, PJ | 1 |
Wilson, R | 1 |
Greenstone, MA | 1 |
Mackay, IS | 1 |
Cole, PJ | 1 |
Maxwell, GM | 1 |
Azzar, D | 1 |
Massonnet, B | 1 |
Dupin, JP | 1 |
Perrin-Fayolle, M | 1 |
Bennich, H | 1 |
Johansson, SG | 3 |
Colldahl, H | 1 |
Dahlgren, SE | 1 |
Orell, S | 1 |
Kammermeyer, JK | 1 |
Mathews, KP | 1 |
Salvato, G | 1 |
Gent, M | 1 |
Knowlson, PA | 1 |
Rime, FJ | 1 |
Waldman, RH | 1 |
Newman, M | 1 |
Grunspan, R | 1 |
Chlap, Z | 1 |
Orloś, M | 1 |
Zebrak, J | 1 |
Miller, WF | 1 |
Johnston, FF | 1 |
Tarkoff, MP | 1 |
Yeager, H | 1 |
Lamerz, R | 1 |
Fateh-Moghadam, A | 1 |
Khosla, T | 1 |
Lowe, CR | 1 |
Marriott, C | 2 |
Richards, JH | 2 |
Lourenço, RV | 1 |
Charman, J | 1 |
Lopez-Vidriero, T | 1 |
Keal, E | 2 |
Deuschl, H | 1 |
Racoveanu, C | 1 |
Nicolaescu, V | 1 |
Berman, SZ | 1 |
Usselman, JA | 1 |
Shore, S | 1 |
Tan, EM | 1 |
Bennich, HH | 1 |
Berg, T | 1 |
Takino, Y | 1 |
Takino, M | 1 |
Robinson, AE | 1 |
Campbell, JB | 1 |
Blue, JA | 1 |
van der Meulen, GG | 1 |
Wever-Hess, J | 1 |
Lewis, RW | 2 |
Thomas, HM | 1 |
Perezagua Clamagirand, C | 1 |
Díaz-Rubio García, E | 1 |
Kleisbauer, JP | 1 |
Poirier, R | 1 |
Laurent, C | 1 |
Besson, J | 1 |
Rinaldi, R | 1 |
Goddard, RF | 1 |
Mercer, TT | 1 |
O'Neill, PX | 1 |
Flores, RL | 1 |
Sanchez, R | 1 |
Bateman, PP | 1 |
Petty, TL | 1 |
Thurlbeck, WM | 1 |
Licht, W | 2 |
Struckmeier, HF | 1 |
Trendelenburg, F | 1 |
Gibbs, NM | 1 |
French, LW | 1 |
Hirsch, A | 1 |
Vazquez, JJ | 1 |
Pain, MC | 1 |
Denborough, MA | 1 |
Gregg, I | 3 |
Székely, E | 2 |
Farkas, E | 2 |
Flaherty, GN | 1 |
Stebbings, JH | 1 |
Kilburn, KH | 2 |
Marks, MB | 1 |
Smith, RE | 1 |
Boyd, EM | 1 |
Boyd, CE | 1 |
Zenarruza, GA | 1 |
Morgan, AD | 1 |
Bogomoletz, W | 1 |
Trapnell, DH | 1 |
Batten, J | 1 |
Köhler, H | 1 |
Grundon, W | 1 |
Seal, RM | 1 |
Leopold, JG | 1 |
Urschel, HC | 1 |
Paulson, DL | 1 |
Shaw, RR | 1 |
Salama-Robino, G | 1 |
Vismara, E | 1 |
Bianchi, C | 1 |
Tsai, SH | 1 |
Jenne, JW | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC[NCT06152653] | Phase 4 | 20 participants (Anticipated) | Interventional | 2023-11-21 | Recruiting | ||
A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI[NCT03733535] | 29 participants (Actual) | Interventional | 2022-03-01 | Active, not recruiting | |||
The Effect of Immunostimulation With Polyvalent Mechanical Bacterial Lysate on Changes in the Concentration of iNKT Cells in Children With Allergic Rhinitis.[NCT04802616] | Phase 3 | 80 participants (Actual) | Interventional | 2021-03-22 | Completed | ||
The Effect Of Polivalent Mechanical Bacterial Lysate On The Clinical Course Of Grass Pollen-Induced Allergic Rhinitis In Children[NCT04270552] | Phase 3 | 76 participants (Actual) | Interventional | 2018-04-22 | Completed | ||
The Effect of Polyvalent Mechanical Bacterial Lysate on the Reduction of Nasal Staphylococcus Aureus Carriage in Children With Pollen Allergic Rhinitis[NCT04637425] | Phase 3 | 70 participants (Actual) | Interventional | 2018-04-22 | Completed | ||
Severe Asthma Research Program (SARP) - University of Wisconsin[NCT01760915] | 107 participants (Actual) | Observational | 2012-11-28 | Completed | |||
Clinical and Molecular Phenotypes of Severe Asthma[NCT01718197] | 151 participants (Actual) | Observational | 2012-11-30 | Completed | |||
A Two-arm, Placebo-controlled, Randomized Clinical Trial to Evaluate the Effect of Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma[NCT05280418] | Phase 3 | 30 participants (Anticipated) | Interventional | 2022-11-08 | Recruiting | ||
Severe Asthma Research Program[NCT01606826] | 1,100 participants (Anticipated) | Observational | 2012-10-31 | Active, not recruiting | |||
Severe Asthma Research Program[NCT01759186] | 300 participants (Anticipated) | Observational | 2012-12-31 | Active, not recruiting | |||
Severe Asthma Research Program (SARP)-Washington University[NCT01716494] | 121 participants (Actual) | Observational | 2012-10-31 | Active, not recruiting | |||
The Severe Asthma Research Program at Wake Forest University - Longitudinal Phenomics and Genetics of Severe Asthma.[NCT01750411] | 87 participants (Actual) | Observational | 2012-12-31 | Completed | |||
ALXR/FPR Mediated Signaling in Severe Asthma (AMSA)-The Severe Asthma Research Program (SARP) III[NCT01761630] | 126 participants (Actual) | Observational | 2012-12-31 | Completed | |||
"Validation of a Questionnaire to Assess Bronchial Mucus Hypersecretion in Asthmatic Patients. Questionnaire T-sec (Secretion Test)."[NCT05546645] | 100 participants (Anticipated) | Observational | 2023-10-01 | Recruiting | |||
A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection[NCT04784754] | Phase 2 | 0 participants (Actual) | Interventional | 2021-04-01 | Withdrawn (stopped due to lack of subject enrollment) | ||
A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection[NCT04474483] | Phase 2 | 8 participants (Actual) | Interventional | 2020-11-06 | Terminated (stopped due to difficult recruitment and complete first visit in person during thne hight of tne pandemic and later not enough subjects) | ||
Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation[NCT03513458] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2020-09-30 | Withdrawn (stopped due to [The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.) | ||
Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation[NCT03513471] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2019-08-09 | Withdrawn (stopped due to The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.) | ||
A Randomized, Double-Blind, Parallel Group Study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, Both Twice Daily, in a Pediatric Population During the Fall Viral Season.[NCT01192178] | Phase 4 | 339 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
Evaluating the Effects of Curcumin in Moderate to Severe Asthmatics[NCT04353310] | Phase 2 | 0 participants (Actual) | Interventional | 2021-09-30 | Withdrawn (stopped due to No funding) | ||
Role of Cough Assist Device in Mechanically Ventilated Patients in Respiratory Intensive Care Unit : Assiut University Experience[NCT05480371] | 200 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190] | Phase 1 | 6 participants (Actual) | Interventional | 2017-06-05 | Terminated (stopped due to Phase II funding not available) | ||
Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608] | 29 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Evidence that the dose is insufficient.) | |||
Efficacy and Safety of Fluticasone Furoate/Vilanterol vs. Umeclidinium/Vilanterol in Patients With COPD-asthma Phenotype vs. Emphysema Phenotype. A Controled Clinical Trial.[NCT05342558] | Phase 4 | 133 participants (Actual) | Interventional | 2017-09-19 | Completed | ||
Raman Analysis of Saliva From COPD Patients as New Biomarker: AI-based Point-of-care for the Disease Monitoring and Management[NCT04628962] | 250 participants (Anticipated) | Observational | 2022-02-01 | Recruiting | |||
Phenotyping Disease Severity in Asthma: Molecular Investigations of Corticosteroid[NCT05078021] | 60 participants (Anticipated) | Observational | 2022-04-21 | Recruiting | |||
A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)[NCT01097694] | Phase 2 | 176 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype[NCT02075151] | 50 participants (Anticipated) | Interventional | 2014-02-28 | Not yet recruiting | |||
Clinical Trial of NAC in Asthma[NCT02605824] | Phase 4 | 1 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to The study was closed after we determined that this albuterol/NAC regimen may be associated with excessive bronchoconstriction.) | ||
The Effect of NAC on Lung Function and CT Mucus Score[NCT03822637] | Phase 4 | 30 participants (Anticipated) | Interventional | 2019-02-20 | Recruiting | ||
Inpatient Clinical Trial of NAC[NCT03581084] | Phase 4 | 1 participants (Actual) | Interventional | 2018-07-06 | Terminated (stopped due to The study was redesigned to be conducted in an outpatient setting.) | ||
A Phase 2 Study of the Safety and Efficacy of BIO-11006 in the Treatment of Recurrent Osteosarcoma and Ewing's Sarcoma in Patients With Lung Metastases[NCT04183062] | Phase 2 | 10 participants (Anticipated) | Interventional | 2019-10-04 | Active, not recruiting | ||
Anti-inflammatory Effects of Tiotropium in Patients With Stable COPD- A Multicenter Randomized Controlled Double-blind Study[NCT04061161] | Phase 4 | 50 participants (Anticipated) | Interventional | 2019-08-19 | Recruiting | ||
: A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis.[NCT00669331] | Phase 3 | 485 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
Clinical Evaluation of Low Power Radiofrequency Energy Applied to the Posterior Nasal Nerve Area for Symptomatic Relief of Chronic Rhinitis[NCT03727347] | 50 participants (Actual) | Interventional | 2018-10-16 | Completed | |||
Effect of Exposure to Allergens and Air Pollution on Lung Function and Immunity[NCT01792232] | 18 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
[NCT00005284] | 0 participants | Observational | 1985-01-31 | Completed | |||
Assessment of Radio(Chemo)Therapy-related Dysphagia in Head and Neck Cancer Patients Based on Cough-related Acoustic Features[NCT05865756] | 40 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
A worsening asthma day is one on which any of the following occurred: rescue albuterol use above baseline, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than study medication, asthma symptom scores >=3, nighttime awakenings, unscheduled health care visits, or missed school due to asthma. The duration of worsening asthma is the number of consecutive worsening asthma days after the date of a URTS score of 2 (moderate) or 3 (severe) or collection of a mucus sample containing RV (whichever occurred first). Each span of consecutive days is a participant interval. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])
Intervention | Days per participant interval (Mean) |
---|---|
FSC DISKUS 100/50 mcg BID | 4.1 |
FP DISKUS 100 mcg BID | 4.0 |
An asthma-control day was defined as a day without any of the following: rescue albuterol use, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than double-blind study treatment, asthma symptom score >0, nighttime awakenings due to asthma, unscheduled health care visits (defined as home visits, office visits, or urgent care visits), ER visits, hospitalizations for asthma, or school absenteeism due to asthma. The percentage of asthma-control days = the number (No.) of asthma-control days divided by the No. of days of treatment exposure, multiplied by 100. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])
Intervention | Percentage of days (Mean) |
---|---|
FSC DISKUS 100/50 mcg BID | 48.3 |
FP DISKUS 100 mcg BID | 49.7 |
An EF day was defined as a day without any of the following: rescue albuterol use, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than study treatment, asthma symptom score >0, nighttime awakenings due to asthma, unscheduled health care visits (defined as home visits, office visits, or urgent care visits), ER visits, hospitalizations for asthma, school absenteeism due to asthma, or morning peak expiratory flow (measure of maximum airflow) <80% of baseline. Percentage of EF days=No. of EF days divided by No. of days of treatment exposure, multiplied by 100. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])
Intervention | Percentage of days (Mean) |
---|---|
FSC DISKUS 100/50 mcg BID | 42.4 |
FP DISKUS 100 mcg BID | 44.5 |
A rescue-free day was defined as a day during the Peak Viral Period on which no puffs of rescue medication were recorded. Percentage of rescue-free days was defined as the number of days during the Peak Viral Period on which no puffs of rescue medication were recorded, divided by the number of days in that same period on which non-missing values were recorded, multiplied by 100. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])
Intervention | Percentage of days (Mean) |
---|---|
FSC DISKUS 100/50 mcg BID | 92.1 |
FP DISKUS 100 mcg BID | 91.7 |
A symptom-free day was defined as a day during the Peak Viral Period on which the asthma symptom score was zero. The daily asthma symptom score (measured during the day and the previous night) was reported on a 6-point scale (ranging from 0=no symptoms to 5=severe symptoms). Percentage of symptom-free days was defined as the number of days during the Peak Viral Period on which the asthma symptom score=0, divided by the number of days in that same period on which non-missing values were recorded, multiplied by 100. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])
Intervention | Percentage of days (Mean) |
---|---|
FSC DISKUS 100/50 mcg BID | 90.1 |
FP DISKUS 100 mcg BID | 91.1 |
Each participant (with assistance from the parent/legal guardian as needed) was instructed to keep an electronic diary (eDiary) with record of daily URTS symptoms that included: runny nose, sneezing, nasal congestion, and sore throat. Based on the best-described aggregate URTS during the previous 24 hours, participants rated symptoms as: 0 = Not present; 1 = Mild, clearly present; 2 = Moderately severe, uncomfortable; and 3 = Severe, interfering with sleep or activity. Mucus samples were collected and analyzed for RVwhen the eDiary alerted for moderate/severe URTS. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])
Intervention | Number of asthma exacerbations (Number) |
---|---|
FSC DISKUS 100/50 mcg BID | 5 |
FP DISKUS 100 mcg BID | 7 |
An asthma exacerbation was defined as deterioration of asthma that required the use of outpatient oral/parenteral corticosteroids (tablets, suspensions, or injection) or an urgent care, hospitalization, or emergency room (ER) visit due to asthma that required oral/parenteral corticosteroids. Two exacerbations (out of a total of 51) were excluded: (1) one exacerbation occurred within 7 days of the resolution of an earlier one, and, per protocol, was combined with the previous exacerbation; and (2) one exacerbation occurred post treatment. (NCT01192178)
Timeframe: From Baseline (Week 1) until the end of treatment (up to Week 16)
Intervention | Number of asthma exacerbations (Number) |
---|---|
FSC DISKUS 100/50 mcg BID | 24 |
FP DISKUS 100 mcg BID | 25 |
Participants recorded their asthma symptom score over the previous 24 hours (during the day and the previous night) using the following 6-point scale: 0=No symptoms; 1=Symptoms for 1 short period; 2=Symptoms for >=2 short periods; 3=Symptoms for most of the day/previous night that did not affect normal daily activities; 4=Symptoms for most of the day/previous night that affected normal daily activities; 5=Symptoms so severe that participant could not perform normal daily activities. The Baseline mean asthma symptom score was calculated as the average score over 7 days prior to Week 1, Visit 2. (NCT01192178)
Timeframe: Baseline (Week 1) and Peak Viral Period ([period during which the greatest number of viral infections is expected] from 30 August 2010 through the end of the treatment period [up to Week 16])
Intervention | Scores on a scale (Mean) | |
---|---|---|
Baseline, n=105, 104 | Peak Viral Period, n=106, 104 | |
FP DISKUS 100 mcg BID | 0.2 | 0.4 |
FSC DISKUS 100/50 mcg BID | 0.2 | 0.5 |
Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks
Intervention | Participants (Count of Participants) |
---|---|
Phase Ib | 0 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
Intervention | mmHg (Mean) |
---|---|
Treatment | -0.6 |
Control | 1 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.
Intervention | beats per minute (Mean) |
---|---|
Treatment | -1.4 |
Control | 4 |
Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8
Intervention | units on a scale (Least Squares Mean) |
---|---|
Treatment | -1.3 |
Control | -0.25 |
Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8
Intervention | units on a scale (Mean) |
---|---|
Treatment | 12.5 |
Control | 17.7 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8
Intervention | units on a scale (Least Squares Mean) |
---|---|
Treatment | -44.03 |
Control | -6.07 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8
Intervention | units on a scale (Least Squares Mean) |
---|---|
Treatment | -27.3 |
Control | 0.4 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
Intervention | mmHg (Mean) |
---|---|
Treatment | -4.5 |
Control | -6.6 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
Open Label | 64.3 | 35.0 | 90.0 | 16.7 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
Open Label | 31.8 | 24.14 | 72.00 | 8.00 |
Change in airway wall area as assessed by computerized tomography (CT) (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | % of area (Mean) |
---|---|
Imatinib Mesylate | 0.0002 |
Placebo | 0.0002 |
Change in airway wall thickness as assessed by computerized tomography (CT) (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | % of airway (Mean) |
---|---|
Imatinib Mesylate | -0.0040 |
Placebo | -0.0027 |
Change in patient-reported ACQ score The six-item Asthma Control Questionnaire (ACQ-6) is a scale from 0 to 6 with a lower value denoting an improvement in asthma control. The minimal important difference is 0.5. (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | units on a scale (Mean) |
---|---|
Imatinib Mesylate | -0.62 |
Placebo | -0.49 |
Change in patient-reported Asthma Quality of Life Questionnaire (AQLQ) score The asthma quality of life questionnaire (AQLQ) is a 32-item scale with a range from 1-7 with a higher value denoting improvement. The minimal important difference is 0.5. (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | units on a scale (Mean) |
---|---|
Imatinib Mesylate | 0.55 |
Placebo | 0.25 |
Change in patient reported ASUI score The asthma symptom utility index (ASUI) is a 10-item weighted scale with a range from 0.2 to 1 with a higher value indicating improvement. The minimal important difference is 0.09. (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | units on a scale (Mean) |
---|---|
Imatinib Mesylate | 0.07 |
Placebo | 0.05 |
Change in BAL eosinophil percentage (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | % eosinophils (Mean) |
---|---|
Imatinib Mesylate | 2.55 |
Placebo | -2.63 |
Change in BAL neutrophil percentage from baseline (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | % neutrophils (Mean) |
---|---|
Imatinib Mesylate | -0.8 |
Placebo | -0.4 |
Change in blood eosinophil count (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | eosinophils per microliter (Mean) |
---|---|
Imatinib Mesylate | -10.2 |
Placebo | -2.6 |
Change in BAL fluid tryptase levels after 24 weeks of imatinib vs. placebo (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | ng/mL (Mean) |
---|---|
Imatinib Mesylate | -0.74 |
Placebo | 0.43 |
Change in bronchoalveolar lavage (BAL) PGD2 levels from baseline at 6 months (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | pg/mL (Mean) |
---|---|
Imatinib Mesylate | 12.2 |
Placebo | -4.2 |
Change in bronchoalveolar lavage cysteinyl leukotrienes levels from baseline (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | pg/mL (Mean) |
---|---|
Imatinib Mesylate | 3.0 |
Placebo | 6.5 |
Change in bronchoalveolar lavage histamine levels from baseline (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | nM (Mean) |
---|---|
Imatinib Mesylate | 2.1 |
Placebo | -1.1 |
(NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | % of predicted (Mean) |
---|---|
Imatinib Mesylate | 0.01 |
Placebo | -0.08 |
"Our primary outcome was change in airway hyperresponsiveness, as assessed by PC20, from baseline to 3 and/or 6 months of therapy in imatinib treated participants as compared with controls. Change in PC20 was assessed using log2-transformed ratios of PC20 at month 3 and /or month 6 vs PC20 at baseline. Our null hypothesis was that the mean of this ratio will be 0 after log2-transformed. We used a linear mixed-effects model for a repeated-measures analysis to compare the primary outcome between the two groups.~PC20 is determined by the provocation concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1)." (NCT01097694)
Timeframe: Over 6 months from beginning of treatment
Intervention | Log2 Ratio (Mean) |
---|---|
Imatinib Mesylate | 1.73 |
Placebo | 1.07 |
Change in the biopsy smooth muscle tryptase-positive mast cells from baseline at 6 months (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | mast cells per mm2 (Mean) |
---|---|
Imatinib Mesylate | -102.7 |
Placebo | -79.2 |
Change in endobronchial biopsy total tryptase-positive mast cells from baseline at 6 months (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | mast cells per mm2 (Mean) |
---|---|
Imatinib Mesylate | -54.2 |
Placebo | -32.3 |
Change in patient-reported evening peak flow measurement (L/s) (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | L/second (Mean) |
---|---|
Imatinib Mesylate | 8.3 |
Placebo | -8.2 |
Change in FEV1 in treatment group compared to placebo group (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | L (Mean) |
---|---|
Imatinib Mesylate | 0.046 |
Placebo | 0 |
Change in FEV1% of predicted (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | % of predicted (Mean) |
---|---|
Imatinib Mesylate | 2.3 |
Placebo | 0.78 |
Change in Fractional Exhaled Nitric Oxide Measurement (ppb) (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | parts per billion (Mean) |
---|---|
Imatinib Mesylate | 7.89 |
Placebo | -5.92 |
Change in patient-reported morning peak flow measurement (L/s) (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | L/second (Mean) |
---|---|
Imatinib Mesylate | 7.3 |
Placebo | -6.4 |
Number of asthma exacerbations experienced from randomization to study completion. (NCT01097694)
Timeframe: Up to 24 weeks
Intervention | events (Number) |
---|---|
Imatinib Mesylate | 16 |
Placebo | 20 |
Change in serum total tryptase after 24 weeks of imatinib vs placebo treatment (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | ng/ml (Mean) |
---|---|
Imatinib Mesylate | -2.02 |
Placebo | -0.56 |
Change in urinary leukotriene E4 levels from baseline (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | ng/mg Creatinine (Mean) |
---|---|
Imatinib Mesylate | 0.07 |
Placebo | 0.01 |
Change in urinary Prostaglandin D2 levels from baseline (NCT01097694)
Timeframe: 6 months after start of treatment
Intervention | ng/mg Creatinine (Mean) |
---|---|
Imatinib Mesylate | -0.30 |
Placebo | 0.39 |
Post-treatment FEV1 is reported. FEV1 is measured via spirometry. (NCT03581084)
Timeframe: end of the one week treatment period
Intervention | liters (Number) |
---|---|
N-acetylcysteine | 0.86 |
Mean rate of hospitalisations (number/year) summarised and analysed to take account of differing follow-up times. (NCT00669331)
Timeframe: 52 weeks
Intervention | hospitalisations/year (Mean) |
---|---|
Mannitol | 0.12 |
Control | 0.20 |
Rate of antibiotic treated graded pulmonary exacerbations, using the same definition of a graded pulmonary exacerbation as the primary endpoint. A graded pulmonary exacerbation was considered to be anti-biotic treated if use of oral, IV or inhaled antibiotic use was recorded related to the GPE event. (NCT00669331)
Timeframe: 52 weeks
Intervention | events/year (Number) |
---|---|
Mannitol | 1.9 |
Control | 2.1 |
Duration of graded exacerbations is defined as the number of days with graded PE within one treatment year. Mean days estimated via negative binomial model with treatment, region and baseline pulmonary exacerbation rate as predictors, with log of follow-up time as the offset variable (NCT00669331)
Timeframe: 52 weeks
Intervention | Days with GPE (Mean) |
---|---|
Mannitol | 31.49 |
Control | 35.74 |
(NCT00669331)
Timeframe: 52 weeks
Intervention | mL/s (Least Squares Mean) |
---|---|
Mannitol | -18.21 |
Control | -3.40 |
(NCT00669331)
Timeframe: 52 weeks
Intervention | mL (Least Squares Mean) |
---|---|
Mannitol | 2.36 |
Control | -5.20 |
FEV1 expressed as a ratio of FVC. Endpoint is expressed as a percentage ie FEV1/FVC*100 (NCT00669331)
Timeframe: 52 weeks
Intervention | ratio (expressed as a %) (Least Squares Mean) |
---|---|
Mannitol | -0.08 |
Control | 0.09 |
(NCT00669331)
Timeframe: 52 weeks
Intervention | mL (Least Squares Mean) |
---|---|
Mannitol | 0.15 |
Control | -15.70 |
hematology assessed as clinically significant abnormal FBC (Full Blood count) at any point post baseline. (NCT00669331)
Timeframe: 52 weeks
Intervention | participants (Number) |
---|---|
Mannitol | 13 |
Control | 5 |
sputum microbiology assessed as the presence of abnormal flora in sputum sample taken at any post baseline visit (NCT00669331)
Timeframe: 52 weeks
Intervention | participants (Number) |
---|---|
Mannitol | 81 |
Control | 81 |
Time to first graded exacerbation is defined as the duration (in months) from the randomisation date to the start of the first reported graded PE during the on-treatment period. Patients without reported graded PE event will be censored at the last participation. (NCT00669331)
Timeframe: 52 weeks
Intervention | months (Median) |
---|---|
Mannitol | 5.4 |
Control | 4.1 |
Epworth Sleepiness Scale (ESS) score was calculated as the sum of scores for each of eight individual questions, such that a total score of zero represents no daytime sleepiness, and a total score of 24 represents the maximum degree of daytime sleepiness. Measured at baseline, 6 weeks, 16 weeks, 28 weeks, 40 weeks, 52 weeks (NCT00669331)
Timeframe: 52 weeks
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Week 6 | Week 16 | Week 28 | Week 40 | Week 52 | |
Control | 6.89 | 6.87 | 6.50 | 6.57 | 6.33 | 6.34 |
Mannitol | 7.23 | 6.07 | 6.21 | 6.05 | 6.32 | 6.09 |
The SGRQ was collected at baseline, week 6, week 16, week 28, week 40 and week 52. Change in total score was calculated from baseline. Total scores are a weighted sum across all questions. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. Higher scores indicate lower quality of life. Outcome data table gives the raw mean total score at each visit. (NCT00669331)
Timeframe: 52 weeks
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Week 6 | Week 16 | Week 28 | Week 40 | Week 52 | |
Control | 52.22 | 44.55 | 44.23 | 43.46 | 43.51 | 42.25 |
Mannitol | 52.98 | 44.09 | 40.67 | 41.45 | 40.39 | 41.43 |
A graded pulmonary exacerbation was defined as a worsening in signs and symptoms requiring a change in treatment (Center for Drug Evaluation and Research (CDER), 2007). Grade I was required 3 main signs and symptoms, Grade II 2 main signs and symptoms and Grade III 1 main and one or more minor signs and symptoms. Main signs and symptoms were increased cough, sputum volume or sputum purulence. Minor were upper respiratory tract infection, fever, increased wheezing, increased dyspnea, increase in respiratory rate, increase in cardiac frequency of >20%, and increased malaise, fatigue or lethargy. Rate is defined as the number of all GPE events observed in one treatment year (NCT00669331)
Timeframe: 52 weeks
Intervention | GPE events per year (Number) | |
---|---|---|
Raw rate | Rate from negative binomial model | |
Control | 2.10 | 1.84 |
Mannitol | 1.95 | 1.69 |
Clinical chemistry was assessed as clinically significant abnormal liver function test and clinically significant abnormal urea/electrolyte test at any point post baseline. (NCT00669331)
Timeframe: 52 weeks
Intervention | participants (Number) | |
---|---|---|
Subjects with Clin sig liver funtion tests at wk52 | Subjects with clin sig urea/electrolyte test wk52 | |
Control | 0 | 0 |
Mannitol | 2 | 3 |
24 hour sputum weight, measured at baseline, week 6, week 16, week 28, week 40, week 52 (NCT00669331)
Timeframe: 52 weeks
Intervention | g (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Week 6 | Week 16 | Week 28 | Week 40 | Week 52 | |
Control | 28.96 | 22.82 | 20.25 | 18.88 | 18.17 | 18.33 |
Mannitol | 28.88 | 24.97 | 23.69 | 22.92 | 21.56 | 20.54 |
"Mean change in Reflective Total Nasal Symptoms Score (rTNSS) from baseline to 12 weeks post-study procedure. Improvement (12 week score - baseline score) is signified by a negative value.~The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. This study will measure the mean change in the rTNSS total score from Baseline to 12 week follow up visit" (NCT03727347)
Timeframe: Comparison of scores at Baseline and 12 weeks post procedure
Intervention | units on a scale (Mean) |
---|---|
InSeca Stylus Treatment Group | -5.1 |
"Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores range from 0 to 12. A higher score indicates increased symptom severity.~The mean change in the rTNSS total score from Baseline to each follow up visit: 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure will be recorded." (NCT03727347)
Timeframe: Baseline to each Follow Up Visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure.
Intervention | score on a scale (Mean) |
---|---|
Treatment Group - Baseline | 8.5 |
Treatment Group - 2 Week Data | 4.8 |
Treatment Group - 4 Week Data | 3.6 |
Treatment Group - 12 Week Data | 3.4 |
Treatment Group - 26 Week Data | 3.3 |
Treatment Group - 52 Week Data | 3.6 |
"Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure. Subjects were asked about possible side effects or adverse experiences related to the study procedure at each follow up visit. Each event was documented and identified as to its relationship and level of relatedness to the study device and/or study procedure.~This measure includes any subject who experienced at least one event considered definitely, probably, or possibly related to the device or procedure." (NCT03727347)
Timeframe: At or following the study procedure, and up to the final study visit at 1 year.
Intervention | Participants (Count of Participants) |
---|---|
InSeca Stylus Treatment Group | 8 |
"The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity.~Subjects who showed at least a 1 point improvement (decrease) in the reflective Total Nasal Symptom Score (rTNSS) were categorized as responders. An overall responder rate of at least 55% was expected." (NCT03727347)
Timeframe: Comparison of scores at Baseline and 12 weeks post procedure
Intervention | Participants (Count of Participants) |
---|---|
InSeca Stylus Treatment Group | 46 |
"Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity.~Scores from each of the four components of the questionnaire (rhinorrhea, nasal congestion, nasal itching, and sneezing) will be evaluated at each follow up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. Individual component scores can range from 0 to 3, with a higher score indicating increased symptom severity." (NCT03727347)
Timeframe: Baseline to each Follow Up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure
Intervention | score on a scale (Mean) | |||
---|---|---|---|---|
Rhinorrhea | Nasal Congestion | Nasal Itching | Sneezing | |
Treatment Group - 12 Week Data | 1.0 | 1.1 | 0.5 | 0.9 |
Treatment Group - 2 Week Data | 1.6 | 1.5 | 0.7 | 1.0 |
Treatment Group - 26 Week Data | 0.9 | 1.1 | 0.5 | 0.8 |
Treatment Group - 4 Week Data | 1.2 | 1.1 | 0.4 | 0.8 |
Treatment Group - 52 Week Data | 1.1 | 1.2 | 0.5 | 0.8 |
Treatment Group - Baseline | 2.5 | 2.5 | 1.7 | 1.9 |
"This Quality-of-Life (QOL) instrument is a 9-item patient self-reported questionnaire developed by Aerin Medical to gain understanding of the impact of chronic rhinitis on daily activities, feelings, symptoms and medication use. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative.~Section 1 asks Please indicate how often you experience the following for 6 items. For items 1, 3, 4 and 5, those who answered never/rarely were considered to have a positive (favorable) response. For questions 2 and 6, those who answered frequently/very frequently were considered to have a positive (favorable) response. Section 2 requests Please indicate how often you use each of the following products to help you with your chronic rhinitis. For 3 items in this section, those who answered never/rarely were considered to have a positive (favorable) response." (NCT03727347)
Timeframe: The QOL was to be completed by the subject at baseline prior to the treatment procedure, and at the 12 week, 26 week and 52 week visits post procedure.
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Section 1, Item 1: Difficulty falling asleep72500892 | Section 1, Item 1: Difficulty falling asleep72500885 | Section 1, Item 1: Difficulty falling asleep72500891 | Section 1, Item 1: Difficulty falling asleep72500893 | Section 1, Item 2: Good sleep throughout the night72500885 | Section 1, Item 2: Good sleep throughout the night72500891 | Section 1, Item 2: Good sleep throughout the night72500892 | Section 1, Item 2: Good sleep throughout the night72500893 | Section 1, Item 3: Feeling fatigued during the day72500885 | Section 1, Item 3: Feeling fatigued during the day72500891 | Section 1, Item 3: Feeling fatigued during the day72500892 | Section 1, Item 3: Feeling fatigued during the day72500893 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500885 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500891 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500892 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500893 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500885 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500891 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500892 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500893 | Section 1, Item 6: Having a good sense of overall well-being72500885 | Section 1, Item 6: Having a good sense of overall well-being72500891 | Section 1, Item 6: Having a good sense of overall well-being72500892 | Section 1, Item 6: Having a good sense of overall well-being72500893 | Section 2, Item 1: Oral medications72500885 | Section 2, Item 1: Oral medications72500891 | Section 2, Item 1: Oral medications72500892 | Section 2, Item 1: Oral medications72500893 | Section 2, Item 2: Nasal sprays72500885 | Section 2, Item 2: Nasal sprays72500891 | Section 2, Item 2: Nasal sprays72500892 | Section 2, Item 2: Nasal sprays72500893 | Section 2, Item 3: Nasal breathing strips72500885 | Section 2, Item 3: Nasal breathing strips72500891 | Section 2, Item 3: Nasal breathing strips72500892 | Section 2, Item 3: Nasal breathing strips72500893 | |||||||||||||||||||||||||||||||||||||
Positive (favorable) response | Neutral or Negative response | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 34 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 40 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 41 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - Baseline | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 12 Week Data | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 26 Week Data | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment Group - 52 Week Data | 2 |
125 reviews available for guaifenesin and Asthma
Article | Year |
---|---|
Role of mucolytics in wet cough.
Topics: Ambroxol; Asthma; Bronchodilator Agents; Cholinergic Antagonists; Cough; Cystic Fibrosis; Expectoran | 2013 |
"Combination" anti-asthmatic therapy: recent developments.
Topics: Aminophylline; Asthma; Barbiturates; Ephedrine; Expectorants; Guaifenesin; Humans; Hydroxyzine; Hypn | 1974 |
Drug treatment in bronchial asthma.
Topics: Acetylcysteine; Anti-Bacterial Agents; Asthma; Bronchodilator Agents; Caffeine; Drug Combinations; E | 1973 |
Nanoparticles for local delivery of siRNA in lung therapy.
Topics: Administration, Inhalation; Asthma; Drug Carriers; Humans; Lung; Lung Neoplasms; Macrophages, Alveol | 2021 |
Nanocarrier-based approaches to combat chronic obstructive pulmonary disease.
Topics: Asthma; Chronic Disease; Humans; Mucus; Pulmonary Disease, Chronic Obstructive | 2022 |
The Pathology of Asthma: What Is Obstructing Our View?
Topics: Asthma; Humans; Inflammation; Mucus; Sputum | 2023 |
Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers.
Topics: Asthma; Cystic Fibrosis; Humans; Lung; Mucus; Pulmonary Disease, Chronic Obstructive | 2023 |
More Than Just a Barrier: The Immune Functions of the Airway Epithelium in Asthma Pathogenesis.
Topics: Airway Remodeling; Animals; Asthma; Chemokines; Epithelial Cells; Epithelium; Humans; Immunoglobulin | 2020 |
Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases.
Topics: Asthma; Cystic Fibrosis; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Histone C | 2018 |
Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition).
Topics: Animals; Asthma; Bronchiectasis; China; Consensus; Cystic Fibrosis; Drainage; Expectorants; Humans; | 2018 |
Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.
Topics: Animals; Asthma; Cystic Fibrosis; Humans; Mucus; Neuropeptides; Pulmonary Disease, Chronic Obstructi | 2018 |
Role of microRNAs and exosomes in asthma.
Topics: Asthma; Exosomes; Gene Expression Profiling; Genome-Wide Association Study; Humans; MicroRNAs; Mucus | 2019 |
Autopsy and Imaging Studies of Mucus in Asthma. Lessons Learned about Disease Mechanisms and the Role of Mucus in Airflow Obstruction.
Topics: Airway Obstruction; Asthma; Autopsy; Cytokines; Eosinophils; Humans; Mucus; Multidetector Computed T | 2018 |
Adverse immunological imprinting by cytomegalovirus sensitizing for allergic airway disease.
Topics: Animals; Asthma; Cell Differentiation; Cytokines; Cytomegalovirus Infections; Dendritic Cells; Disea | 2019 |
The role of macrolides in asthma: current evidence and future directions.
Topics: Anti-Infective Agents; Asthma; Disease Progression; Humans; Immunomodulation; Macrolides; Mucus; Phe | 2014 |
Secretory hyperresponsiveness and pulmonary mucus hypersecretion.
Topics: Animals; Asthma; Autonomic Nervous System; Bronchi; Bronchoconstriction; Humans; Mucus | 2014 |
CLCA1 and TMEM16A: the link towards a potential cure for airway diseases.
Topics: Anoctamin-1; Asthma; Cell Transdifferentiation; Chloride Channels; Epithelial Cells; Humans; Mucus; | 2015 |
Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases.
Topics: Airway Remodeling; Asthma; Chloride Channels; Ellagic Acid; ErbB Receptors; GABA Antagonists; Ginkgo | 2016 |
Structural aspects of airway remodeling in asthma.
Topics: Animals; Asthma; Cell Proliferation; Cytokines; Epithelial Cells; Extracellular Matrix Proteins; Fib | 2008 |
Novel approaches for inhibition of mucus hypersecretion in asthma.
Topics: Airway Obstruction; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Elasticity; Ex | 2007 |
Mucus hypersecretion in asthma: causes and effects.
Topics: Airway Obstruction; Asthma; Humans; Lung; Mucin 5AC; Mucin-5B; Mucus | 2009 |
Mucins, mucus, and sputum.
Topics: Asthma; Bronchitis, Chronic; Cystic Fibrosis; Female; Humans; Male; Mucins; Mucociliary Clearance; M | 2009 |
Gamma-aminobutyric acid nurtures allergic asthma.
Topics: Animals; Asthma; Bronchi; Epithelial Cells; gamma-Aminobutyric Acid; Humans; Models, Immunological; | 2009 |
The mechanism of mucus production in bronchial asthma.
Topics: Animals; Asthma; Chloride Channels; Gene Expression; Goblet Cells; Humans; Interleukin-13; Mucin 5AC | 2009 |
Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy.
Topics: Animals; Asthma; Drug Delivery Systems; Drug Therapy; ErbB Receptors; Goblet Cells; Humans; Hyperpla | 2010 |
Interrupting the cough reflex in asthma.
Topics: Adrenal Cortex Hormones; Asthma; Cough; Expectorants; Humans; Mucus; Reflex | 2010 |
The future in paediatric respirology.
Topics: Adult; Asthma; Bronchopulmonary Dysplasia; Child; Chronic Disease; Cystic Fibrosis; Humans; Infant, | 2010 |
Role of transforming growth factor-β in airway remodeling in asthma.
Topics: Airway Remodeling; Animals; Asthma; Eosinophils; Goblet Cells; Humans; Inflammation Mediators; Lung; | 2011 |
New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.
Topics: Animals; Asthma; Cyclooxygenase 2; Cytokines; Drug Delivery Systems; Goblet Cells; Humans; Hyperplas | 2010 |
[Voice disorders in asthma].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Asthma; Dysphonia; Humans; Laryngopharyngeal Re | 2010 |
Airway mucus function and dysfunction.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr | 2010 |
Airway mucus function and dysfunction.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr | 2010 |
Airway mucus function and dysfunction.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr | 2010 |
Airway mucus function and dysfunction.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr | 2010 |
[Mechanotransduction and the bronchoalveolar epithelium].
Topics: Apoptosis; Asthma; Bronchi; Cilia; Collagen; Cytokines; Epithelial Cells; Epithelium; ErbB Receptors | 2010 |
The sentinel role of the airway epithelium in asthma pathogenesis.
Topics: Adaptive Immunity; Adult; Airway Remodeling; Allergens; Animals; Anti-Inflammatory Agents; Asthma; C | 2011 |
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato | 2012 |
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato | 2012 |
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato | 2012 |
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato | 2012 |
The airway epithelium in asthma.
Topics: Airway Remodeling; Allergens; Animals; Asthma; Basement Membrane; Cell Communication; Cytokines; Den | 2012 |
Airway goblet cell hyperplasia in asthma: hypersecretory and anti-inflammatory?
Topics: Animals; Asthma; Goblet Cells; Guinea Pigs; Humans; Hyperplasia; Interleukins; Mice; Models, Animal; | 2002 |
Regulation of the depth and composition of airway surface liquid.
Topics: Animals; Asthma; Body Water; Bronchitis; Cystic Fibrosis; Ion Channels; Mucus; Respiratory Mucosa; R | 2002 |
Post-secretory fate of host defence components in mucus.
Topics: Animals; Asthma; Cattle; Cilia; Humans; Hyaluronic Acid; Kallikreins; Lactoperoxidase; Mucins; Mucus | 2002 |
Current and future therapies for airway mucus hypersecretion.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Chloride Channels; Cystic Fibrosis; Drug De | 2002 |
Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy.
Topics: Asthma; Capillary Permeability; Chloride Channels; Glucocorticoids; Histamine Antagonists; Humans; M | 2003 |
Pulmonary mucus: Pediatric perspective.
Topics: Adult; Age Factors; Antioxidants; Asthma; Bronchitis; Child; Cholinergic Antagonists; Cytokines; Enz | 2003 |
[Mechanisms and control of airway remodeling].
Topics: Airway Obstruction; Asthma; Basement Membrane; Bronchi; Bronchial Hyperreactivity; Constriction, Pat | 2003 |
Interleukin-13 in asthma pathogenesis.
Topics: Asthma; Eosinophilia; Epithelial Cells; Humans; Interleukin-13; Interleukin-13 Receptor alpha1 Subun | 2004 |
Airway mucus hypersecretion in asthma: an undervalued pathology?
Topics: Airway Obstruction; Asthma; Cytokines; Humans; Mucus; Phenotype; Pulmonary Disease, Chronic Obstruct | 2004 |
Post-nasal drip syndrome--a symptom to be sniffed at?
Topics: Asthma; Cough; Diagnosis, Differential; Gastroesophageal Reflux; Humans; Mucus; Nasal Cavity; Rhinit | 2004 |
Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections.
Topics: Anti-Bacterial Agents; Asthma; Bronchiolitis; Cystic Fibrosis; Cytokines; Gene Expression; Humans; I | 2005 |
Structural changes in the airways in asthma: observations and consequences.
Topics: Adult; Asthma; Bronchial Hyperreactivity; Bronchoconstriction; Child; Humans; Lung; Mucus; Muscle, S | 2005 |
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologist.
Topics: Angiotensin-Converting Enzyme Inhibitors; Asthma; Bronchitis, Chronic; Chronic Disease; Cough; Eosin | 2005 |
Mucus and MUC in asthma.
Topics: Asthma; Chronic Disease; Humans; Mucins; Mucus; Phenotype; Respiratory Mucosa | 2006 |
Milk consumption does not lead to mucus production or occurrence of asthma.
Topics: Animals; Asthma; Evidence-Based Medicine; Humans; Milk; Mucus; Nasal Mucosa; Perception | 2005 |
Regulation of mucin genes in chronic inflammatory airway diseases.
Topics: Animals; Asthma; Cystic Fibrosis; Cytokines; Disease Models, Animal; Gene Expression Regulation; Hum | 2006 |
Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.
Topics: Animals; Asthma; Bronchodilator Agents; Humans; Lung; Mucus; Neuropeptides; Pituitary Adenylate Cycl | 2006 |
Treatment of airway mucus hypersecretion.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchitis, Chronic; Drug Design; Goblet Ce | 2006 |
Is the neutrophil a worthy target in severe asthma and chronic obstructive pulmonary disease?
Topics: Asthma; Humans; Interleukin-5; Lung; Mucus; Neutrophils; Pulmonary Disease, Chronic Obstructive; Tre | 2006 |
Muscarinic receptor signaling in the pathophysiology of asthma and COPD.
Topics: Acetylcholine; Animals; Asthma; Bronchodilator Agents; Cell Differentiation; Cell Proliferation; Fib | 2006 |
Asthma exacerbations . 3: Pathogenesis.
Topics: Acute Disease; Allergens; Asthma; Bronchiolitis; Disease Susceptibility; Environmental Pollutants; H | 2006 |
Novel medications for asthma: a look at the future.
Topics: Airway Obstruction; Animals; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Drug Delivery | 2007 |
Respiratory syncytial virus-induced pulmonary disease and exacerbation of allergic asthma.
Topics: Animals; Asthma; Chemokines; Dendritic Cells; Disease Models, Animal; Humans; Immunity, Innate; Mice | 2007 |
Physiology of airway mucus secretion and pathophysiology of hypersecretion.
Topics: Anti-Inflammatory Agents; Asthma; Bronchi; Cystic Fibrosis; Humans; Inhalation Exposure; Intracellul | 2007 |
Role of airway epithelial cells in development of asthma and allergic rhinitis.
Topics: Asthma; Bronchi; Cytokines; Epithelial Cells; Humans; Inflammation Mediators; Mucus; Rhinitis; Th2 C | 2008 |
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
Topics: Animals; Anti-Bacterial Agents; Asthma; Chronic Disease; Cystic Fibrosis; Defensins; Epithelial Cell | 2008 |
Emerging mucus regulating drugs in inflammatory and allergic lung disease.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases, Obstructive; Mucins; Mucus; Respiratory System Agent | 2008 |
IL-13 as a therapeutic target for respiratory disease.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Fibrosis; Humans; Inflammation; Interleukin-13; Interleu | 2008 |
Acute bronchial asthma.
Topics: Acute Disease; Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Aero | 1983 |
The airway mucociliary system.
Topics: Animals; Asthma; Autonomic Nervous System; Biological Transport; Bronchi; Bronchitis; Calcium; Cats; | 1981 |
The pathology of asthma.
Topics: Asthma; Bronchi; Bronchial Spasm; Edema; Humans; Mucous Membrane; Mucus; Muscle, Smooth | 1984 |
Experimental models of asthma.
Topics: Airway Resistance; Animals; Asthma; Bronchi; Bronchial Provocation Tests; Cilia; Disease Models, Ani | 1982 |
Management of asthma in the child aged under 6 years.
Topics: Allergens; Asthma; Attitude to Health; Bronchodilator Agents; Child; Child, Preschool; Cromolyn Sodi | 1981 |
Cellular mechanisms in the pathogenesis and pathophysiology of asthma.
Topics: Aged; Airway Obstruction; Asthma; Atropine; Bronchial Spasm; Calcium; Eosinophils; Humans; Immunity, | 1981 |
Chronic cough and expectoration in patients with asthma and in patients with alpha1-antitrypsin deficiency.
Topics: alpha 1-Antitrypsin Deficiency; Asthma; Bronchitis; Chronic Disease; Cough; Female; Humans; Male; Mu | 1982 |
[Dysphonia produced by corticoid inhalation: truth or myth?].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Child; Female; Glottis; Humans; | 1995 |
[Mechanisms of bronchial hyperreactivity. Role of the epithelium].
Topics: Animals; Antigens, CD; Asthma; Biopsy; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Capi | 1994 |
Airway goblet cells: responsive and adaptable front-line defenders.
Topics: Animals; Asthma; Bronchitis; Cystic Fibrosis; Exocrine Glands; Humans; Hyperplasia; Mucins; Mucus; P | 1994 |
[Bronchial asthma with hypersecretion].
Topics: Asthma; Humans; Mucus | 1994 |
[Bronchial hyperreactivity: neurogenic factors].
Topics: Adrenergic Fibers; Afferent Pathways; Asthma; Autonomic Nervous System; Bronchial Hyperreactivity; C | 1994 |
Late-phase reaction in asthma: basic mechanisms.
Topics: Asthma; Basophils; Bronchoconstriction; Cell Degranulation; Eosinophils; Forced Expiratory Volume; H | 1993 |
Smooth muscle as a direct or indirect target accounting for bronchopulmonary hyperresponsiveness.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchoconstriction; Humans; Inflammation; Inflammation | 1997 |
[Airway hypersecretion and mucociliary dysfunction in asthma].
Topics: Animals; Asthma; Bronchi; Humans; Mucociliary Clearance; Mucus | 1998 |
Plasma-derived proteins in airway defence, disease and repair of epithelial injury.
Topics: Animals; Asthma; Blood Proteins; Epithelium; Exudates and Transudates; Humans; Mucous Membrane; Mucu | 1998 |
Allergic bronchopulmonary aspergillosis.
Topics: Administration, Oral; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigatus; Asthma; Bronc | 1999 |
Therapeutic aerosols and airway secretions.
Topics: Aerosols; Animals; Anti-Asthmatic Agents; Asthma; Cystic Fibrosis; Drug Combinations; Fatty Alcohols | 1996 |
Therapeutic advances: leukotriene antagonists for the treatment of asthma.
Topics: Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; Capillary Permeability; Child | 1999 |
Airway inflammation and remodeling in asthma.
Topics: Airway Obstruction; Asthma; Basement Membrane; Bronchi; Bronchial Hyperreactivity; Bronchitis; Const | 2000 |
Exogenous surfactant therapy and mucus rheology in chronic obstructive airway diseases.
Topics: Animals; Asthma; Bronchitis; Cystic Fibrosis; Humans; Mucociliary Clearance; Mucus; Pulmonary Surfac | 2000 |
Inflammatory and structural changes in the airways of patients with asthma.
Topics: Asthma; Bronchi; Circadian Rhythm; Epithelium; Humans; Mucus; Respiratory System | 2000 |
The effect of inflammation on mucociliary clearance in asthma: an overview.
Topics: Animals; Asthma; Biomarkers; Bronchitis; Chronic Disease; Histamine; Humans; Leukotrienes; Mucocilia | 2000 |
Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Enzyme Inhibitors; Expectorants; Humans; Lung Disea | 2000 |
Biopsy markers of airway inflammation and remodelling.
Topics: Asthma; Biomarkers; Biopsy; Bronchitis; Chronic Disease; Growth Substances; Humans; Mucus; Muscle, S | 2000 |
Leukotrienes as mediators of asthma.
Topics: Animals; Asthma; Cell Division; Humans; Inflammation; Leukotriene Antagonists; Leukotrienes; Mucus; | 2001 |
Role of epidermal growth factor receptor activation in regulating mucin synthesis.
Topics: Animals; Asthma; Cell Differentiation; Cell Division; Epithelial Cells; ErbB Receptors; Goblet Cells | 2001 |
Remodeling of the airway epithelium in asthma.
Topics: Animals; Asthma; Biopsy; Bronchi; Bronchoconstriction; Capillary Permeability; Cell Degranulation; C | 2001 |
Mucoactive drugs for asthma and COPD: any place in therapy?
Topics: Asthma; Clinical Trials as Topic; Deoxyribonuclease I; Expectorants; Humans; Iodides; Mucins; Mucus; | 2002 |
Effects of drugs on mucus glycoproteins and water in bronchial secretion.
Topics: Adrenergic beta-Agonists; Animals; Asthma; Bronchi; Bronchodilator Agents; Carbocysteine; Cyclic AMP | 1979 |
Clinical aspects of mucociliary transport.
Topics: Air Pollutants; Anesthetics; Animals; Asthma; Bronchitis; Chronic Disease; Cilia; Cystic Fibrosis; H | 1977 |
The role of mucociliary dysfunction in bronchial asthma.
Topics: Animals; Antigens; Ascaris; Asthma; Bronchi; Bronchial Spasm; Cilia; Dogs; Humans; Hypersensitivity, | 1979 |
Asthma: the important questions. Part 2.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Asthma; Body Temperature Regulation; Chronic Dise | 1992 |
Azelastine: a multifaceted drug for asthma therapy.
Topics: Animals; Asthma; Free Radicals; Histamine H1 Antagonists; Humans; Interleukin-1; Mucociliary Clearan | 1991 |
The role of mast cells in bronchial asthma: mechanisms and possible therapeutic implications.
Topics: Animals; Asthma; Bronchial Spasm; Humans; Mast Cells; Mucous Membrane; Mucus | 1991 |
The lung mucosa: a critical environmental battleground.
Topics: Adult; Air Pollutants; Asthma; Child; Humans; Lung; Lung Diseases, Obstructive; Mucociliary Clearanc | 1991 |
Permeability of the airway mucosa in asthma.
Topics: Animals; Asthma; Extracellular Space; Humans; Mucous Membrane; Mucus; Permeability; Respiratory Syst | 1991 |
The potential roles of leukotrienes in bronchial asthma.
Topics: Airway Obstruction; Asthma; Edema; Humans; Hypersensitivity, Immediate; Leukotriene Antagonists; Leu | 1991 |
Morphology of the airway wall in asthma and in chronic obstructive pulmonary disease.
Topics: Asthma; Bronchi; Humans; Lung; Lung Diseases, Obstructive; Microscopy, Electron; Microscopy, Electro | 1991 |
Mechanisms by which glucocorticosteroids inhibit secretion of mucus in asthmatic airways.
Topics: Animals; Asthma; Eicosanoids; Glucocorticoids; Humans; Models, Biological; Mucus; Respiratory System | 1990 |
Mechanisms of glucocorticosteroid action in bronchial asthma.
Topics: Adenylyl Cyclases; Arachidonic Acid; Arachidonic Acids; Asthma; Basophils; Bronchial Spasm; Capillar | 1985 |
Mode of action of corticosteroids in asthma and rhinitis.
Topics: Adrenal Cortex Hormones; Asthma; Basophils; Bronchi; Eosinophils; Histamine Release; Humans; Immunog | 1986 |
Role of airway epithelial cells in the defense of airways.
Topics: Asthma; Bronchi; Epithelial Cells; Humans; Ion Channels; Mucus; Muscle, Smooth; Trachea | 1988 |
Anticholinergic drugs in the treatment of airways disease.
Topics: Adrenergic beta-Agonists; Asthma; Atropine; Atropine Derivatives; Bronchi; Bronchial Provocation Tes | 1985 |
Calcium, calcium channel blockade and airways function.
Topics: Adrenergic beta-Agonists; Allergens; Angina Pectoris; Animals; Asthma; Bronchi; Calcium; Calcium Cha | 1986 |
Airway mucus membrane: effects of beta-adrenergic and anticholinergic stimulation.
Topics: Adrenergic beta-Agonists; Aerosols; Asthma; Biological Transport; Bronchodilator Agents; Epithelium; | 1986 |
Mast cell mediators and asthma.
Topics: Animals; Asthma; Autacoids; Bronchial Spasm; Cytoplasmic Granules; Edema; Humans; Immunoglobulin E; | 1987 |
[Bronchial asthma and prostaglandin related substances].
Topics: Animals; Arachidonic Acids; Asthma; Bronchi; Capillary Permeability; Guinea Pigs; Humans; In Vitro T | 1985 |
The role of eicosanoids in respiratory mucus hypersecretion.
Topics: Animals; Arachidonic Acids; Aspirin; Asthma; Bronchial Diseases; Cells, Cultured; Fatty Acids, Unsat | 1985 |
The role of leukotrienes in asthma.
Topics: Airway Resistance; Animals; Asthma; Bronchi; Chemical Phenomena; Chemistry; Hemodynamics; Humans; In | 1985 |
Lipid-derived and other chemical mediators of inflammation in the lung.
Topics: Anaphylatoxins; Arachidonic Acid; Arachidonic Acids; Asthma; Eicosanoic Acids; Fatty Acids; Humans; | 1987 |
Prostaglandins and the lung.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Asthma; Bronchi; Heart Defects, Congenital; Humans; In | 1986 |
Theophylline and mucociliary clearance.
Topics: Aminophylline; Animals; Asthma; Bronchitis; Cilia; Clinical Trials as Topic; Dogs; Humans; Lung Dise | 1987 |
Epidemiology of bronchial hypersecretion: recent studies.
Topics: Airway Obstruction; Anti-Bacterial Agents; Asthma; Bronchial Diseases; Bronchitis; Epidemiologic Met | 1987 |
The pathology of obstructive and inflammatory airway diseases.
Topics: Animals; Asthma; Bronchi; Bronchiectasis; Bronchiolitis, Viral; Bronchitis; Child; Dogs; Humans; Lun | 1986 |
Continuing medical education. Asthma in infants and children: Part 1.
Topics: Airway Resistance; Allergens; Aspirin; Asthma; Asthma, Exercise-Induced; Bronchi; Child; Child, Pres | 1985 |
Effects of inhaled acids on respiratory tract defense mechanisms.
Topics: Acids; Aerosols; Air Pollutants; Animals; Asthma; Bronchi; Dose-Response Relationship, Drug; Epithel | 1985 |
Clinical aspects of mucus and mucous plugging in asthma.
Topics: Acetylcysteine; Asthma; Biological Transport; Bronchi; Cilia; Expectorants; Humans; Mucus; Pulmonary | 1985 |
Immunoglobulin E and immediate hypersensitivity.
Topics: Adolescent; Antibodies; Antibodies, Anti-Idiotypic; Antibody Formation; Ascariasis; Asthma; Binding | 1970 |
Tracheobronchial secretions.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibody Formation; Asthma; Atropine; Bronchi; Bronchitis; Carb | 1971 |
[Normal and pathological bronchial secretion].
Topics: Asthma; Bronchi; Bronchial Diseases; Bronchitis; Chromatography; Cystic Fibrosis; Elasticity; Humans | 1973 |
The clinical significance of IgE.
Topics: Absorption; Antibodies, Heterophile; Antibody Specificity; Asthma; Binding, Competitive; Colostrum; | 1972 |
26 trials available for guaifenesin and Asthma
Article | Year |
---|---|
Controlled assessment of oral bronchodilators for asthmatic children.
Topics: Administration, Oral; Adolescent; Asthma; Barbiturates; Bronchodilator Agents; Child; Clinical Trial | 1978 |
Effect of bromhexine and guaiphenesine on clinical state, ventilatory capacity and sputum viscosity in chronic asthma.
Topics: Airway Resistance; Asthma; Bromhexine; Chronic Disease; Clinical Trials as Topic; Female; Guaifenesi | 1976 |
Clinical evaluation of terbutaline and glyceryl guaiacolate in chronic obstructive lung disease.
Topics: Adult; Aged; Asthma; Bronchitis; Chronic Disease; Clinical Trials as Topic; Female; Guaifenesin; Hum | 1976 |
The use of Duopect as expectorant--antitussive agent.
Topics: Adolescent; Adult; Aged; Asthma; Bronchiectasis; Bronchitis; Chronic Disease; Clinical Trials as Top | 1975 |
Guaiphenesin and iodide.
Topics: Asthma; Clinical Trials as Topic; Double-Blind Method; Guaifenesin; Humans; Iodides; Lung Diseases; | 1985 |
Clinical trial with terbutaline and guajacol.
Topics: Adult; Aged; Asthma; Bronchodilator Agents; Butylamines; Clinical Trials as Topic; Cough; Drug Combi | 1973 |
Changes in the fibre system and viscosity of the sputum of bronchitis during treatment with bromhexine and guaiphenesin (guaiacol glyceryl ether).
Topics: Adult; Aged; Asthma; Bromhexine; Bronchitis; Clinical Trials as Topic; Depression, Chemical; DNA; Fe | 1974 |
Double-blind evaluation of an anti-asthmatic agent.
Topics: Adolescent; Adult; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Female; Guaifenes | 1967 |
A controlled evaluation of oral theophylline in asthmatic children.
Topics: Asthma; Capsules; Child; Clinical Trials as Topic; Drug Synergism; Epinephrine; Female; Guaifenesin; | 1968 |
Asthma Control, Airway Mucus, and
Topics: Airway Management; Airway Obstruction; Anti-Asthmatic Agents; Antibodies, Monoclonal, Humanized; Ast | 2022 |
Effects of Dupilumab on Mucus Plugging and Ventilation Defects in Patients with Moderate-to-Severe Asthma: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Antibodies, Monoclonal, Humanized; Asthma; Double-Blind Method; Humans; Injections, Subcutaneous; Mu | 2023 |
Randomised study of the immunomodulatory effects of azithromycin in severely asthmatic horses.
Topics: Airway Remodeling; Animals; Asthma; Azithromycin; Cross-Over Studies; Female; Horse Diseases; Horses | 2019 |
The assessment and management of chronic cough in children according to the British Thoracic Society guidelines: descriptive, prospective, clinical trial.
Topics: Adolescent; Asthma; Bronchitis; Child; Child, Preschool; Chronic Disease; Cough; Female; Gastroesoph | 2014 |
The association between seasonal asthma exacerbations and viral respiratory infections in a pediatric population receiving inhaled corticosteroid therapy with or without long-acting beta-adrenoceptor agonist: a randomized study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Asthma; Bronchodilato | 2015 |
Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement.
Topics: Adolescent; Adult; Asthma; Clinical Trials as Topic; Complement System Proteins; Cromolyn Sodium; Fe | 1984 |
Cough and expectoration: general discussion.
Topics: Acute Disease; Asthma; Biological Transport; Bronchitis; Chronic Disease; Cilia; Clinical Trials as | 1980 |
Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm: role of slow reacting substance of anaphylaxis.
Topics: Adolescent; Adult; Airway Resistance; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Chromone | 1981 |
The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Asthma; Breathing Exercises; Combined Modality Therapy; Community Health Se | 1997 |
Substance P and its receptor neurokinin 1 expression in asthmatic airways.
Topics: Adult; Anti-Bacterial Agents; Asthma; Biopsy; Bronchi; Epithelium; Female; Forced Expiratory Volume; | 2000 |
The protective effect of ketotifen in bronchial asthma.
Topics: Adolescent; Adult; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Dyspnea; | 1978 |
A double blind trial of a 2% solution of sodium cromoglycate in perennial rhinitis.
Topics: Adolescent; Adult; Allergens; Asthma; Child; Clinical Trials as Topic; Cromolyn Sodium; Desensitizat | 1975 |
The effect of unproductive coughing/FET on regional mucus movement in the human lungs.
Topics: Aerosols; Aged; Asthma; Bronchitis; Cough; Female; Humans; Lung; Male; Middle Aged; Mucociliary Clea | 1991 |
Theophylline and mucociliary clearance.
Topics: Aminophylline; Animals; Asthma; Bronchitis; Cilia; Clinical Trials as Topic; Dogs; Humans; Lung Dise | 1987 |
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases.
Topics: Adult; Airway Resistance; Aniline Compounds; Asthma; Chronic Disease; Clinical Trials as Topic; Fema | 1969 |
A new mucolytic, bromhexine ("bisolvon"). A double-blind study.
Topics: Aniline Compounds; Asthma; Bronchiectasis; Bronchitis; Clinical Trials as Topic; Expectorants; Femal | 1971 |
The acute action of urea on ventilatory function in patients with asthma.
Topics: Adult; Aerosols; Aged; Asthma; Clinical Trials as Topic; Female; Humans; Isoproterenol; Male; Middle | 1967 |
555 other studies available for guaifenesin and Asthma
Article | Year |
---|---|
High throughput virtual screening strategy to develop a potential treatment for bronchial asthma by targeting interleukin 13 cytokine signaling.
Topics: Animals; Asthma; Child; Cytokines; Disease Models, Animal; Epinephrine; Guaifenesin; Humans; Hyperse | 2022 |
Theophylline glyceryl guaiacolate (Quibron) in bronchial asthma.
Topics: Asthma; Guaifenesin; Theophylline | 1962 |
ADDITION OF GLYCERYL GUAIACOLATE TO OXTRIPHYLLINE IN CHRONIC ASTHMA: A DOUBLE BLIND STUDY.
Topics: Asthma; Choline; Double-Blind Method; Guaifenesin; Humans; Theophylline | 1963 |
A DOUBLE BLIND CLINICAL EVALUATION OF GLYCERYL GUAIACOLATE.
Topics: Asthma; Bronchiectasis; Bronchitis; Choline; Cough; Double-Blind Method; Guaifenesin; Pulmonary Emph | 1963 |
THEOPHYLLINE-GLYCERYL GUAIACOLATE CAPSULES (QUIBRON). CLINICAL RESULTS IN BRONCHIAL ASTHMA.
Topics: Asthma; Capsules; Guaiacol; Guaifenesin; Humans; Theophylline; Toxicology | 1963 |
CLINICAL EVALUATION OF A BRONCHODILATOR DRUG COMBINATION IN CHILDREN WITH CHRONIC BRONCHIAL ASTHMA.
Topics: Adolescent; Aerosols; Anti-Allergic Agents; Asthma; Bronchodilator Agents; Child; Drug Combinations; | 1964 |
TREATMENT OF BRONCHIAL AND PULMONARY PARENCHYMAL DISORDERS.
Topics: Asthma; Bronchitis; Geriatrics; Guaifenesin; Humans; Lung Diseases; Pulmonary Emphysema; Pulmonary F | 1964 |
OXTRIPHYLLINE-GLYCERYL GUAIACOLATE ELIXIR AS EFFECTIVE THERAPY FOR CHRONIC BRONCHITIS AND ASTHMA.
Topics: Adolescent; Asthma; Bronchitis; Bronchitis, Chronic; Child; Choline; Geriatrics; Guaifenesin; Humans | 1964 |
GUAIACOL GLYCERYL ETHER THEOPHYLLINATE. ITS VALUE FOR RELIEF OF BRONCHIAL ASTHMA AND RELATED BRONCHOSPASTIC CONDITIONS.
Topics: Aminophylline; Asthma; Blood; Bronchial Spasm; Drug Therapy; Guaifenesin; Humans; Theophylline | 1964 |
OXTRIPHYLLINE GLYCERYL GUAIACOLATE ELIXIR IN PEDIATRIC ASTHMA: WITH A THEOPHYLLINE REVIEW.
Topics: Adolescent; Asthma; Biomedical Research; Child; Choline; Drug Therapy; Expectorants; Glycerol; Guaia | 1965 |
Theophylline-glyceryl guaiacolate elixir (Quibron) clinical and blood level studies in bronchial asthma in children.
Topics: Asthma; Cardiovascular Agents; Guaifenesin; Muscle Relaxants, Central; Research; Theophylline | 1962 |
Spontaneous dissolution of a guaifenesin stone.
Topics: Adult; Asthma; Expectorants; Guaifenesin; Humans; Male; Remission, Spontaneous; Urinary Calculi | 2005 |
Effect of an anti-asthmatic compound on blood pressure of hypertensive asthmatic patients.
Topics: Adult; Aged; Asthma; Blood Pressure; Female; Guaifenesin; Humans; Hypertension; Male; Middle Aged; P | 1967 |
Drugs used in the treatment of asthma.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Aerosols; Asthma; Cromolyn Sodium; Dexamethasone; Drug Comb | 1977 |
Nasal congestion as a side effect of cromolyn sodium.
Topics: Asthma; Cromolyn Sodium; Guaifenesin; Humans; Male; Nasal Mucosa; Prednisone; Skin Tests; Theophylli | 1974 |
Clinical evaluation of an antiasthmatic compound. Correlation of absorption with blood levels of theophylline.
Topics: Adult; Aged; Asthma; Guaifenesin; Humans; Male; Middle Aged; Phenylpropanolamine; Sympathomimetics; | 1966 |
[Therapy of bronchial asthma].
Topics: Adrenal Cortex Hormones; Aminophylline; Asthma; Breathing Exercises; Bromhexine; Cromolyn Sodium; Cy | 1974 |
The effect of the combination of phenobarbitone, ephedrine, aminophylline and glyceryl guaiacolate on asthma and chronic bronchitis.
Topics: Adult; Aminophylline; Asthma; Bronchitis; Drug Combinations; Ephedrine; Female; Guaifenesin; Humans; | 1973 |
False-positive tests for urinary 5-hydroxyindoleacetic acid. Error in laboratory determinations caused by glyceryl guaiacolate.
Topics: Asthma; Carcinoid Tumor; False Positive Reactions; Guaifenesin; Humans; Hydroxyindoleacetic Acid | 1970 |
Gekko gecko extract attenuates airway inflammation and mucus hypersecretion in a murine model of ovalbumin-induced asthma.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; COVID-19; Cytokines; Female; F | 2022 |
Titanium Dioxide Nanoparticles Exacerbate Allergic Airway Inflammation via TXNIP Upregulation in a Mouse Model of Asthma.
Topics: Animals; Apoptosis; Asthma; bcl-2-Associated X Protein; Bronchoalveolar Lavage Fluid; Carrier Protei | 2021 |
Mucus targeting as a plausible approach to improve lung function in COVID-19 patients.
Topics: Asthma; COVID-19; Humans; Lung; Mucus; SARS-CoV-2 | 2021 |
Ding Chuan Tang Attenuates Airway Inflammation and Eosinophil Infiltration in Ovalbumin-Sensitized Asthmatic Mice.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Down-Regulation; Eosinophi | 2021 |
Pathophysiological relevance of sputum MUC5AC and MUC5B levels in patients with mild asthma.
Topics: Asthma; Case-Control Studies; Cross-Sectional Studies; Enzyme-Linked Immunosorbent Assay; Humans; Mu | 2022 |
Mucus Plugs in Asthma at CT Associated with Regional Ventilation Defects at
Topics: Asthma; Female; Helium; Humans; Lung; Magnetic Resonance Imaging; Male; Mucus; Respiration Disorders | 2022 |
The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of anti-IL-5R treatment.
Topics: Asthma; Eosinophils; Humans; Mucus; Prevalence; Pulmonary Eosinophilia; Treatment Outcome | 2022 |
Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma.
Topics: Animals; Asthma; Humans; Lung; Macrophages; Mice; Mucus; Oncostatin M | 2022 |
CTNNAL1 participates in the regulation of mucus overproduction in HDM-induced asthma mouse model through the YAP-ROCK2 pathway.
Topics: alpha Catenin; Animals; Asthma; Disease Models, Animal; Humans; Interleukin-13; Interleukin-4; Lung; | 2022 |
Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time.
Topics: Asthma; Cross-Sectional Studies; Humans; Lung; Mucus; Respiratory Function Tests | 2022 |
Airway Delivery of Hydrogel-Encapsulated Niclosamide for the Treatment of Inflammatory Airway Disease.
Topics: Animals; Asthma; Cells, Cultured; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Drug Ca | 2022 |
Persistent Airway Plugs: A Call for Clinical Recognition and Novel Therapies.
Topics: Asthma; Humans; Lung; Mucus | 2022 |
Nasal airway transcriptome-wide association study of asthma reveals genetically driven mucus pathobiology.
Topics: Asthma; Child; Epithelium; Humans; Metaplasia; Mucin 5AC; Mucus; Transcriptome | 2022 |
Azithromycin inhibits mucin secretion, mucous metaplasia, airway inflammation, and airways hyperresponsiveness in mice exposed to house dust mite extract.
Topics: Adenosine Triphosphate; Allergens; Animals; Asthma; Azithromycin; Disease Models, Animal; Inflammati | 2022 |
Study Effect of Azithromycin and Doxycycline in Mucus Producing and Inflammatory Signaling Pathways of Allergic Asthma.
Topics: Animals; Asthma; Azithromycin; Cyclooxygenase 2; Doxycycline; Humans; Immunoglobulin E; Inflammation | 2022 |
Processed product (Pinelliae Rhizoma Praeparatum) of Pinellia ternata (Thunb.) Breit. Alleviates the allergic airway inflammation of cold phlegm via regulation of PKC/EGFR/MAPK/PI3K-AKT signaling pathway.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; ErbB Receptors; Expectorants; Inflammation | 2022 |
Iristectorigenin A exerts novel protective properties against airway inflammation and mucus hypersecretion in OVA-induced asthmatic mice: Iristectorigenin A ameliorates asthma phenotype.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Immunoglobulin E; Immunoglobu | 2022 |
Selective Pharmaceutical Inhibition of PARP14 Mitigates Allergen-Induced IgE and Mucus Overproduction in a Mouse Model of Pulmonary Allergic Response.
Topics: Allergens; Animals; Asthma; Disease Models, Animal; Immunoglobulin E; Mice; Mucus; Pharmaceutical Pr | 2022 |
[Research on function of Feilike Mixture in stopping cough, eliminating phlegm and relieving asthma based on animal experiments and network pharmacology].
Topics: Animal Experimentation; Animals; Asthma; Cough; Drugs, Chinese Herbal; Guinea Pigs; Mice; Mucus; Net | 2022 |
Oxysophocarpine inhibits airway inflammation and mucus hypersecretion through JNK/AP-1 pathway in vivo and in vitro.
Topics: Alkaloids; Animals; Antioxidants; Asthma; Cytokines; Disease Models, Animal; Eosine Yellowish-(YS); | 2022 |
Intravital imaging of mucus transport in asthmatic mice using microscopic optical coherence tomography.
Topics: Adenosine Triphosphate; Animals; Asthma; Interleukin-13; Intravital Microscopy; Mice; Mucus; Saline | 2022 |
Autocrine TGF-alpha is associated with Benzo(a)pyrene-induced mucus production and MUC5AC expression during allergic asthma.
Topics: Animals; Asthma; Benzo(a)pyrene; Cytokines; ErbB Receptors; Humans; Lung; Mice; Mice, Inbred BALB C; | 2022 |
[Artificial intelligence-assisted identification of mucus plugs in asthma].
Topics: Artificial Intelligence; Asthma; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Tomography, | 2022 |
Luminal mucus plugs are spatially associated with airway wall thickening in severe COPD and asthma: A single-centered, retrospective, observational study.
Topics: Aged; Asthma; Female; Humans; Lung; Male; Middle Aged; Mucus; Pulmonary Disease, Chronic Obstructive | 2022 |
Juvenile arsenic exposure aggravates goblet cell hyperplasia and airway mucus secretion in ovalbumin-sensitized mice.
Topics: Animals; Arsenic; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Drinking | 2022 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
Topics: Asthma; Eosinophils; Humans; Inflammation; Lung; Mucus; Smoking; Sputum | 2023 |
CT Mucus Score and
Topics: Airway Obstruction; Anti-Asthmatic Agents; Asthma; Humans; Magnetic Resonance Imaging; Mucus; Nitric | 2023 |
Importance of mucus burden and mucociliary impairment in asthma.
Topics: Asthma; Bronchi; Cilia; Humans; Mucociliary Clearance; Mucus | 2023 |
Effects of Shiwei Longdanhua formula on LPS induced airway mucus hypersecretion, cough hypersensitivity, oxidative stress and pulmonary inflammation.
Topics: Animals; Asthma; Chronic Disease; Cough; Hypersensitivity; Inflammation; Lipopolysaccharides; Mice; | 2023 |
Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma.
Topics: Anti-Asthmatic Agents; Asthma; Disease Progression; Eosinophils; Humans; Mucus; Pulmonary Eosinophil | 2023 |
Imaging Regional Airway Involvement of Asthma: Heterogeneity in Ventilation, Mucus Plugs and Remodeling.
Topics: Asthma; Humans; Lung; Mucus; Respiration; Tomography, X-Ray Computed | 2023 |
An asthma phenotype comprising bronchial wall thickening and mucus plugging confers worse clinical outcomes.
Topics: Asthma; Bronchi; Humans; Mucus; Phenotype | 2023 |
Lactobacillus rhamnosus 76 alleviates airway inflammation in ovalbumin-allergic mice and improves mucus secretion by down-regulating STAT6/SPDEF pathway.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Humans; Hypersensitivity; Inf | 2023 |
Qufeng Xuanbi Formula inhibited benzo[a]pyrene-induced aggravated asthma airway mucus secretion by AhR/ROS/ERK pathway.
Topics: Air Pollutants; Animals; Asthma; Benzo(a)pyrene; Disease Models, Animal; Extracellular Signal-Regula | 2024 |
Melia azedarach L. reduces pulmonary inflammation and mucus hypersecretion on a murine model of ovalbumin exposed asthma.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Inflammation; Meli | 2024 |
Niclosamide repurposed for the treatment of inflammatory airway disease.
Topics: Animals; Anoctamins; Anti-Inflammatory Agents; Asthma; Bronchi; Cell Line, Tumor; Cystic Fibrosis; D | 2019 |
Piperlongumine reduces ovalbumin‑induced asthma and airway inflammation by regulating nuclear factor‑κB activation.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Dioxolanes; Fibrosis; Humans; I | 2019 |
Butylphthalide ameliorates airway inflammation and mucus hypersecretion via NF-κB in a murine asthma model.
Topics: Allergens; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Benzofurans; Bronchoalv | 2019 |
MiR-31-5p: A shared regulator of chronic mucus hypersecretion in asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Humans; MicroRNAs; Mucus; Pulmonary Disease, Chronic Obstructive | 2020 |
CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma.
Topics: Asthma; Humans; Magnetic Resonance Imaging; Mucus; Respiratory System; Tomography, X-Ray Computed | 2019 |
Response.
Topics: Asthma; Humans; Magnetic Resonance Imaging; Mucus; Respiratory System; Tomography, X-Ray Computed | 2019 |
Targeted deletion of NFAT-Interacting-Protein-(NIP) 45 resolves experimental asthma by inhibiting Innate Lymphoid Cells group 2 (ILC2).
Topics: Animals; Asthma; Carrier Proteins; Child; Child, Preschool; Disease Models, Animal; Female; Humans; | 2019 |
Baicalein attenuates OVA-induced allergic airway inflammation through the inhibition of the NF-κB signaling pathway.
Topics: Animals; Antioxidants; Asthma; Cell Line; Collagen; Drug Evaluation, Preclinical; Flavanones; Immuno | 2019 |
4-Hydroxycinnamic acid suppresses airway inflammation and mucus hypersecretion in allergic asthma induced by ovalbumin challenge.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Coumaric Acids; Cyclooxygen | 2020 |
Effect of NF-κB signal pathway on mucus secretion induced by atmospheric PM
Topics: Air Pollutants; Animals; Asthma; Female; Inflammation; Lung; Male; Mucus; NF-kappa B; NF-KappaB Inhi | 2020 |
Tree Nuts Anaphylaxis in Preschool Age Children.
Topics: Allergens; Anacardium; Anaphylaxis; Asthma; Child, Preschool; Cross Reactions; Female; Humans; Immun | 2020 |
Changes in airway diameter and mucus plugs in patients with asthma exacerbation.
Topics: Airway Obstruction; Asthma; Bronchi; Female; Humans; Male; Middle Aged; Mucus; Prognosis; Tomography | 2020 |
Warifteine and methylwarifteine inhibited the type 2 immune response on combined allergic rhinitis and asthma syndrome (CARAS) experimental model through NF-кB pathway.
Topics: Alkaloids; Animals; Anti-Allergic Agents; Asthma; Behavior, Animal; Bronchoalveolar Lavage Fluid; Ci | 2020 |
Single-Cell and Population Transcriptomics Reveal Pan-epithelial Remodeling in Type 2-High Asthma.
Topics: Asthma; Biological Transport; Cellular Reprogramming; Child; Cilia; Down-Regulation; Endoplasmic Ret | 2020 |
Panax notoginseng saponin R1 modulates TNF-α/NF-κB signaling and attenuates allergic airway inflammation in asthma.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; Cell Line; Disease Models, Ani | 2020 |
The establishment of humanized IL-4/IL-4RA mouse model by gene editing and efficacy evaluation.
Topics: Allergens; Animals; Antibodies, Monoclonal; Asthma; Bronchoalveolar Lavage Fluid; Cells, Cultured; D | 2020 |
Monocyte chemotactic protein-inducing protein 1 negatively regulating asthmatic airway inflammation and mucus hypersecretion involving γ-aminobutyric acid type A receptor signaling pathway in vivo and in vitro.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; gamma-Aminobutyric Acid; Inflammation; Mice; Mice, In | 2020 |
4-Carvomenthenol ameliorates the murine combined allergic rhinitis and asthma syndrome by inhibiting IL-13 and mucus production via p38MAPK/NF-κB signaling pathway axis.
Topics: Allergens; Animals; Anti-Allergic Agents; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Female; I | 2020 |
Procedures to Evaluate Inflammatory and Pathological Changes During Allergic Airway Inflammation.
Topics: Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Progression; Lung; Mice | 2021 |
TMT-based quantitative proteomics reveals suppression of SLC3A2 and ATP1A3 expression contributes to the inhibitory role of acupuncture on airway inflammation in an OVA-induced mouse asthma model.
Topics: Acupuncture Therapy; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Anima | 2021 |
Disulfide disruption reverses mucus dysfunction in allergic airway disease.
Topics: Adolescent; Adult; Animals; Asthma; Disease Models, Animal; Disulfides; Expectorants; Female; Glycop | 2021 |
Long non-coding RNA TUG1 promotes airway remodeling and mucus production in asthmatic mice through the microRNA-181b/HMGB1 axis.
Topics: Airway Remodeling; Allergens; Animals; Asthma; Cells, Cultured; Disease Models, Animal; Female; HMGB | 2021 |
Epithelial miR-141 regulates IL-13-induced airway mucus production.
Topics: Airway Remodeling; Animals; Aspergillus; Asthma; Cell Differentiation; Cells, Cultured; Clustered Re | 2021 |
Lignosus rhinocerotis Cooke Ryvarden ameliorates airway inflammation, mucus hypersecretion and airway hyperresponsiveness in a murine model of asthma.
Topics: Animals; Asthma; Disease Models, Animal; Mice; Mucus; Polyporaceae; Th2 Cells | 2021 |
Modeling Airway Dysfunction in Asthma Using Synthetic Mucus Biomaterials.
Topics: Adult; Asthma; Biocompatible Materials; Child; Humans; Interleukin-13; Mucus; Respiratory Mucosa | 2021 |
Tectochrysin ameliorates murine allergic airway inflammation by suppressing Th2 response and oxidative stress.
Topics: Allergens; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Basophil | 2021 |
Eosinophil Extracellular Traps in the Casts of Plastic Bronchitis Associated With Influenza Virus Infection.
Topics: Airway Obstruction; Asthma; Bronchitis; Cell Aggregation; Cell Death; Child; Chromatin; Eosinophils; | 2021 |
sRAGE Inhibits the Mucus Hypersecretion in a Mouse Model with Neutrophilic Asthma.
Topics: Animals; Asthma; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Glyco | 2022 |
Mucociliary Clearance Differs in Mild Asthma by Levels of Type 2 Inflammation.
Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoscopy; Cell Adhesion Molecules; Chemokine CCL26; | 2021 |
Interesting case of allergic broncho pulmonary aspergillosis (ABPA) with high-attenuation mucus (HAM).
Topics: Adult; Aspergillosis, Allergic Bronchopulmonary; Asthma; Bronchiectasis; Humans; Lung; Male; Mucus | 2021 |
Pingchuan formula attenuates airway mucus hypersecretion via regulation of the PNEC-GABA-IL13-Muc5ac axis in asthmatic mice.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; Cell Proliferation; Cytokines; | 2021 |
CLCA1 Regulates Airway Mucus Production and Ion Secretion Through TMEM16A.
Topics: Animals; Anoctamin-1; Asthma; Chloride Channels; Goblet Cells; Metaplasia; Mice; Mucus; Ovalbumin; R | 2021 |
Association of the CFTR gene with asthma and airway mucus hypersecretion.
Topics: Asthma; Cough; Cross-Sectional Studies; Cystic Fibrosis Transmembrane Conductance Regulator; Eosinop | 2021 |
Targeting TL1A/DR3 Signaling Offers a Therapeutic Advantage to Neutralizing IL13/IL4Rα in Muco-Secretory Fibrotic Disorders.
Topics: Animals; Asthma; DNA-Binding Proteins; Female; Fibrosis; Interleukin-13; Interleukin-4 Receptor alph | 2021 |
Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease.
Topics: Animals; Anoctamin-1; Asthma; Constriction, Pathologic; Cystic Fibrosis; HEK293 Cells; Humans; Infla | 2021 |
IRE1β does not affect mucus secretion during allergic asthma development in a house dust mite murine model.
Topics: Allergens; Animals; Asthma; Disease Models, Animal; Humans; Mice; Mucus; Pyroglyphidae | 2021 |
Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus.
Topics: Adult; Aged; Animals; Asthma; Chronic Disease; Disease Models, Animal; Eosinophils; Female; Fibrin; | 2017 |
Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients.
Topics: Animals; Asthma; Disease Models, Animal; Epithelial Cells; Humans; Immunity, Innate; Interleukin-13; | 2018 |
Anti‑inflammatory effects of dihydromyricetin in a mouse model of asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, | 2017 |
Bitter Taste Receptor Agonists Mitigate Features of Allergic Asthma in Mice.
Topics: Airway Remodeling; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Flu | 2017 |
BMAL1 links the circadian clock to viral airway pathology and asthma phenotypes.
Topics: Airway Remodeling; Airway Resistance; Animals; ARNTL Transcription Factors; Asthma; Bronchiolitis, V | 2018 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid | 2017 |
Isoimperatorin attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma.
Topics: Allergens; Animals; Anti-Inflammatory Agents; Asthma; Cytokines; Disease Models, Animal; Female; Fur | 2017 |
Roles for Myoepithelial Cells in the Formation and Maintenance of Submucosal Glands.
Topics: Animals; Asthma; Cystic Fibrosis; Epithelial Cells; Exocrine Glands; Humans; Lung; Mucus; Pulmonary | 2017 |
MUC5AC and a Glycosylated Variant of MUC5B Alter Mucin Composition in Children With Acute Asthma.
Topics: Acute Disease; Adolescent; Asthma; Biomarkers; Blotting, Western; Child; Child, Preschool; Female; H | 2017 |
Therapeutic intranasal instillation of allergen-loaded microbubbles suppresses experimental allergic asthma in mice.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Allergens; Animals; Antibody Formation; Asthma; | 2017 |
Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma.
Topics: Animals; Arginase; Asthma; Bronchoalveolar Lavage Fluid; Cell Differentiation; Disease Models, Anima | 2017 |
Artemisia argyi attenuates airway inflammation in ovalbumin-induced asthmatic animals.
Topics: Animals; Artemisia; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Extracellular Signal-Regulated | 2017 |
Leptin positively regulates MUC5AC production and secretion induced by interleukin-13 in human bronchial epithelial cells.
Topics: Asthma; Bronchi; Cell Line; Humans; Interleukin-13; Janus Kinase 2; Leptin; Mucin 5AC; Mucus; Respir | 2017 |
Inverted Mucoid Impaction Signal in Allergic Bronchopulmonary Aspergillosis: Are We Calling a Spade a Big Spoon?
Topics: Aspergillosis, Allergic Bronchopulmonary; Asthma; Humans; Mucus | 2017 |
[Receptor for advanced glycation end products upregulates MUC5AC expression and promotes mucus overproduction in mice with toluene diisocyanate-induced asthma].
Topics: Animals; Asthma; Benzamides; Butadienes; Extracellular Signal-Regulated MAP Kinases; Mice; Mice, Inb | 2017 |
Activating prostaglandin E2 receptor subtype EP4 increases secreted mucin from airway goblet cells.
Topics: Asthma; Bronchi; Cells, Cultured; Dinoprostone; Epithelial Cells; Goblet Cells; Humans; Interleukin- | 2018 |
Experimental asthma persists in IL-33 receptor knockout mice because of the emergence of thymic stromal lymphopoietin-driven IL-9
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Female; Interleukin-1 Receptor-Like 1 Prot | 2018 |
[Clinical therapeutic effect on bronchial asthma in children of different body constitutions treated with
Topics: Acupuncture Points; Asthma; Body Constitution; Child; Humans; Immunoglobulin A; Immunoglobulin G; Im | 2017 |
Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo.
Topics: Allergens; Alternaria; Animals; Asthma; Cytokines; Dermatophagoides pteronyssinus; Eosinophilia; Fem | 2018 |
All plugged up - noninvasive mucus score to assess airway dysfunction in asthma.
Topics: Asthma; Eosinophilia; Humans; Lung; Mucus | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema | 2018 |
Spatiotemporal organization of cilia drives multiscale mucus swirls in model human bronchial epithelium.
Topics: Asthma; Biomechanical Phenomena; Bronchi; Bronchoscopy; Case-Control Studies; Cilia; Humans; Hydrody | 2018 |
Mucus hypersecretion in asthma is associated with rhinosinusitis, polyps and exacerbations.
Topics: Adult; Aged; Asthma; Cough; Disease Progression; Female; Humans; Male; Middle Aged; Mucus; Olfaction | 2018 |
Effects of ozone repeated short exposures on the airway/lung inflammation, airway hyperresponsiveness and mucus production in a mouse model of ovalbumin-induced asthma.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Disease Models, Animal; Enzyme-Linked Immunosorbent Assa | 2018 |
Casticin alleviates lipopolysaccharide-induced inflammatory responses and expression of mucus and extracellular matrix in human airway epithelial cells through Nrf2/Keap1 and NF-κB pathways.
Topics: Animals; Asthma; Epithelial Cells; Extracellular Matrix; Flavonoids; Humans; Lipopolysaccharides; Mu | 2018 |
LPS Exposure in Early Life Protects Against Mucus Hypersecretion in Ovalbumin-Induced Asthma by Down-Regulation of the IL-13 and JAK-STAT6 Pathways.
Topics: Administration, Intranasal; Animals; Asthma; Cell Line; Disease Models, Animal; Down-Regulation; Hum | 2018 |
Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma.
Topics: Animals; Asthma; Biomarkers; Bone Marrow; Bronchoalveolar Lavage Fluid; Cytokines; Eicosapentaenoic | 2018 |
Profiling of healthy and asthmatic airway smooth muscle cells following interleukin-1β treatment: a novel role for CCL20 in chronic mucus hypersecretion.
Topics: Adolescent; Adult; Aged; Asthma; Case-Control Studies; Cells, Cultured; Chemokine CCL20; Epithelial | 2018 |
Airway smooth muscle may drive mucus hypersecretion in asthma.
Topics: Asthma; Chemokine CCL20; Humans; Interleukin-1beta; Mucus; Muscle, Smooth; Myocytes, Smooth Muscle | 2018 |
An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness.
Topics: Airway Remodeling; Airway Resistance; Animals; Asthma; Bronchi; Cell Count; Disease Models, Animal; | 2018 |
An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.
Topics: Acetylcysteine; Animals; Asthma; Cystic Fibrosis; Disease Models, Animal; Dithiothreitol; Expectoran | 2019 |
Fra2 Overexpression in Mice Leads to Non-allergic Asthma Development in an IL-13 Dependent Manner.
Topics: Animals; Antibodies, Blocking; Asthma; Cell Proliferation; Cells, Cultured; Cytokines; Disease Model | 2018 |
Petiveria alliacea Suppresses Airway Inflammation and Allergen-Specific Th2 Responses in Ovalbumin-Sensitized Murine Model of Asthma.
Topics: Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Chemokines; Dis | 2018 |
Pulmonary Neuroendocrine Cells Secrete γ-Aminobutyric Acid to Induce Goblet Cell Hyperplasia in Primate Models.
Topics: Acute Lung Injury; Animals; Asthma; Bronchi; Disease Models, Animal; Epithelial Cells; gamma-Aminobu | 2019 |
S-Allyl cysteine reduces eosinophilic airway inflammation and mucus overproduction on ovalbumin-induced allergic asthma model.
Topics: Allergens; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage | 2019 |
Bronchial Thermoplasty for Severe Asthma with Mucus Hypersecretion.
Topics: Asthma; Biopsy; Bronchi; Bronchial Thermoplasty; Bronchoscopy; Forced Expiratory Volume; Humans; Mal | 2019 |
Increase in secreted airway mucins and partial Muc5b STAT6/FoxA2 regulation during Pneumocystis primary infection.
Topics: Animals; Asthma; Epithelial Cells; Female; Hepatocyte Nuclear Factor 3-beta; Humans; Infant; Infant, | 2019 |
SMAD Signaling Restricts Mucous Cell Differentiation in Human Airway Epithelium.
Topics: Asthma; Cell Differentiation; Epithelium; Goblet Cells; Humans; Lung; Metaplasia; Mucus; Respiratory | 2019 |
CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma.
Topics: Airway Management; Airway Obstruction; Asthma; Biomarkers; Correlation of Data; Eosinophils; Female; | 2019 |
The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungs.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cells, Cultured; Cytokines; Epithelial Cells; Humans; | 2019 |
Protein crystallization promotes type 2 immunity and is reversible by antibody treatment.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Animals; Asthma; Bronchial Hyperreactivity; Crystallizati | 2019 |
Rho-kinase inhibitor attenuates airway mucus hypersecretion and inflammation partly by downregulation of IL-13 and the JNK1/2-AP1 signaling pathway.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Down-Regulation; Female; Infl | 2019 |
ORMDL3 knockdown in the lungs alleviates airway inflammation and airway remodeling in asthmatic mice via JNK1/2-MMP-9 pathway.
Topics: Airway Remodeling; Animals; Asthma; Bronchoalveolar Lavage Fluid; Child; Disease Models, Animal; Fem | 2019 |
Anti-inflammatory activity of SintMed65, an N-acylhydrazone derivative, in a mouse model of allergic airway inflammation.
Topics: Allergens; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage | 2019 |
EBM84 attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma.
Topics: Analysis of Variance; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Eosinophilia; Female | 2013 |
Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model.
Topics: Animals; Asthma; Disease Models, Animal; Female; Fluorescent Dyes; Glycerol; Immunoglobulin G; Infla | 2013 |
Aldose reductase inhibition prevents allergic airway remodeling through PI3K/AKT/GSK3β pathway in mice.
Topics: Airway Remodeling; Aldehyde Reductase; Animals; Asthma; Biomarkers; Chronic Disease; Disease Models, | 2013 |
Pinellia ternata Breitenbach attenuates ovalbumin-induced allergic airway inflammation and mucus secretion in a murine model of asthma.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; Cell Count; Cytokines; Disease | 2013 |
Dihydroartemisinin suppresses ovalbumin-induced airway inflammation in a mouse allergic asthma model.
Topics: Animals; Anti-Asthmatic Agents; Artemisinins; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disea | 2013 |
Chronic cough and sputum production are associated with worse clinical outcomes in stable asthma.
Topics: Adolescent; Adult; Aged; Asthma; Chronic Disease; Cough; Cross-Sectional Studies; Forced Expiratory | 2013 |
Thrombin promotes airway remodeling via protease-activated receptor-1 and transforming growth factor-β1 in ovalbumin-allergic rats.
Topics: Airway Remodeling; Animals; Asthma; Bronchoalveolar Lavage Fluid; Collagen; Dose-Response Relationsh | 2013 |
Tiotropium bromide inhibits relapsing allergic asthma in BALB/c mice.
Topics: Airway Remodeling; Animals; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Dexamethasone; | 2014 |
Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma.
Topics: Acetates; Allergens; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; Cycloprop | 2013 |
Mast cell-deficient kit mice develop house dust mite-induced lung inflammation despite impaired eosinophil recruitment.
Topics: Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Chemokine CCL11; Disease Models, Animal; E | 2014 |
Early-life exposure to combustion-derived particulate matter causes pulmonary immunosuppression.
Topics: Adoptive Transfer; Allergens; Animals; Animals, Newborn; Antigens; Asthma; Dendritic Cells; Disease | 2014 |
Naringenin inhibits allergen‑induced airway remodeling in a murine model of asthma.
Topics: Airway Remodeling; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Flu | 2014 |
Bangpungtongseong-san, a traditional herbal medicine, attenuates chronic asthmatic effects induced by repeated ovalbumin challenge.
Topics: Animals; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Cell Count; Chemokine CC | 2014 |
Interleukin-13-induced MUC5AC expression is regulated by a PI3K-NFAT3 pathway in mouse tracheal epithelial cells.
Topics: Animals; Asthma; Cells, Cultured; Chloride Channels; Chromones; Cyclosporine; Hepatocyte Nuclear Fac | 2014 |
Th2-type cytokine-induced mucus metaplasia decreases susceptibility of human bronchial epithelium to rhinovirus infection.
Topics: Adult; Airway Remodeling; Asthma; Bronchi; Case-Control Studies; Cells, Cultured; Cytokines; Disease | 2014 |
Intelectin-1 is a prominent protein constituent of pathologic mucus associated with eosinophilic airway inflammation in asthma.
Topics: Asthma; Case-Control Studies; Cytokines; Disease Progression; Eosinophils; GPI-Linked Proteins; Huma | 2014 |
Protective effects of the polyphenol sesamin on allergen-induced T(H)2 responses and airway inflammation in mice.
Topics: Active Transport, Cell Nucleus; Allergens; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; | 2014 |
Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma.
Topics: Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Disease Models, | 2014 |
Respiratory disease in United States farmers.
Topics: Adult; Aged; Aged, 80 and over; Agriculture; Air Pollutants; Asthma; Cough; Female; Humans; Iowa; Ma | 2014 |
[Effects of inhaled LPS on inflammation and mucus hypersecretion in the airway of asthmatic mice].
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Inflammation; Interleukin-4; Lipopolysaccharides; Lun | 2014 |
Siegesbeckia glabrescens attenuates allergic airway inflammation in LPS-stimulated RAW 264.7 cells and OVA induced asthma murine model.
Topics: Animals; Anti-Inflammatory Agents; Asteraceae; Asthma; Bronchoalveolar Lavage Fluid; Cell Count; Cel | 2014 |
No adjuvant effect of Bacillus thuringiensis-maize on allergic responses in mice.
Topics: Adjuvants, Immunologic; Animals; Antibody Formation; Asthma; Bacillus thuringiensis; Female; Hyperse | 2014 |
Pdcd4 modulates markers of macrophage alternative activation and airway remodeling in antigen-induced pulmonary inflammation.
Topics: Airway Remodeling; Animals; Apoptosis Regulatory Proteins; Arginase; Asthma; beta-N-Acetylhexosamini | 2014 |
Airway remodeling is reversed by aerobic training in a murine model of chronic asthma.
Topics: Airway Remodeling; Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Cell Movement; Chemokine | 2015 |
Melatonin reduces airway inflammation in ovalbumin-induced asthma.
Topics: Animals; Antibody Formation; Asthma; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Disease Mod | 2014 |
Melatonin reduces airway inflammation in ovalbumin-induced asthma.
Topics: Animals; Antibody Formation; Asthma; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Disease Mod | 2014 |
Melatonin reduces airway inflammation in ovalbumin-induced asthma.
Topics: Animals; Antibody Formation; Asthma; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Disease Mod | 2014 |
Melatonin reduces airway inflammation in ovalbumin-induced asthma.
Topics: Animals; Antibody Formation; Asthma; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Disease Mod | 2014 |
Mucus plugging mimicking a left hilar mass.
Topics: Airway Obstruction; Asthma; Diagnosis, Differential; Humans; Lung; Lung Neoplasms; Male; Middle Aged | 2014 |
Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Disease Models, Animal; Eosino | 2015 |
Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactiv | 2015 |
Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma.
Topics: Airway Remodeling; Animals; Asthma; Blotting, Western; Bronchi; Bronchoalveolar Lavage Fluid; Diseas | 2015 |
No direct association between asthma and the microbiome based on currently available techniques.
Topics: Adult; Aged; Aged, 80 and over; Asthma; Female; Humans; Male; Microbiota; Middle Aged; Mucus; Respir | 2014 |
Occupational sensitization to African penguin serum and mucus proteins.
Topics: Adult; Allergens; Animals; Asthma; Blood Proteins; Bronchial Spasm; Cross Reactions; Female; Fenoter | 2015 |
The polymeric mucin Muc5ac is required for allergic airway hyperreactivity.
Topics: Allergens; Animals; Aspergillus oryzae; Asthma; Bronchial Hyperreactivity; Female; Immunohistochemis | 2015 |
The polymeric mucin Muc5ac is required for allergic airway hyperreactivity.
Topics: Allergens; Animals; Aspergillus oryzae; Asthma; Bronchial Hyperreactivity; Female; Immunohistochemis | 2015 |
The polymeric mucin Muc5ac is required for allergic airway hyperreactivity.
Topics: Allergens; Animals; Aspergillus oryzae; Asthma; Bronchial Hyperreactivity; Female; Immunohistochemis | 2015 |
The polymeric mucin Muc5ac is required for allergic airway hyperreactivity.
Topics: Allergens; Animals; Aspergillus oryzae; Asthma; Bronchial Hyperreactivity; Female; Immunohistochemis | 2015 |
Distal airways are protected from goblet cell metaplasia by diminished expression of IL-13 signalling components.
Topics: Animals; Asthma; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Re | 2015 |
The Flavonoid 7,4'-Dihydroxyflavone Inhibits MUC5AC Gene Expression, Production, and Secretion via Regulation of NF-κB, STAT6, and HDAC2.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Line; Disease Models, Animal; Epithelial Cells; | 2015 |
The sickle cell mouse lung: proinflammatory and primed for allergic inflammation.
Topics: Anemia, Sickle Cell; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cytok | 2015 |
Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Cordyceps; Cytokines; Deoxyade | 2015 |
The anti-allergic activity of Cymbopogon citratus is mediated via inhibition of nuclear factor kappa B (Nf-Κb) activation.
Topics: Allergens; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage F | 2015 |
Exposure to Deepwater Horizon Crude Oil Burnoff Particulate Matter Induces Pulmonary Inflammation and Alters Adaptive Immune Response.
Topics: Adaptive Immunity; Animals; Asthma; Cell Death; Cell Line; Cell Survival; Dinoprost; Disease Models, | 2015 |
SP600125 promotes resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model.
Topics: Acute Disease; Animals; Anthracenes; Asthma; Bronchoalveolar Lavage Fluid; Cell Count; Cytokines; Di | 2015 |
PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
Topics: Adoptive Transfer; Animals; Antigens, CD; Asthma; Bronchial Hyperreactivity; CD4-Positive T-Lymphocy | 2015 |
Rho-kinase inhibitor fasudil reduces allergic airway inflammation and mucus hypersecretion by regulating STAT6 and NFκB.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Allergens; Animals; Asthma; Case-Control Studies; Cel | 2015 |
[Effects of ozone oxidative stress on the airway hyperresponsiveness and mucus production in mice with acute allergic airway inflammation].
Topics: Animals; Asthma; Bronchoalveolar Lavage; Disease Models, Animal; Female; Inflammation; Interleukin-1 | 2015 |
Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cyclic AMP-Dependent Protein Kinases; Cytokines; Dise | 2015 |
Copper oxide nanoparticles aggravate airway inflammation and mucus production in asthmatic mice via MAPK signaling.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Count; Copper; Cytokines; Disease Models, Animal | 2016 |
Resveratrol inhibits mucus overproduction and MUC5AC expression in a murine model of asthma.
Topics: Animals; Asthma; Cell Line; Disease Models, Animal; Epithelial Cells; Female; Gene Expression Regula | 2016 |
[Improvement of Awareness and Diagnosis for Chronic Obstructive Pulmonary Disease (COPD) by General Physician. Topics: II. Diagnosis of COPD in primary care physicians].
Topics: Asthma; Cough; Diagnosis, Differential; Humans; Mucus; Physicians, Primary Care; Pulmonary Disease, | 2015 |
Continuous Exposure to Low-Dose-Rate Gamma Irradiation Reduces Airway Inflammation in Ovalbumin-Induced Asthma.
Topics: Animals; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Choline; Disease Models, | 2015 |
Decreased Bronchial Eosinophilic Inflammation and Mucus Hypersecretion in Asthmatic Mice Lacking All Nitric Oxide Synthase Isoforms.
Topics: Animals; Asthma; Bronchitis; Chemokine CCL11; Chemokine CCL17; Chemokine CCL2; Cytokines; Eosinophil | 2016 |
Molecular Mechanisms of Airway Hyperresponsiveness in a Murine Model of Steroid-Resistant Airway Inflammation.
Topics: Adoptive Transfer; Animals; Asthma; Disease Models, Animal; Drug Resistance; Immunoblotting; Interle | 2016 |
Kinin B1 receptor antagonist BI113823 reduces allergen-induced airway inflammation and mucus secretion in mice.
Topics: Allergens; Animals; Anti-Inflammatory Agents; Asthma; Bradykinin B1 Receptor Antagonists; Bronchoalv | 2016 |
Suhuang antitussive capsule at lower doses attenuates airway hyperresponsiveness, inflammation, and remodeling in a murine model of chronic asthma.
Topics: Airway Remodeling; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; | 2016 |
Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Animals; Asthma; Benzamides; Bronchial Hyperrea | 2016 |
Polygonum multiflorum Decreases Airway Allergic Symptoms in a Murine Model of Asthma.
Topics: Administration, Oral; Animals; Anti-Asthmatic Agents; Asthma; Cytokines; Disease Models, Animal; Dos | 2016 |
Recombinant human deoxyribonuclease therapy improves airway resistance and reduces DNA extracellular traps in a murine acute asthma model.
Topics: Administration, Intranasal; Airway Obstruction; Airway Resistance; Allergens; Animals; Asthma; Bronc | 2016 |
Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma.
Topics: Airway Obstruction; Asthma; Case-Control Studies; Gels; Humans; Mucin 5AC; Mucin-5B; Mucociliary Cle | 2016 |
Cylindromatosis (Cyld) gene mutation in T cells promotes the development of an IL-9-dependent allergic phenotype in experimental asthma.
Topics: Animals; Asthma; CD4-Positive T-Lymphocytes; Deubiquitinating Enzyme CYLD; Eosinophils; Humans; Hype | 2016 |
Pentraxin 3 deletion aggravates allergic inflammation through a T
Topics: Adult; Aged; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; C-Reactive Protein; CD4-Posit | 2017 |
Luteolin Attenuates Airway Mucus Overproduction via Inhibition of the GABAergic System.
Topics: A549 Cells; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; GABA-A Receptor Antagonists; Goblet Cel | 2016 |
Astragalus polysaccharide modulates ER stress response in an OVA-LPS induced murine model of severe asthma.
Topics: Active Transport, Cell Nucleus; Animals; Anti-Asthmatic Agents; Asthma; Astragalus Plant; Endoplasmi | 2016 |
IFN-γ Blocks Development of an Asthma Phenotype in Rhinovirus-Infected Baby Mice by Inhibiting Type 2 Innate Lymphoid Cells.
Topics: Animals; Animals, Newborn; Asthma; Cell Lineage; Epithelial Cells; Gene Expression Regulation; HeLa | 2017 |
Allergic asthma is distinguished by sensitivity of allergen-specific CD4+ T cells and airway structural cells to type 2 inflammation.
Topics: Adult; Allergens; Asthma; Cytokines; Humans; Hypersensitivity; Inflammation; Lung; Mucus; Muscle, Sm | 2016 |
Abnormalities in MUC5AC and MUC5B Protein in Airway Mucus in Asthma.
Topics: Adult; Asthma; Female; Gene Expression; Humans; Male; Middle Aged; Mucin 5AC; Mucin-5B; Mucus | 2016 |
IκBNS induces Muc5ac expression in epithelial cells and causes airway hyper-responsiveness in murine asthma models.
Topics: Allergens; Animals; Asthma; Blood Cells; Cytokines; Dermatophagoides pteronyssinus; Disease Models, | 2017 |
Reduced allergic lung inflammation by root extracts from two species of Peucedanum through inhibition of Th2 cell activation.
Topics: Allergens; Animals; Anti-Asthmatic Agents; Apiaceae; Asthma; Bronchoalveolar Lavage Fluid; CD4-Posit | 2017 |
Lyn kinase represses mucus hypersecretion by regulating IL-13-induced endoplasmic reticulum stress in asthma.
Topics: Animals; Asthma; Biomarkers; Case-Control Studies; Cytokines; Disease Models, Animal; Endoplasmic Re | 2017 |
Unusual Mucus Impaction in an Adolescent Patient With Severe Asthma.
Topics: Adolescent; Asthma; Bronchoscopy; Glucocorticoids; Humans; Lung; Male; Mucus; Nitric Oxide; Pulmonar | 2017 |
Attenuated airway hyperresponsiveness and mucus secretion in HDM-exposed Igf1r-deficient mice.
Topics: Animals; Asthma; Eosinophils; Female; Insulin-Like Growth Factor I; Mice; Mucus; Pyroglyphidae; Resp | 2017 |
Depletion of CD8+ T cells enhances airway remodelling in a rodent model of asthma.
Topics: Allergens; Animals; Antibodies, Monoclonal; Asthma; Bronchoalveolar Lavage Fluid; CD8 Antigens; CD8- | 2009 |
Inhibitory effects of astragaloside IV on ovalbumin-induced chronic experimental asthma.
Topics: Actins; Allergens; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Ch | 2008 |
GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway inflammation in mice.
Topics: Administration, Intranasal; Animals; Antigens; Asthma; Benzoates; Cell Differentiation; I-kappa B Pr | 2008 |
CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling.
Topics: Adoptive Transfer; Allergens; Animals; Asthma; Cell Separation; Collagen; Eosinophils; Female; Immun | 2008 |
Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs.
Topics: Administration, Oral; Animals; Asthma; Bronchoconstriction; Capillary Permeability; Capsaicin; Cough | 2008 |
Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Movement; Cell Polarity; Cytokines; Dendritic Ce | 2008 |
Endothelin A receptor antagonist modulates lymphocyte and eosinophil infiltration, hyperreactivity and mucus in murine asthma.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Disease Models, Animal; En | 2008 |
[Plastic bronchitis: report of a pediatric case].
Topics: Asthma; Bronchi; Bronchitis; Bronchoscopy; Child, Preschool; Croup; Follow-Up Studies; Humans; Male; | 2008 |
Inhibitory effect of kefiran on ovalbumin-induced lung inflammation in a murine model of asthma.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cell Count; Cytokines; Fem | 2008 |
Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchoalveolar Lav | 2009 |
A novel (S)-(+)-decursin derivative, (S)-(+)-3-(3,4-dihydroxy-phenyl)-acrylic acid 2,2-dimethyl-8-oxo-3,4-dihydro-2H,8H-pyrano[3,2-g]chromen-3-yl-ester, inhibits ovalbumin-induced lung inflammation in a mouse model of asthma.
Topics: Acrylates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Benzopyrans; Butyrates; Chroman | 2009 |
Different doses of lipopolysaccharides regulate the lung inflammation of asthmatic mice via TLR4 pathway in alveolar macrophages.
Topics: Animals; Asthma; Dose-Response Relationship, Drug; Eosinophils; Female; Inflammation; Interferon-gam | 2009 |
Irreversiblity of remodeled features on high-resolution computerized tomography scans of asthmatic patients on conventional therapy: a 6-year longitudinal study.
Topics: Adult; Anti-Asthmatic Agents; Asthma; Bronchi; Female; Humans; Lung; Male; Middle Aged; Mucus; Prosp | 2009 |
Expression of survivin in lung eosinophils is associated with pathology in a mouse model of allergic asthma.
Topics: Airway Obstruction; Allergens; Animals; Apoptosis; Asthma; Cell Adhesion; Cytokines; Disease Models, | 2009 |
Environmental tobacco smoke exposure does not prevent corticosteroids reducing inflammation, remodeling, and airway hyperreactivity in mice exposed to allergen.
Topics: Adrenal Cortex Hormones; Allergens; Animals; Asthma; Bronchi; Bronchial Hyperreactivity; Disease Mod | 2009 |
Distinct roles of FOXA2 and FOXA3 in allergic airway disease and asthma.
Topics: Animals; Asthma; Disease Models, Animal; Epithelial Cells; Gene Expression; Hepatocyte Nuclear Facto | 2009 |
Preventive and curative glycoside kaempferol treatments attenuate the TH2-driven allergic airway disease.
Topics: Animals; Antigens, CD; Asthma; Bronchoalveolar Lavage Fluid; Cell Count; Disaccharides; Eosinophils; | 2009 |
Anti-inflammatory and anti-asthmatic effects of Viola mandshurica W. Becker (VM) ethanolic (EtOH) extract on airway inflammation in a mouse model of allergic asthma.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchi; Bronchial | 2010 |
Petasites extract Ze 339 (PET) inhibits allergen-induced Th2 responses, airway inflammation and airway hyperreactivity in mice.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Chemokine CCL5; Disease Mo | 2010 |
Does milk increase mucus production?
Topics: Animals; Asthma; Endorphins; Gastrointestinal Tract; Goblet Cells; Humans; Milk; Mucus; Peptide Frag | 2010 |
Increased myoepithelial cells of bronchial submucosal glands in fatal asthma.
Topics: Adult; Asthma; Autopsy; Bronchi; Epithelial Cells; Exocrine Glands; Female; Humans; Male; Middle Age | 2010 |
Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Animals; Aspergillus fumigatus; Asthma; Bronchia | 2010 |
Helminth infection inhibits airway allergic reaction and dendritic cells are involved in the modulation process.
Topics: Adoptive Transfer; Animals; Asthma; Bronchial Hyperreactivity; Dendritic Cells; Eosinophilia; Female | 2010 |
The plant extract Isatis tinctoria L. extract (ITE) inhibits allergen-induced airway inflammation and hyperreactivity in mice.
Topics: Allergens; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lav | 2010 |
Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma.
Topics: Alanine Transaminase; Allantoin; Animals; Aspartate Aminotransferases; Asthma; Bronchoalveolar Lavag | 2010 |
Uncoordinated 119 preferentially induces Th2 differentiation and promotes the development of asthma.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Animals; Arthritis, Experimental; Ast | 2010 |
Ozone increases airway hyperreactivity and mucus hyperproduction in mice previously exposed to allergen.
Topics: Air Pollutants; Allergens; Animals; Asthma; Biomarkers; Bronchial Hyperreactivity; Bronchoalveolar L | 2010 |
Allergic airway inflammation induces a pro-secretory epithelial ion transport phenotype in mice.
Topics: 1-Methyl-3-isobutylxanthine; Allergens; Amiloride; Animals; Aspergillus fumigatus; Asthma; Bronchoal | 2010 |
The overexpression of heparin-binding epidermal growth factor is responsible for Th17-induced airway remodeling in an experimental asthma model.
Topics: Adoptive Transfer; Airway Remodeling; Animals; Antibodies, Monoclonal; Asthma; Blotting, Western; Cy | 2010 |
Role of aquaporin 5 in antigen-induced airway inflammation and mucous hyperproduction in mice.
Topics: Animals; Antigens; Aquaporin 5; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Gene Deletion; Hype | 2011 |
Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to asthma.
Topics: Airway Remodeling; Animals; Arginine; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Flui | 2011 |
Anti-asthmatic effect of Sanguisorba officinalis L. and potential role of heme oxygenase-1 in an ovalbumin-induced murine asthma model.
Topics: Analysis of Variance; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; Cytokine | 2010 |
Anti-inflammatory effects of ethanolic extract from Lagerstroemia indica on airway inflammation in mice.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Eosin | 2011 |
Chronic mucus hypersecretion: prevalence and risk factors in younger individuals.
Topics: Adolescent; Adult; Age Factors; Asthma; Child; Denmark; Diseases in Twins; Female; Humans; Male; Muc | 2010 |
Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-κB inhibition.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Biological Transport; Bronchoalveolar Lavage Fluid; Cell | 2011 |
Anti-asthmatic effects of an Amomum compactum extract on an ovalbumin (OVA)-induced murine asthma model.
Topics: Amomum; Animals; Asthma; Dose-Response Relationship, Drug; Eosinophils; Immunoglobulin E; Immunologi | 2010 |
Effects of astragaloside IV on IFN-gamma level and prolonged airway dysfunction in a murine model of chronic asthma.
Topics: Animals; Asthma; Astragalus Plant; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Chronic | 2011 |
A nonredundant role for mouse Serpinb3a in the induction of mucus production in asthma.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Separation; Enzyme-Linked Immunosorbent Assay; F | 2011 |
Inhibition of airway inflammation, hyperresponsiveness and remodeling by soy isoflavone in a murine model of allergic asthma.
Topics: Airway Remodeling; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Chemoki | 2011 |
Chronic OVA allergen challenged TNF p55/p75 receptor deficient mice have reduced airway remodeling.
Topics: Airway Remodeling; Allergens; Animals; Asthma; Bronchi; Collagen; Eosinophils; Extracellular Matrix | 2011 |
Prostanoid DP receptor antagonists suppress symptomatic asthma-like manifestation by distinct actions from a glucocorticoid in rats.
Topics: Acetylcholine; Aged; Animals; Antigens; Asthma; Bronchial Hyperreactivity; Chemokines; Female; Gene | 2011 |
Flow cytometry of sputum: assessing inflammation and immune response elements in the bronchial airways.
Topics: Asthma; B-Lymphocytes; Biomarkers; Bronchi; Dendritic Cells; Eosinophils; Epithelial Cells; Flow Cyt | 2011 |
Blockade of human group X secreted phospholipase A2 (GX-sPLA2)-induced airway inflammation and hyperresponsiveness in a mouse asthma model by a selective GX-sPLA2 inhibitor.
Topics: Allergens; Animals; Asthma; Disease Models, Animal; Enzyme Inhibitors; Gene Knock-In Techniques; Gro | 2011 |
Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway.
Topics: Animals; Anti-Inflammatory Agents; Antimalarials; Artemisinins; Artesunate; Asthma; Bronchi; Broncho | 2011 |
STAT6 links IL-4/IL-13 stimulation with pendrin expression in asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Base Pairing; Binding Sites; Cell Line; Epithelial Cells; Gene Expression Regulation; Humans | 2011 |
Environmental tobacco smoke and progesterone alter lung inflammation and mucous metaplasia in a mouse model of allergic airway disease.
Topics: Allergens; Animals; Asthma; Disease Models, Animal; Female; Humans; Hypersensitivity, Immediate; Mal | 2012 |
The role of SPINK5 in asthma related physiological events in the airway epithelium.
Topics: Apoptosis; Asthma; Cell Survival; Cells, Cultured; Cytokines; Epithelial Cells; Genetic Vectors; Hum | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-κB.
Topics: Airway Resistance; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Adhesion Molecules; Cell Coun | 2012 |
Milk consumption and mucus production in children with asthma.
Topics: Animals; Asthma; Child; Humans; Milk; Mucus | 2012 |
Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation.
Topics: Adoptive Transfer; Allergens; Animals; Asthma; Cytokines; Disease Models, Animal; Gene Expression Pr | 2012 |
Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells.
Topics: Adoptive Transfer; Animals; Asthma; Bacterial Capsules; Bacterial Proteins; Disease Models, Animal; | 2012 |
CD137 deficiency does not affect development of airway inflammation or respiratory tolerance induction in murine models.
Topics: Allergens; Animals; Asthma; Cytokines; Disease Models, Animal; Eosinophils; Humans; Immune Tolerance | 2012 |
IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease.
Topics: Allergens; Asthma; Disease Progression; Humans; Hypersensitivity; Interleukin-17; Lung; Molecular Ta | 2012 |
Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor.
Topics: Animals; Asthma; Chronic Disease; Disease Models, Animal; Female; Fluorobenzenes; GABA-A Receptor An | 2012 |
Genes associated with MUC5AC expression in small airway epithelium of human smokers and non-smokers.
Topics: Adult; Asthma; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networ | 2012 |
Effects and mechanism of arsenic trioxide on reversing the asthma pathologies including Th17-IL-17 axis in a mouse model.
Topics: Animals; Anti-Asthmatic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Bronchial Hyperreac | 2012 |
Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma.
Topics: Anesthetics, Local; Animals; Asthma; Bronchi; Disease Models, Animal; Fibrosis; GATA3 Transcription | 2012 |
SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation.
Topics: 3' Untranslated Regions; Airway Obstruction; Animals; Antiporters; Asthma; Bronchitis; Calcium; Chil | 2012 |
PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production.
Topics: Allergens; Animals; Antibodies, Monoclonal; Asthma; Bronchial Hyperreactivity; Dendritic Cells; Gene | 2013 |
The AGC kinase inhibitor H89 attenuates airway inflammation in mouse models of asthma.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Immunoglobulin E; | 2012 |
Lipopolysaccharide inhibits Th2 lung inflammation induced by house dust mite allergens in mice.
Topics: Animals; Antigens, Dermatophagoides; Asthma; Complement Activation; Cytokines; Disease Models, Anima | 2013 |
Tripterygium polyglycosid attenuates the established airway inflammation in asthmatic mice.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cytokines; Dexamethasone; | 2013 |
[The cutting-edge of medicine; Management and therapy for airway mucus hypersecretion].
Topics: Asthma; Bronchiolitis Obliterans; Cystic Fibrosis; Humans; Mucus; Pulmonary Disease, Chronic Obstruc | 2012 |
Effect of dexamethasone on expression of AGR2 protein in asthmatic mice.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Dexamethasone; Female; Interleukin-13; Lung; Mice; Mice, | 2013 |
Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma.
Topics: Adult; Asthma; Autopsy; Case-Control Studies; Cell Count; Cell Degranulation; Exocrine Glands; Femal | 2002 |
Long-lived Th2 memory in experimental allergic asthma.
Topics: Acute Disease; Aerosols; Animals; Asthma; Bronchial Hyperreactivity; Cytokines; Female; Immunoglobul | 2002 |
A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model.
Topics: Administration, Intranasal; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar L | 2002 |
Mucus hypersecretion in respiratory disease. Chair's introduction.
Topics: Animals; Asthma; Chloride Channels; Exocytosis; Humans; Inflammation; Lymphokines; Mice; Mucus; Pulm | 2002 |
Cytokine regulation of mucus production in a model of allergic asthma.
Topics: Administration, Inhalation; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cells, Cultured; Exocytos | 2002 |
Bronchial asthma--"the plumbing".
Topics: Asthma; Bronchial Hyperreactivity; Humans; Lung; Mucus; Muscle, Smooth; Risk Factors | 2003 |
Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity.
Topics: Administration, Inhalation; Allergens; Animals; Anti-Allergic Agents; Asthma; Bronchi; Bronchial Hyp | 2003 |
Characterization of airway plugging in fatal asthma.
Topics: Adolescent; Adult; Aged; Airway Obstruction; Asthma; Bronchi; Cell Culture Techniques; Child; Humans | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
The role of mucus in fatal asthma.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchi; Humans; Mucins; Mucus; Muscle, Smooth | 2003 |
[Mucous plugs of the bronchis in patients with asthma and Hoffman and Teichmuller's eosinophilic catarrh].
Topics: Asthma; Bronchi; Bronchial Diseases; Common Cold; Disease; Eosinophilia; Humans; Mucus | 1956 |
[Mucous plugs of the bronchis in patients with asthma and Hoffman and Teichmuller's eosinophilic catarrh].
Topics: Asthma; Bronchi; Bronchial Diseases; Common Cold; Disease; Eosinophilia; Humans; Mucus | 1956 |
[Mucous plugs of the bronchis in patients with asthma and Hoffman and Teichmuller's eosinophilic catarrh].
Topics: Asthma; Bronchi; Bronchial Diseases; Common Cold; Disease; Eosinophilia; Humans; Mucus | 1956 |
[Mucous plugs of the bronchis in patients with asthma and Hoffman and Teichmuller's eosinophilic catarrh].
Topics: Asthma; Bronchi; Bronchial Diseases; Common Cold; Disease; Eosinophilia; Humans; Mucus | 1956 |
[Mucous plugs of bronchi in asthma & Hoffmann & Teichmüller eosinophilic catarrhs].
Topics: Asthma; Bronchi; Common Cold; Humans; Mucus; Pulmonary Eosinophilia; Respiratory Tract Diseases | 1957 |
[Results in aspiration of mucus & hyaluronidase-hydrocortisone aerosol therapy of bronchial asthma].
Topics: Aerosols; Asthma; Humans; Hyaluronoglucosaminidase; Hydrocortisone; Mucus | 1958 |
[Therapy of bronchial asthma by mucus drainage and hyaluronidase-hydrocortisone-prednisone aerosol].
Topics: Aerosols; Asthma; Body Fluids; Drainage; Humans; Hyaluronoglucosaminidase; Hydrocortisone; Mucus; Pr | 1958 |
[The action of cortisone-like substances on the secretion of bronchial mucus in asthma].
Topics: Adrenal Cortex Hormones; Asthma; Bronchi; Cortisone; Humans; Mucus; Respiratory System | 1963 |
[THE GLYCOPROTEINS OF BRONCHIAL SECRETIONS].
Topics: Antibodies; Asthma; Beta-Globulins; Blood Group Antigens; Bronchitis; Chromatography; Chymotrypsin; | 1963 |
MUCOID IMPACTION OF THE BRONCHI.
Topics: Asthma; Blood Cell Count; Bronchi; Bronchial Diseases; Bronchitis; Bronchoscopy; Humans; Hypersensit | 1964 |
MUCOID IMPACTION OF THE BRONCHI.
Topics: Asthma; Bronchi; Bronchial Diseases; Bronchiectasis; Bronchoscopy; Humans; Mucus; Pulmonary Atelecta | 1964 |
NEW MUCOLYTIC AGENTS FOR SPUTUM LIQUEFACTION.
Topics: Acetylcysteine; Asthma; Bronchial Diseases; Cysteine; Cystic Fibrosis; Expectorants; Fibrin; Humans; | 1964 |
BRONCHOSCOPIC LAVAGE IN BRONCHIAL ASTHMA.
Topics: Asthma; Bronchoalveolar Lavage; Bronchoscopy; Humans; Mucus; Therapeutic Irrigation; Therapeutics | 1965 |
ASTHMA AND COUGHING.
Topics: Asthma; Cough; Humans; Mucus; Therapeutics | 1965 |
HISTOCHEMICAL AND ENZYME STUDIES OF BRONCHIAL MUCUS.
Topics: Asthma; Bronchi; Bronchitis; Cystic Fibrosis; Glycosaminoglycans; Histocytochemistry; Humans; Mucous | 1965 |
THE SPUTUM IN BRONCHIAL ASTHMA: PATHOGNOMONIC PATTERNS.
Topics: Asthma; Bronchial Diseases; Cell Aggregation; Diagnosis, Differential; Eosinophils; Humans; Leukocyt | 1965 |
Mucus and fatal asthma.
Topics: Airway Obstruction; Asthma; Cell Count; Goblet Cells; Humans; Mucin 5AC; Mucin-5B; Mucins; Mucus; Re | 2004 |
A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma.
Topics: Animals; Asthma; Bronchi; Bronchial Provocation Tests; Cytoplasmic Granules; Disease Models, Animal; | 2004 |
Exacerbated Th2-mediated airway inflammation and hyperresponsiveness in autoimmune diabetes-prone NOD mice: a critical role for CD1d-dependent NKT cells.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD1; Antigens, CD1d; Asthma; Bronchial Hyperreactivity; B | 2004 |
Inhaled dexamethasone differentially attenuates disease relapse and established allergic asthma in mice.
Topics: Administration, Inhalation; Animals; Anti-Allergic Agents; Asthma; Bronchoalveolar Lavage; Dexametha | 2004 |
Association of vitamin D binding protein variants with chronic mucus hypersecretion in Iceland.
Topics: Asthma; Base Sequence; Case-Control Studies; Chronic Disease; DNA Primers; Humans; Iceland; Mucus; P | 2004 |
Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; | 2004 |
Mucus hypersecretion: a common symptom, a common mechanism?
Topics: Asthma; Chloride Channels; Cystic Fibrosis; Humans; Inflammation; Interleukin-9; Mucus; Receptors, I | 2004 |
STAT6-mediated signaling in Th2-dependent allergic asthma: critical role for the development of eosinophilia, airway hyper-responsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation.
Topics: Administration, Intranasal; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid | 2004 |
Biomedicine. Eosinophils in asthma: remodeling a tangled tale.
Topics: Animals; Asthma; Cytokines; DNA-Binding Proteins; Eosinophil Peroxidase; Eosinophils; Erythroid-Spec | 2004 |
Defining a link with asthma in mice congenitally deficient in eosinophils.
Topics: Allergens; Animals; Asthma; Diphtheria Toxin; Eosinophil Peroxidase; Eosinophils; Gene Targeting; Le | 2004 |
A critical role for eosinophils in allergic airways remodeling.
Topics: Animals; Asthma; Bronchi; Cell Division; Collagen; Eosinophils; Interleukins; Leukocyte Count; Lung; | 2004 |
Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma.
Topics: Allergens; Animals; Apoptosis; Asthma; Bronchial Hyperreactivity; Chemokine CCL11; Chemokines, CC; F | 2004 |
Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice.
Topics: Administration, Inhalation; Aerosols; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar La | 2005 |
[Severe asthma complicated with large mucoid impaction: successful removal with balloon catheter].
Topics: Adult; Airway Obstruction; Asthma; Bronchoscopy; Catheterization; Female; Humans; Kidney Transplanta | 2004 |
Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model.
Topics: Animals; Asthma; Cytokines; Disease Models, Animal; Female; Heterozygote; Immunization; Immunoglobul | 2005 |
Respiratory syncytial virus-induced exaggeration of allergic airway disease is dependent upon CCR1-associated immune responses.
Topics: Allergens; Animals; Asthma; Cockroaches; Female; Humans; Immunity, Cellular; Interleukin-13; Lung; M | 2005 |
Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice.
Topics: Animals; Antibodies, Monoclonal; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Ch | 2005 |
[Concentrations of carcinoembryonic antigen in serum and bronchoalveolar lavage fluid of asthmatic patients with mucoid impaction].
Topics: Aged; Airway Obstruction; Asthma; Bronchial Diseases; Bronchiectasis; Bronchoalveolar Lavage Fluid; | 2004 |
An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Cell Movement; Chromones; C | 2005 |
[Effects of interleukin-13 on the gob-5 and MUC5AC expression in lungs of a murine asthmatic model].
Topics: Animals; Asthma; Chloride Channels; Disease Models, Animal; Immunohistochemistry; Interleukin-13; Ma | 2004 |
[The preventive effect of bacillus Calmette-Guerin vaccination in early life on airway inflammation and mucus production in a murine model of asthma].
Topics: Animals; Asthma; BCG Vaccine; Bronchi; Disease Models, Animal; Lung; Mice; Mice, Inbred C57BL; Mucin | 2005 |
Therapeutic administration of Budesonide ameliorates allergen-induced airway remodelling.
Topics: Allergens; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchial Hyperreactivity; Bronchoalveol | 2005 |
Atelectasis of the right medial basal segment mimicking primary lung cancer in an asthmatic patient.
Topics: Asthma; Diagnosis, Differential; Female; Humans; Lung Neoplasms; Middle Aged; Mucus; Pulmonary Atele | 2005 |
A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion.
Topics: Analysis of Variance; Asthma; Biomarkers; Bronchoalveolar Lavage Fluid; Bronchoscopy; Case-Control S | 2005 |
Gob-5 is not essential for mucus overproduction in preclinical murine models of allergic asthma.
Topics: Animals; Asthma; Cells, Cultured; Chloride Channels; Disease Models, Animal; Female; Gastrointestina | 2005 |
Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Apoptosis; Asthma; Bronchial Hyperreactivity; Disease | 2005 |
Characteristic features of allergic airway inflammation in a murine model of infantile asthma.
Topics: Age Factors; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cytokines; Di | 2005 |
Antibody-antigen interaction in the airway drives early granulocyte recruitment through BLT1.
Topics: Animals; Antigen-Antibody Reactions; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid | 2006 |
Time to death, airway wall inflammation and remodelling in fatal asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Death; Female; Humans; Lung; Male; Mucu | 2005 |
IL-4 receptor signaling in Clara cells is required for allergen-induced mucus production.
Topics: Allergens; Animals; Asthma; Interleukin-13; Interleukin-4; Mice; Mice, Inbred BALB C; Mice, Transgen | 2005 |
Effect of disodium cromoglycate on airway mucus secretion during antigen-induced late asthmatic responses in a murine model of asthma.
Topics: Airway Obstruction; Animals; Anti-Asthmatic Agents; Antigens; Asthma; Bronchoalveolar Lavage Fluid; | 2005 |
Chronic mucus hypersecretion: a marker of asthma in young adults?
Topics: Adult; Asthma; Bronchial Provocation Tests; Chi-Square Distribution; Chronic Disease; Cross-Sectiona | 2005 |
Chronic exposure to TNF-alpha increases airway mucus gene expression in vivo.
Topics: Animals; Asthma; Body Temperature; Body Weight; Bronchial Hyperreactivity; Chloride Channels; Cytoki | 2005 |
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma.
Topics: Animals; Antibodies, Monoclonal; Asthma; Cytokines; Disease Models, Animal; Female; Hepatitis A Viru | 2005 |
Erratum: name change.
Topics: Animals; Asthma; Chloride Channels; Disease Models, Animal; Mice; Mucoproteins; Mucus; Respiratory M | 2006 |
Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model.
Topics: Adenine; Animals; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoalveolar La | 2006 |
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma.
Topics: Allergens; Animals; Asthma; Bronchi; Bronchial Hyperreactivity; Dendritic Cells; Disease Models, Ani | 2006 |
Niflumic acid suppresses interleukin-13-induced asthma phenotypes.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Chloride Channels; Eosinophils; Goblet Cells; Hyperpl | 2006 |
Chronic cough. It can be helped.
Topics: Angiotensin-Converting Enzyme Inhibitors; Asthma; Chronic Disease; Cough; Gastroesophageal Reflux; H | 2006 |
Contribution of IL-18-induced innate T cell activation to airway inflammation with mucus hypersecretion and airway hyperresponsiveness.
Topics: Animals; Asthma; Cytokines; Disease Models, Animal; DNA-Binding Proteins; Embryo, Mammalian; Eosinop | 2006 |
Effects of ultrafine carbon particle inhalation on allergic inflammation of the lung.
Topics: Administration, Inhalation; Air Pollutants; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid | 2006 |
Suppressive effect of verproside isolated from Pseudolysimachion longifolium on airway inflammation in a mouse model of allergic asthma.
Topics: Acetates; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; Cyclopropanes; Disea | 2006 |
The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
Topics: Acetates; Airway Obstruction; Animals; Anti-Asthmatic Agents; Asthma; Collagen; Cyclopropanes; Cyste | 2006 |
Death receptor-6 regulates the development of pulmonary eosinophilia and airway inflammation in a mouse model of asthma.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Cytokines; Disease Models, Animal; Interferon-gamma; Mic | 2006 |
Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung.
Topics: Alcohol Dehydrogenase; Animals; Asthma; Dendritic Cells; Exocrine Glands; Glutathione Reductase; Inf | 2006 |
Follistatin is a candidate endogenous negative regulator of activin A in experimental allergic asthma.
Topics: Activins; Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Female; Follistatin | 2006 |
ADAM33 is not essential for growth and development and does not modulate allergic asthma in mice.
Topics: ADAM Proteins; Allergens; Animals; Asthma; Breeding; Bronchial Hyperreactivity; Female; Gene Targeti | 2006 |
Secretory phospholipases A2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in ferret trachea.
Topics: Animals; Asthma; Ferrets; Glycoconjugates; Group II Phospholipases A2; Humans; In Vitro Techniques; | 2007 |
CCR3 monoclonal antibody inhibits airway eosinophilic inflammation and mucus overproduction in a mouse model of asthma.
Topics: Animals; Antibodies, Monoclonal; Asthma; Bronchoalveolar Lavage Fluid; Eosinophilia; Eosinophils; Er | 2006 |
Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling.
Topics: Animals; Asthma; Chemokine CCL11; Chemokines, CC; Collagen; Eosinophils; Inflammation; Interleukin-1 | 2006 |
[Effects of glucocorticoid on airway mucus secretion in asthma: experiment with asthmatic mouse model].
Topics: Aluminum Hydroxide; Animals; Asthma; Bronchoalveolar Lavage Fluid; Dexamethasone; Disease Models, An | 2006 |
Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity.
Topics: Animals; Arginase; Asthma; Biomarkers; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cells | 2006 |
IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells.
Topics: Animals; Asthma; Chemokine CCL11; Chemokines, CC; Epithelial Cells; Hematopoietic Stem Cell Transpla | 2007 |
Macrophage migration inhibitory factor is essential for allergic asthma but not for Th2 differentiation.
Topics: Allergens; Animals; Asthma; Cell Differentiation; Immune Sera; Intramolecular Oxidoreductases; Macro | 2007 |
Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice.
Topics: Animals; Asthma; B7-1 Antigen; B7-2 Antigen; Bronchoalveolar Lavage Fluid; Cell Line; Chemokine CCL1 | 2007 |
Coexposure to environmental tobacco smoke increases levels of allergen-induced airway remodeling in mice.
Topics: Actins; Allergens; Animals; Asthma; Bronchi; Bronchial Hyperreactivity; Chemokine CCL11; Chemokines, | 2007 |
The tick salivary protein, Salp15, inhibits the development of experimental asthma.
Topics: Adjuvants, Immunologic; Animals; Asthma; Bronchial Hyperreactivity; CD4-Positive T-Lymphocytes; Dise | 2007 |
Plasminogen is an important regulator in the pathogenesis of a murine model of asthma.
Topics: Animals; Antifibrinolytic Agents; Asthma; Bronchoalveolar Lavage Fluid; Collagen; Disease Models, An | 2007 |
Glycogen synthase kinase-3beta inhibition attenuates asthma in mice.
Topics: Analysis of Variance; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Enzyme Inhibitors; E | 2007 |
A GABAergic system in airway epithelium is essential for mucus overproduction in asthma.
Topics: Animals; Asthma; Cells, Cultured; Female; gamma-Aminobutyric Acid; Humans; Mice; Mice, Inbred BALB C | 2007 |
A new link to airway obstruction in asthma.
Topics: Airway Obstruction; Asthma; gamma-Aminobutyric Acid; Humans; Mucus; Respiratory System; Signal Trans | 2007 |
Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide.
Topics: Acute Disease; Administration, Intranasal; Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Mo | 2007 |
Increased expression of human calcium-activated chloride channel 1 gene is correlated with mucus overproduction in Chinese asthmatic airway.
Topics: Aged; Asthma; Calcium; China; Chloride Channels; Female; Gene Expression; Humans; Male; Middle Aged; | 2007 |
Effect of ageing on pulmonary inflammation, airway hyperresponsiveness and T and B cell responses in antigen-sensitized and -challenged mice.
Topics: Aging; Animals; Asthma; B-Lymphocytes; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Enzy | 2007 |
Anti-inflammatory and anti-allergic effects of kefir in a mouse asthma model.
Topics: Administration, Oral; Animals; Asthma; Bronchial Hyperreactivity; Cultured Milk Products; Cytokines; | 2007 |
Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion.
Topics: Aged; Asthma; Bronchodilator Agents; Diuretics, Osmotic; Elasticity; Ethanolamines; Female; Formoter | 2007 |
The involvement of type 1a angiotensin II receptors in the regulation of airway inflammation in a murine model of allergic asthma.
Topics: Animals; Asthma; Bronchitis; Bronchoalveolar Lavage Fluid; Cell Count; Cell Differentiation; Cytokin | 2007 |
IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchitis; Fibrosis; Granuloma; Interleukin-10; Interle | 2007 |
Glutamine preferentially inhibits T-helper type 2 cell-mediated airway inflammation and late airway hyperresponsiveness through the inhibition of cytosolic phospholipase A(2) activity in a murine asthma model.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchitis; Cytokines; Disease Models, Animal; Eosinophi | 2008 |
Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease.
Topics: Aged; Animals; Asthma; Chlorocebus aethiops; COS Cells; Disease Models, Animal; Epithelial Cells; Fe | 2008 |
Mucous obstruction and airway hyperresponsiveness in mice.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Disease Models, Animal; Mic | 2008 |
Fatal bronchial asthma in children: report of three cases.
Topics: Asthma; Bronchi; Child, Preschool; Death; Female; Humans; Male; Mucus; Pulmonary Emphysema; Pulmonar | 1967 |
The pharmacologic basis of asthma therapy.
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Asthma; Bronchi; Cromolyn Sodium; Humans; Mas | 1980 |
Pulmonary mucociliary clearance.
Topics: Asthma; Cilia; Cystic Fibrosis; Humans; Kartagener Syndrome; Lung; Mucus; Respiratory Tract Diseases | 1982 |
An early Southern description of Curschmann's spirals.
Topics: Asthma; History, 19th Century; Humans; Ipecac; Male; Mucus; Tennessee | 1982 |
Long-term ipratropium bromide nebuliser therapy and lung mucociliary clearance.
Topics: Asthma; Atropine Derivatives; Bronchitis; Cilia; Humans; Ipratropium; Lung; Mucus; Respiratory Thera | 1982 |
[The role of bronchial hyperresponsiveness in airway mucus secretion].
Topics: Adult; Animals; Asthma; Dogs; Exocrine Glands; Female; Histamine H1 Antagonists; Humans; In Vitro Te | 1983 |
Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma.
Topics: Adult; Aged; Asthma; Blood Proteins; Bronchi; Child; Eosinophil Granule Proteins; Eosinophils; Femal | 1982 |
Effect of inhaled ipratropium bromide on tracheal mucociliary transport in bronchial asthma.
Topics: Asthma; Atropine Derivatives; Cilia; Humans; Ipratropium; Mucus | 1984 |
Mast cells and asthma. The role of mast cell mediators in the pathogenesis of allergic asthma.
Topics: Airway Obstruction; Asthma; Bradykinin; Capillary Permeability; Histamine; Humans; Leukotriene E4; M | 1983 |
Possible mechanisms underlying mucus secretion in aspirin-sensitive asthma.
Topics: Aspirin; Asthma; Bronchi; Humans; Lipoxygenase; Models, Biological; Mucus; Prostaglandins | 1983 |
Diurnal variation in asthma.
Topics: Airway Resistance; Asthma; Bronchodilator Agents; Circadian Rhythm; Epinephrine; Gastroesophageal Re | 1984 |
Treatment of bronchial asthma.
Topics: Anti-Inflammatory Agents; Asthma; Cilia; Humans; Immunosuppressive Agents; Mucus; Respiratory Hypers | 1984 |
Acute respiratory failure in a young asthmatic patient.
Topics: Acute Disease; Adult; Asthma; Bronchography; Female; Humans; Mucus; Pneumothorax; Respiratory Distre | 1983 |
A model for assessing bronchial mucus transport.
Topics: Adolescent; Adult; Aerosols; Aged; Asthma; Biological Transport; Bronchi; Female; Humans; Krypton; M | 1984 |
Allergic mucociliary dysfunction.
Topics: Antigens; Asthma; Cilia; Humans; Mucous Membrane; Mucus; Rhinitis, Allergic, Seasonal; SRS-A; Trache | 1983 |
Status Asthmaticus: use of acetylcysteine during bronchoscopy and lavage to remove mucous plugs.
Topics: Acetylcysteine; Adult; Asthma; Bronchoscopy; Child; Female; Humans; Male; Middle Aged; Mucus; Therap | 1983 |
Control and modulation of airway epithelial cells and their secretions.
Topics: Animals; Asthma; Bronchitis; Chronic Disease; Cystic Fibrosis; Disease Models, Animal; Dogs; Epithel | 1983 |
The structure of bronchial plugs in mucoid impaction, bronchocentric granulomatosis and asthma.
Topics: Adult; Aged; Aspergillosis, Allergic Bronchopulmonary; Asthma; Bronchi; Bronchoscopy; Eosinophils; F | 1983 |
Calcium blockers and bronchoconstriction.
Topics: Animals; Asthma; Bronchi; Bronchial Spasm; Calcium Channel Blockers; Humans; Mucus; Muscle, Smooth; | 1983 |
Impaired tracheobronchial clearance in patients with mild stable asthma.
Topics: Adult; Aerosols; Asthma; Bronchi; Cilia; Female; Humans; Lung; Male; Mucus; Polystyrenes; Respirator | 1983 |
[Expectorant and liquescent preparations in the therapy of bronchial asthma and nonspecific lung diseases and their prevention].
Topics: Asthma; Drug Evaluation; Drug Therapy, Combination; Expectorants; Humans; Lung Diseases; Mucus; Pept | 1980 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1982. A 51-year-old woman with chronic asthma and hemoptysis.
Topics: Aspergillosis, Allergic Bronchopulmonary; Asthma; Bronchi; Bronchial Diseases; Bronchiectasis; Diagn | 1982 |
Recurrent mucoid impaction in an asthmatic infant with cow's milk protein allergy.
Topics: Animals; Asthma; Bronchoscopy; Cattle; Humans; Immunoglobulin E; Infant; Male; Milk Proteins; Mucus; | 1982 |
The pathophysiology of asthma.
Topics: Animals; Asthma; Bronchial Spasm; Bronchitis; Edema; Guinea Pigs; Humans; Lung; Mast Cells; Mucous M | 1982 |
Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro.
Topics: Asthma; Culture Techniques; Dose-Response Relationship, Drug; Humans; Lung; Mucus; Respiratory Hyper | 1982 |
Lung mucociliary function in man: interdependence of bronchial and tracheal mucus transport velocities with lung clearance in bronchial asthma and healthy subjects.
Topics: Adult; Aerosols; Asthma; Cilia; Female; Humans; Male; Middle Aged; Mucus; Respiratory System | 1982 |
Tracheobronchial mucus: abnormalities related to asthma and its treatment.
Topics: Airway Obstruction; Animals; Asthma; Biological Transport; Bronchi; Cilia; Constriction, Pathologic; | 1981 |
[Accumulation of eosinophils in the nasal secretion in patients with bronchial asthma].
Topics: Asthma; Bronchi; Eosinophils; Humans; Mucus; Nasal Mucosa | 1981 |
Application of density gradient methods for the study of mucus glycoprotein and other macromolecular components of the sol and gel phases of asthmatic sputa.
Topics: Amino Acids; Asthma; Carbohydrates; Centrifugation, Density Gradient; Gels; Glycoproteins; Humans; M | 1981 |
[Eosinophil concentration in nasal secretion in bronchial asthma].
Topics: Asthma; Diagnosis, Differential; Eosinophils; Humans; Leukocyte Count; Mucus; Nasal Mucosa; Rhinitis | 1981 |
Mucous secretions.
Topics: Asthma; Fluid Therapy; Humans; Mucus; Respiratory System | 1981 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 49-1981. Hyperinflated right middle lobe in a 15-year-old asthmatic girl.
Topics: Adolescent; Asthma; Bronchi; Bronchial Diseases; Diagnosis, Differential; Female; Humans; Lung; Mucu | 1981 |
Alteration of tracheal mucociliary transport in airway disease. Effect of pharmacologic agents.
Topics: Animals; Asthma; Bronchitis; Bronchodilator Agents; Chromones; Cilia; Cystic Fibrosis; Dogs; Humans; | 1981 |
Mucociliary dysfunction in bronchial asthma.
Topics: Asthma; Cilia; Humans; Mucus | 1981 |
[Modifiers of bronchial secretions in the asthmatic patient].
Topics: Asthma; Biological Transport; Bronchi; Cilia; Exocrine Glands; Expectorants; Humans; Mucous Membrane | 1981 |
Exercise-induced asthma.
Topics: Asthma; Asthma, Exercise-Induced; Cold Temperature; Humans; Mucus | 1980 |
Nocturnal asthma and circulating epinephrine, histamine, and cortisol.
Topics: Asthma; Circadian Rhythm; Humans; Mucus | 1980 |
Effect of dexamethasone on antigen-induced high molecular weight glycoconjugate secretion in allergic guinea pigs.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Dexamethasone; Disease Models, Animal; Eosinophils; G | 1995 |
Socioeconomic status and indicators of asthma in children.
Topics: Adolescent; Animals; Animals, Domestic; Asthma; Asthma, Exercise-Induced; Bronchial Hyperreactivity; | 1995 |
The pathophysiological role of mucus production in inflammatory airway diseases.
Topics: Asthma; Bronchitis; Cystic Fibrosis; Forced Expiratory Volume; Humans; Lung Diseases, Obstructive; M | 1995 |
Theoretic effects of mucus gland discharge on airway resistance in asthma.
Topics: Airway Resistance; Asthma; Bronchi; Humans; Mucus | 1995 |
Identification of two major populations of mucins in respiratory secretions.
Topics: Amino Acids; Asthma; Bronchitis; Chronic Disease; Humans; Methods; Microscopy, Electron; Molecular W | 1994 |
[Case of bronchial asthma with bronchorrhea].
Topics: Aged; Asthma; Bronchi; Humans; Male; Mucus | 1993 |
Mucus hypersecretion and eosinophils in bronchoalveolar lavage fluid in adult patients with bronchial asthma.
Topics: Adult; Age Factors; Aged; Asthma; Bronchoalveolar Lavage Fluid; Eosinophils; Female; Humans; Immunog | 1993 |
[Clinical features of bronchial asthma with mucus hypersecretion].
Topics: Adult; Aged; Asthma; Bronchoalveolar Lavage Fluid; Female; Humans; Male; Middle Aged; Mucus; Respira | 1993 |
Atopy, bronchial responsiveness, and symptoms in wheezy 3 year olds.
Topics: Asthma; Bronchitis; Child, Preschool; Humans; Mucus; Parasympatholytics; Respiratory Sounds | 1993 |
Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects.
Topics: Adult; Aged; Asthma; DNA; Female; Glycoproteins; Humans; Lactoferrin; Male; Middle Aged; Mucins; Muc | 1993 |
Abnormalities of the airways and lung parenchyma in asthmatics: CT observations in 50 patients and inter- and intraobserver variability.
Topics: Adult; Aged; Aged, 80 and over; Asthma; Bronchi; Bronchiectasis; Bronchography; Female; Forced Expir | 1996 |
Biological effects of diesel exhaust particles (DEP). III. Pathogenesis of asthma like symptoms in mice.
Topics: Animals; Asthma; Bronchi; Bronchoconstriction; Eosinophils; Free Radical Scavengers; Lung; Male; Mic | 1996 |
Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma.
Topics: Age Factors; Asthma; Bronchi; Bronchitis; Case-Control Studies; Eosinophils; Epithelium; Exocrine Gl | 1996 |
The importance of leukotrienes in airway inflammation in a mouse model of asthma.
Topics: 5-Lipoxygenase-Activating Proteins; Allergens; Animals; Asthma; Bronchial Provocation Tests; Broncho | 1996 |
Histamine H2 receptor-mediated airway goblet cell secretion and its modulation by histamine-degrading enzymes.
Topics: Amine Oxidase (Copper-Containing); Animals; Asthma; Cimetidine; Dimaprit; Dose-Response Relationship | 1997 |
[A patient with bronchial asthma and mucoid impaction who presented with a high concentration of carcinoembryonic antigen in serum].
Topics: Adult; Asthma; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Carcinoembryonic Antigen; Femal | 1997 |
Goblet cell degranulation after antigen challenge in sensitized guinea pigs. Role of neutrophils.
Topics: 3,3'-Diaminobenzidine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Antigens; Asthm | 1998 |
Diagnostic value of nasal provocation challenge with allergens in children.
Topics: Adolescent; Allergens; Antigens, Dermatophagoides; Asthma; Cell Count; Child; Child, Preschool; Conj | 1998 |
[Effect of heparin on airway goblet cell secretion in sensitized guinea pigs].
Topics: Animals; Asthma; Depression, Chemical; Dose-Response Relationship, Drug; Goblet Cells; Guinea Pigs; | 1998 |
Physical characterization of a low-charge glycoform of the MUC5B mucin comprising the gel-phase of an asthmatic respiratory mucous plug.
Topics: Asthma; Chromatography, Ion Exchange; Electrophoresis, Agar Gel; Humans; Microscopy, Electron; Mucin | 1999 |
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.
Topics: Airway Resistance; Animals; Asthma; Bronchi; Bronchoconstrictor Agents; Chemokine CCL11; Chemokines, | 1999 |
Mechanisms of hypersecretion in acute asthma, proposed cause of death, and novel therapy.
Topics: Animals; Asthma; Cause of Death; Goblet Cells; Guinea Pigs; Humans; Leukocyte Elastase; Mucus; Neutr | 1999 |
Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma.
Topics: Aerosols; Allergens; Animals; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Bronchoconst | 1999 |
Th2-induced airway mucus production is dependent on IL-4Ralpha, but not on eosinophils.
Topics: Administration, Inhalation; Animals; Asthma; Bronchi; Eosinophilia; Eosinophils; Interleukin-13 Rece | 1999 |
Mucus impaction presenting as a lung mass in an AIDS patient with asthma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Asthma; Diagnosis, Differential; Humans; Lung; Lung Neopl | 1999 |
T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production.
Topics: Animals; Asthma; Disease Models, Animal; Eosinophilia; Flow Cytometry; Hypersensitivity; Inflammatio | 1999 |
Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3.
Topics: Aerosols; Amino Acid Substitution; Animals; Asthma; Bronchoalveolar Lavage Fluid; DNA-Binding Protei | 1999 |
Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma.
Topics: Administration, Intranasal; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar L | 2000 |
Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allergens; Animals; Anti-Inflammatory Agents, Non-St | 2000 |
Prostaglandin D2 as a mediator of allergic asthma.
Topics: Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Crosses, Geneti | 2000 |
Distribution and severity of bronchiectasis in allergic bronchopulmonary aspergillosis (ABPA).
Topics: Aspergillosis, Allergic Bronchopulmonary; Asthma; Bronchi; Bronchiectasis; Bronchography; Humans; Mu | 2000 |
Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance.
Topics: Adult; Aged; Asthma; Female; Humans; Inflammation Mediators; Interleukin-8; Intubation, Intratrachea | 2000 |
Interleukin-9 upregulates mucus expression in the airways.
Topics: Animals; Asthma; Carcinoma, Squamous Cell; DNA Primers; Epithelial Cells; Gene Expression; Glycoprot | 2000 |
Macrolides, asthma, inflammation, and infection.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Asthma; Bronchiolitis; Bronchitis; Humans; Mucus; T | 2000 |
Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; | 2000 |
Mucus plugging as a cause of acute lobar overdistension.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchoscopy; Child, Preschool; Cough; Diagnosis, Differe | 2001 |
The homeostatic rôle of bronchoconstriction.
Topics: Asthma; Bronchoconstriction; Homeostasis; Humans; Mucociliary Clearance; Mucus; Respiratory Muscles; | 2001 |
Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma.
Topics: Animals; Asthma; Cell Line; Chloride Channels; Cloning, Molecular; Disease Models, Animal; Epitheliu | 2001 |
Suppression of asthma-like responses in different mouse strains by oral tolerance.
Topics: Administration, Inhalation; Administration, Oral; Animals; Antibodies; Antigens; Asthma; Bronchial P | 2001 |
Gob genes, mucus and asthma.
Topics: Animals; Asthma; Chloride Channels; Goblet Cells; Humans; Mucoproteins; Mucus | 2001 |
[Plastic bronchitis and mucoid impaction--uncommon disease syndromes with expectoration mucus plugs].
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Aspergillosis, Allergic Bronchopulmonary; Asthma | 2001 |
Murine cytomegalovirus infection alters Th1/Th2 cytokine expression, decreases airway eosinophilia, and enhances mucus production in allergic airway disease.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Cytomegalovirus Infections; Disease Models | 2001 |
Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion.
Topics: Adjuvants, Immunologic; Animals; Asthma; Bronchial Hyperreactivity; Bronchitis; Bronchoconstrictor A | 2001 |
Exposure to diesel exhaust exacerbates allergen-induced airway responses in guinea pigs.
Topics: Allergens; Analysis of Variance; Animals; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavag | 2001 |
Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B.
Topics: Asthma; Blotting, Western; Cystic Fibrosis; Dose-Response Relationship, Drug; Electrophoresis, Agar | 2002 |
Tryptase inhibition blocks airway inflammation in a mouse asthma model.
Topics: Animals; Asthma; Bridged Bicyclo Compounds, Heterocyclic; Bronchial Diseases; Bronchial Hyperreactiv | 2002 |
A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma.
Topics: Adult; Asthma; Biopsy; Bronchi; Chloride Channels; Forced Expiratory Volume; Gene Expression Regulat | 2002 |
Histopathology of fatal asthma: drowning in mucus.
Topics: Adolescent; Adult; Airway Obstruction; Asthma; Drowning; Female; Humans; Male; Middle Aged; Mucus | 2001 |
Pulmonary inflammation monitored noninvasively by MRI in freely breathing rats.
Topics: Allergens; Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Budesonide; Eosi | 2002 |
Gene therapy of mucus hypersecretion in experimental asthma.
Topics: Animals; Asthma; Genetic Therapy; Mice; Mucus; Munc18 Proteins; Nerve Tissue Proteins; Proteins; Tra | 2002 |
Mycobacterial infection inhibits established allergic inflammatory responses via alteration of cytokine production and vascular cell adhesion molecule-1 expression.
Topics: Animals; Antigens; Asthma; Cytokines; Endothelium, Vascular; Female; Immune Tolerance; Immunoglobuli | 2002 |
CD4(+) T cell-dependent airway mucus production occurs in response to IL-5 expression in lung.
Topics: Allergens; Animals; Asthma; CD4-Positive T-Lymphocytes; Eosinophils; Gene Expression; Goblet Cells; | 2002 |
Increased expression of the human Ca2+-activated Cl- channel 1 (CaCC1) gene in the asthmatic airway.
Topics: Asthma; Bronchi; Calcium; Cell Line; Chloride Channels; Gene Expression Regulation; Goblet Cells; Hu | 2002 |
Does mucus hypersecretion matter in airway disease?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Female; Humans; Male; Mice; Mucus; Niflumi | 2002 |
Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma.
Topics: Animals; Asthma; Bronchial Hyperreactivity; Epithelial Cells; Humans; In Situ Hybridization; Interle | 2002 |
[Effect of beta-adrenergic drugs on bronchial secretion].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchitis; Drug Evaluation; Female; Hu | 1976 |
Mucus antibodies in pulmonary tuberculosis and chronic obstructive lung disease.
Topics: Animals; Antigen-Antibody Reactions; Asthma; Autoantibodies; Bronchitis; Fluorescent Antibody Techni | 1976 |
Mucopolysaccharides in bronchial secretion of children.
Topics: Asthma; Bronchi; Bronchitis; Child; Cystic Fibrosis; Glycosaminoglycans; Humans; Infant; Mucus | 1978 |
The parasympathetic nervous system in airways disease.
Topics: Animals; Asthma; Bronchial Spasm; Disease Models, Animal; Dogs; Humans; Lung; Mucus; Parasympathetic | 1979 |
Mucociliary clearance in anti-asthmatic drug evaluation.
Topics: Asthma; Bronchi; Bronchodilator Agents; Cilia; Drug Evaluation; Humans; Mucous Membrane; Mucus; Trac | 1979 |
[Bronchial immunoglobulins in chronic and obstructive bronchopathies. Study by immunofluorescence].
Topics: Asthma; Bronchi; Bronchitis; Chronic Disease; Complement System Proteins; Fluorescent Antibody Techn | 1979 |
[Tracheobronchial endoscopy in children].
Topics: Age Factors; Anesthesia; Asthma; Bronchi; Bronchial Diseases; Bronchial Fistula; Bronchial Neoplasms | 1979 |
Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases.
Topics: Asthma; Bronchial Diseases; Bronchiectasis; Bronchitis; Chronic Disease; Cystic Fibrosis; Female; Fu | 1978 |
Histamine in nasal secretions.
Topics: Adolescent; Adult; Asthma; Female; Histamine; Humans; Male; Mucus; Nasal Mucosa; Rhinitis, Allergic, | 1978 |
Technique of coughing.
Topics: Asthma; Breathing Exercises; Bronchitis; Cough; Humans; Mucus; Respiration | 1978 |
Ultrastructure of airways in children with asthma.
Topics: Asthma; Basement Membrane; Bronchi; Child; Epithelium; Female; Humans; Lung; Male; Mucous Membrane; | 1978 |
[Mucus transport in asthma].
Topics: Acetylcholine; Animals; Antigens; Ascaris; Asthma; Biological Transport; Dogs; Histamine; Lung Compl | 1976 |
[Use of the method of express-diagnosis in acute and lingering courses of respiratory-syncytial viral infections in children].
Topics: Acute Disease; Adolescent; Antigens, Viral; Asthma; Bronchitis; Bronchoscopy; Child; Child, Preschoo | 1975 |
A study of western red cedar-induced asthma.
Topics: Acetylcholine; Aerosols; Allergens; Anaphylaxis; Animals; Asthma; Drug Hypersensitivity; Eosinophils | 1975 |
Tracheal mucous transport in experimental canine asthma.
Topics: Animals; Antigens; Ascaris; Asthma; Cilia; Dogs; Lung Compliance; Mucus; Trachea | 1975 |
[Examination of the bronchial secretion for eosinophiles (author's transl)].
Topics: Asthma; Bronchi; Bronchial Diseases; Bronchial Spasm; Diagnosis, Differential; Eosinophils; Humans; | 1975 |
Otitis media and chronic middle ear effusion in the asthmatic pediatric patient.
Topics: Adolescent; Asthma; Child; Child, Preschool; Chronic Disease; Ear, Middle; Humans; Infant; Middle Ea | 1992 |
In vivo detection of a novel macrophage-derived protein involved in the regulation of mucus-like glycoconjugate secretion.
Topics: Adult; Animals; Antibodies, Monoclonal; Asthma; Bronchitis; Bronchoalveolar Lavage Fluid; Cells, Cul | 1992 |
[Airway hyperresponsiveness and mucus secretion].
Topics: Asthma; Autonomic Nervous System; Bronchi; Exocrine Glands; Humans; Mucus; Platelet Activating Facto | 1990 |
Safety and possible efficacy of fiberoptic bronchoscopy with lavage in the management of refractory asthma with mucous impaction.
Topics: Adult; Aged; Asthma; Bronchoscopy; Dyspnea; Female; Fiber Optic Technology; Humans; Hypoxia; Male; M | 1991 |
Asthma, hay fever, and phlegm production associated with distinct patterns of allergy skin test reactivity, eosinophilia, and serum IgE levels. The Normative Aging Study.
Topics: Adult; Aged; Aged, 80 and over; Aging; Asthma; Eosinophilia; Humans; Hypersensitivity; Immunoglobuli | 1991 |
Effect of milk ingestion on pulmonary function in healthy and asthmatic subjects.
Topics: Adult; Airway Resistance; Analysis of Variance; Animals; Asthma; Female; Humans; Male; Middle Aged; | 1991 |
Nearly fatal partial obstruction of the upper airway.
Topics: Adult; Airway Obstruction; Asthma; Bronchi; Female; Histamine H1 Antagonists; Humans; Mucus; Nonpres | 1990 |
Eosinophil cationic protein stimulates and major basic protein inhibits airway mucus secretion.
Topics: Airway Obstruction; Animals; Asthma; Blood Proteins; Cats; Dose-Response Relationship, Drug; Enzyme- | 1991 |
Changes in mucociliary clearance during acute exacerbations of asthma.
Topics: Acute Disease; Adult; Aerosols; Asthma; Female; Humans; Lung; Male; Mucociliary Clearance; Mucus; Ra | 1991 |
Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Bronchial Provocation Tests; Child; Chronic Dise | 1990 |
Mucoid impaction of upper lobe bronchi in the absence of proximal bronchiectasis.
Topics: Adult; Asthma; Bronchi; Bronchiectasis; Bronchography; Female; Humans; Lung; Mucus | 1990 |
Characterization of airway mucus from a fatal case of status asthmaticus.
Topics: Adolescent; Airway Obstruction; Asthma; Centrifugation, Density Gradient; Chromatography, Thin Layer | 1988 |
Regulation of airway secretions.
Topics: Airway Obstruction; Asthma; Biological Transport; Epithelium; Humans; Ion Channels; Mucus; Respirato | 1985 |
Chemical properties of bronchorrhea sputum in bronchial asthma.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Asthma; Bronchial Provocation Tests; Femal | 1988 |
Physiologic implications of the autonomic aberrations in cystic fibrosis.
Topics: Adult; Airway Obstruction; Airway Resistance; Asthma; Autonomic Nervous System; Bronchi; Bronchial P | 1986 |
Asthma as a link between chest illness in childhood and chronic cough and phlegm in young adults.
Topics: Asthma; Bronchitis; Child; Chronic Disease; Cough; Female; Follow-Up Studies; Humans; Male; Mucus; P | 1988 |
[Immunologic study of mucus in patients with allergic rhinopathy and bronchial asthma].
Topics: Asthma; Humans; Immunoglobulins; Mucus; Nasal Mucosa; Rhinitis, Allergic, Seasonal | 1988 |
Effects of the PAF-antagonist CV-3988 on PAF-induced changes in mucus secretion and in respiratory and circulatory variables in ferrets.
Topics: Animals; Asthma; Blood Cells; Ferrets; Mucus; Phospholipid Ethers; Platelet Activating Factor; Thiaz | 1987 |
[Pathophysiology of chronic bronchitis].
Topics: Airway Resistance; Asthma; Bronchitis; Chronic Disease; Humans; Lung Diseases, Obstructive; Mucus; M | 1986 |
[Intrinsic asthma in children].
Topics: Adolescent; Age Factors; Allergens; Asthma; Calcium; Child; Humans; Lung; Mucus; Muscle, Smooth; Res | 1987 |
The presence or absence of bronchial mucus in fatal asthma.
Topics: Airway Obstruction; Asthma; Bronchi; Humans; Mucus | 1987 |
The pathogenesis of severe asthma: a consensus report from the Workshop on Pathogenesis.
Topics: Acute Disease; Airway Obstruction; Asthma; Bronchial Spasm; Humans; Lung; Mast Cells; Mucus; Pulmona | 1987 |
Pulmonary eosinophilia.
Topics: Aspergillosis, Allergic Bronchopulmonary; Asthma; Drug-Related Side Effects and Adverse Reactions; E | 1986 |
Re: Clinical aspects of mucus and mucous plugging in asthma.
Topics: Asthma; Expectorants; Humans; Mucus | 1986 |
Evidence favouring PAF rather than leukotrienes in the pathogenesis of asthma.
Topics: Asthma; Bronchi; Eosinophils; Humans; Inflammation; Mucus; Platelet Activating Factor; Respiratory S | 1986 |
Plastic bronchitis: large, branching, mucoid bronchial casts in children.
Topics: Asthma; Bronchi; Bronchiectasis; Bronchitis; Bronchoscopy; Child; Child, Preschool; Female; Humans; | 1985 |
Tension ball valve mucus plug in asthma.
Topics: Adult; Asthma; Female; Humans; Mucus; Positive-Pressure Respiration; Pulmonary Atelectasis; Radiogra | 1985 |
Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion.
Topics: Airway Obstruction; Asthma; Child, Preschool; Erythromycin; Glucocorticoids; Humans; Male; Mucus; Re | 1986 |
Radioaerosol assessment of mucociliary clearance: towards definition of a normal range.
Topics: Adult; Aerosols; Aged; Asthma; Biological Transport; Bronchi; Bronchitis; Chronic Disease; Cilia; Fe | 1986 |
Tracheobronchial mucociliary clearance in asthma: impairment during remission.
Topics: Adult; Aerosols; Asthma; Bronchi; Female; Humans; Lung; Male; Mucus; Remission, Spontaneous; Respira | 1985 |
Mucoid impaction of the bronchus.
Topics: Asthma; Bronchial Diseases; Bronchitis; Bronchography; Humans; Mucus | 1985 |
Use of acetylcysteine in bronchial asthma--another look.
Topics: Acetylcysteine; Asthma; Bronchoscopy; Humans; Lung; Mucus; Respiratory Therapy; Therapeutic Irrigati | 1985 |
Abnormal nasal mucociliary clearance in patients with rhinitis and its relationship to concomitant chest disease.
Topics: Adolescent; Adult; Asthma; Bronchiectasis; Cilia; Female; Humans; Male; Middle Aged; Mucus; Nose; Rh | 1985 |
The problem of mucus plugging in children with asthma.
Topics: Asthma; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Lung; Lung Diseases, Obs | 1985 |
[Tracheobronchial clearance in the hypersecreting asthmatic patient].
Topics: Adult; Aerosols; Asthma; Bronchi; Cilia; Cough; Female; Humans; Ion Exchange Resins; Male; Middle Ag | 1985 |
Deaths in primary asthma with special reference to pathology.
Topics: Adolescent; Adult; Aged; Asthma; Autopsy; Basement Membrane; Bronchi; Child; Child, Preschool; Eosin | 1971 |
Hypersensitivity to phenylglycine acid chloride.
Topics: Acids; Allergens; Aminocaproates; Asthma; Chemical Industry; Chlorides; Dust; Environmental Exposure | 1973 |
Some histological changes in chronic bronchitis and asthma.
Topics: Adolescent; Adult; Aged; Asthma; Basement Membrane; Biopsy; Bronchi; Bronchitis; Bronchoscopy; Eosin | 1968 |
Immunologic response of young patients with asthma and-or recurrent respiratory infections to aerosol influenza immunization.
Topics: Adult; Aerosols; Antibodies; Antibody Formation; Asthma; Child; Chronic Disease; gamma-Globulins; He | 1970 |
[Cytological and cytochemical examinations in bronchial asthma in children].
Topics: Adolescent; Asthma; Bronchi; Bronchoscopy; Child; Cytodiagnosis; Female; Glycosaminoglycans; Humans; | 1970 |
Use of ultrasonic aerosols with ventilatory assistors.
Topics: Aerosols; Amphotericin B; Asthma; Bronchial Diseases; Bronchodilator Agents; Cystic Fibrosis; Eosino | 1968 |
[Immunoglobulin E. Biochemical, immunological properties and clinical significance (author's transl)].
Topics: Antibodies; Antibodies, Anti-Idiotypic; Asthma; Basophils; Binding Sites, Antibody; Chemical Phenome | 1974 |
Mutually exclusive groups of bronchitics and non-bronchitics in males.
Topics: Adult; Age Factors; Asthma; Body Height; Bronchitis; Cough; Dyspnea; Heart Diseases; Humans; Male; M | 1974 |
The effects of storage and of potassium iodide, urea, N-acetyl-cysteine and triton X-100 on the viscosity of bronchial mucus.
Topics: Acetylcysteine; Asthma; Bronchi; Bronchitis; Centrifugation; Humans; Mucus; Polyethylene Glycols; Po | 1974 |
Conference on the scientific basis of respiratory therapy. Aerosol therapy. Introduction.
Topics: Adrenal Cortex Hormones; Aerosols; Asthma; Bronchi; Bronchodilator Agents; Chronic Disease; Expector | 1974 |
Studies on the variation in the viscosity of bronchial mucus and a technique for reducing such variation.
Topics: Asthma; Bronchi; Bronchitis; Humans; Mucus; Pulmonary Emphysema; Rheology; Sputum; Viscosity | 1974 |
The physical and chemical properties of bronchial secretion.
Topics: Asthma; Bronchi; Bronchiectasis; Bronchitis; Glycoproteins; Molecular Conformation; Mucus; Rheology; | 1974 |
Immunoglobulins in tracheo-bronchial secretion with special reference to IgE.
Topics: Adult; Aged; Asthma; Bronchi; Bronchial Neoplasms; Child, Preschool; Female; Humans; Immunoglobulin | 1974 |
Maxillary sinusitis and bronchial asthma: correlation of roentgenograms, cultures, and thermograms.
Topics: Adult; Aerobiosis; Aged; Asthma; Bronchitis; Escherichia coli; Haemophilus influenzae; Humans; Maxil | 1974 |
Effect of corticosteroid on hyperactive carotid body and carotid sinus in asthmatics.
Topics: Adrenal Cortex Hormones; Adult; Asthma; Carotid Body; Carotid Sinus; Chemoreceptor Cells; Female; Hu | 1972 |
Bronchography in childhood asthma.
Topics: Adolescent; Anesthesia, General; Asthma; Bronchi; Bronchial Spasm; Bronchiectasis; Bronchitis; Bronc | 1972 |
Rare complications of bronchial asthma.
Topics: Adult; Aged; Airway Obstruction; Allergens; Asthma; Bronchial Neoplasms; Bronchiectasis; Bronchitis; | 1972 |
Investigation into observer and seasonal variation of the prevalence of respiratory symptoms at Schiermonnikoog.
Topics: Adolescent; Age Factors; Asthma; Body Height; Cough; Dyspnea; Female; Humans; Laryngismus; Male; Muc | 1972 |
Vitamin A: occurrence and distribution in fractionated mucus.
Topics: Animals; Asthma; Bronchi; Bronchitis; Cattle; Centrifugation; Cervix Mucus; Chromatography, Thin Lay | 1973 |
Mucoid inpaction of the bronchus. Diagnosis and treatment.
Topics: Acetylcysteine; Adult; Airway Obstruction; Asthma; Bronchial Diseases; Bronchitis; Female; Humans; I | 1973 |
[Proteins of the bronchial mucus in intrinsic asthma].
Topics: Asthma; Blood Proteins; Humans; Immunoglobulins; Mucus | 1973 |
[Serum and secretory immunoglobulins during bronchopneumopathies in children].
Topics: Adolescent; Adult; Asthma; Bronchitis; Child; Child, Preschool; Humans; Immunoglobulin A; Immunoglob | 1973 |
Output characteristics and clinical efficacy of ultrasonic nebulizers.
Topics: Acetylcysteine; Aerosols; Asthma; Bronchial Diseases; Child; Cortisone; Cystic Fibrosis; Humans; Muc | 1968 |
Bronchospasm in asthma.
Topics: Airway Resistance; Asthma; Bronchial Spasm; Bronchodilator Agents; Female; Humans; Mucus; Pulmonary | 1972 |
Muscle and mucous gland size in the major bronchi of patients with chronic bronchitis, asthma, and asthmatic bronchitis.
Topics: Adult; Asthma; Autopsy; Bronchi; Bronchitis; Cartilage; Chronic Disease; Connective Tissue; Exocrine | 1971 |
Lipid composition of human bronchial mucus.
Topics: Asthma; Bronchi; Cholesterol; Chromatography, Thin Layer; Esters; Fatty Acids, Nonesterified; Glycer | 1971 |
[Biochemical analysis of bronchial secretions in chronic obstructive lung disease (chronic bronchitis, asthma). I. Homogenizing of bronchial secretions with ultrasound and its importance for biochemical analysis].
Topics: Asthma; Bronchitis; Electrophoresis; Humans; Immunoelectrophoresis; Lung Diseases, Obstructive; Mucu | 1971 |
[Biochemical analysis of bronchial secretions in chronic obstructive lung disease (chronic bronchitis and asthma). II. Classification of bronchial secretions on the basis of biochemical analyses].
Topics: Asthma; Bronchitis; Electrophoresis; Humans; Immunoelectrophoresis; Lung Diseases, Obstructive; Mucu | 1971 |
The colon mucus antibody.
Topics: Antibodies; Asthma; Colitis, Ulcerative; Colon; Fluoresceins; Humans; Immune Sera; Immunoglobulin A; | 1971 |
[Severe asthma. Study of 80 cases of severe and fatal asthma].
Topics: Acid-Base Equilibrium; Acidosis, Respiratory; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti | 1969 |
[Modifications of physico-chemical properties of expectoration in various pathological states and their treatment].
Topics: Adrenal Cortex Hormones; Adult; Asthma; Bronchitis; Chronic Disease; Female; Haemophilus influenzae; | 1970 |
Immunopathologic aspects of lung disease.
Topics: Anaphylaxis; Animals; Anti-Glomerular Basement Membrane Disease; Antibodies, Anti-Idiotypic; Antibod | 1970 |
Infection and chronic bronchitis. A study carried out in general practice.
Topics: Adult; Aged; Antibodies; Asthma; Bronchitis; Chronic Disease; Family Practice; Female; Haemophilus I | 1969 |
[Results of bronchologic studies in children with bronchial asthma syndrome].
Topics: Adolescent; Asthma; Biopsy; Bronchi; Bronchial Diseases; Bronchiectasis; Bronchitis; Bronchoscopy; C | 1969 |
Deaths amongst asthmatics in Tasmania, 1964-1966.
Topics: Adolescent; Adult; Aerosols; Aged; Aminophylline; Asthma; Australia; Autopsy; Child; Child, Preschoo | 1970 |
Chronic respiratory disease among nonsmokers in Hagerstown, Maryland. I. Design of the study and prevalence of symptoms.
Topics: Adult; Age Factors; Asthma; Chronic Disease; Coronary Disease; Cough; Dyspnea; Humans; Hypertension; | 1971 |
Clearance from alveoli to the ciliary escalator: implications for pulmonary diseases.
Topics: Animals; Anura; Asthma; Bronchiolitis, Viral; Bronchitis; Cilia; Foreign Bodies; Mucus; Phagocytosis | 1967 |
Ultrasonic nebulization in the treatment of intractable bronchial asthma in children.
Topics: Adolescent; Aerosols; Asthma; Bronchial Spasm; Child; Female; Humans; Isoproterenol; Isotonic Soluti | 1968 |
Handling emotional problems associated with pediatric allergy.
Topics: Asthma; Blood Volume; Capillaries; Child; Child, Preschool; Emotions; Guilt; Hostility; Humans; Hype | 1968 |
A hypothesis for pulmonary clearance and its implications.
Topics: Animals; Anura; Asthma; Bronchi; Bronchitis; Cilia; Emphysema; Epithelial Cells; Lung; Mucus; Pulmon | 1968 |
Expectorant activity of water in acute asthma attacks.
Topics: Animals; Asthma; Bronchi; Expectorants; Female; Male; Mucus; Rabbits; Water | 1968 |
[Effect of mucolytic agents in the management ofbronchial asthma. Personal experience with 20 cases].
Topics: Asthma; Expectorants; Humans; Mucus | 1968 |
Bacterial flora of bronchial secretion.
Topics: Adolescent; Anti-Bacterial Agents; Asthma; Bacteria; Bronchi; Bronchial Diseases; Bronchiectasis; Br | 1968 |
Mucoid impaction of the bronchi in relation to asthma an plastic bronchitis.
Topics: Adult; Asthma; Bronchial Diseases; Bronchitis; Diagnosis, Differential; Female; Humans; Lung Neoplas | 1968 |
The bronchographic appearances of early chronic bronchitis.
Topics: Asthma; Bronchiectasis; Bronchitis; Bronchography; Chronic Disease; Female; Humans; Male; Mucus; Smo | 1969 |
Sudden death in a young asthmatic.
Topics: Adolescent; Asthma; Bronchi; Chromones; Death, Sudden; Humans; Male; Mucus; Prednisone | 1969 |
[Significance and methods of obtaining bronchial secretion].
Topics: Asthma; Bronchi; Bronchitis; Bronchoscopy; Humans; Intubation, Intratracheal; Mucus; Respiratory Tra | 1969 |
Use of acetylcysteine in bronchial asthma and emphysema.
Topics: Acetylcysteine; Adolescent; Adult; Aerosols; Aged; Asthma; Bronchitis; Child; Chronic Disease; Ethan | 1969 |
[In-vitro studies with the secretolytic agent Bisolvon (supplement to preliminary clinico-experimental experiences)].
Topics: Asthma; Expectorants; Humans; In Vitro Techniques; Mucus; Sputum | 1965 |
Plastic bronchitis, mucoid impaction of the bronchi and allergic broncho-pulmonary aspergillosis, and their relationship to bronchial asthma.
Topics: Adolescent; Adult; Aged; Aspergillosis; Asthma; Bronchial Diseases; Bronchitis; Eosinophilia; Exudat | 1966 |
Mucoid impaction of the bronchi.
Topics: Adolescent; Adult; Aged; Asthma; Bronchial Diseases; Child; Child, Preschool; Expectorants; Female; | 1966 |
[Atelectasis caused by mucoid impaction in 2 asthmatic children].
Topics: Asthma; Child; Humans; Infant; Male; Mucus; Pulmonary Atelectasis | 1966 |
Mucoid impaction of the bronchi.
Topics: Adult; Asthma; Bronchial Diseases; Bronchitis; Bronchography; Female; Humans; Lung Abscess; Male; Mi | 1966 |